<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pulmonary Medicine & Critical Care - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Medicine
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">184</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 20102,
    "choices": [
      {
        "id": 80369,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive lung disease </span></span></span></p>"
      },
      {
        "id": 80370,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive lung disease </span></span></span></p>"
      },
      {
        "id": 80371,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal lung function </span></span></span></p>"
      },
      {
        "id": 80372,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old woman with a 30-pack-year smoking history presents with chronic cough and shortness of breath. Spirometry shows an FEV1/FVC ratio of 0.60. What does this finding suggest?</span></span></span></p>",
    "unique_key": "Q1188041",
    "question_audio": null,
    "question_video": null,
    "map_id": 20055,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>B) Obstructive lung disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A reduced FEV1/FVC ratio (typically &lt; 0.70) is a hallmark of obstructive lung diseases, where airflow is limited, such as COPD and asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Restrictive lung disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterized by reduced lung volumes with a normal or increased FEV1/FVC ratio.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Normal lung function:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Normal PFTs would show a normal FEV1/FVC ratio.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Interstitial lung disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A type of restrictive lung disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A reduced FEV1/FVC ratio (&lt; 0.70) on spirometry is indicative of obstructive lung disease, commonly seen in conditions like COPD and asthma.</span></span></span></p>",
    "correct_choice_id": 80370,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 20103,
    "choices": [
      {
        "id": 80373,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal residual volume (RV) </span></span></span></p>"
      },
      {
        "id": 80374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased forced vital capacity (FVC) </span></span></span></p>"
      },
      {
        "id": 80375,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal vital capacity (VC) </span></span></span></p>"
      },
      {
        "id": 80376,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased FEV1/FVC ratio</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a history of smoking and progressive dyspnea presents with a barrel chest and expiratory wheezing. Which PFT finding is LEAST likely in this patient with suspected emphysema?</span></span></span></p>",
    "unique_key": "Q5675700",
    "question_audio": null,
    "question_video": null,
    "map_id": 20056,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans.&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A) Normal residual volume (RV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emphysema, a type of COPD, is characterized by air trapping and hyperinflation, leading to increased residual volume.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased forced vital capacity (FVC)</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Common in emphysema due to air trapping.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Normal vital capacity (VC):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While possible in early disease, VC often decreases as emphysema progresses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>D. Decreased FEV1/FVC ratio:</strong> Hallmark of obstructive lung disease like emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In emphysema, expect increased residual volume (RV) due to air trapping, along with decreased FEV1/FVC ratio and forced vital capacity (FVC).</span></span></p>",
    "correct_choice_id": 80373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20104,
    "choices": [
      {
        "id": 80377,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tidal volume (TV) </span></span></span></p>"
      },
      {
        "id": 80378,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vital capacity (VC) </span></span></span></p>"
      },
      {
        "id": 80379,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Functional residual capacity (FRC) </span></span></span></p>"
      },
      {
        "id": 80380,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Forced expiratory volume in 1 second (FEV1)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical student is using the following device to assess lung function in a patient with suspected asthma. Which of the following lung volumes cannot be directly measured using this device?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/picture1.jpg\" style=\"height:275px; width:300px\" /></span></span></p>",
    "unique_key": "Q3792907",
    "question_audio": null,
    "question_video": null,
    "map_id": 20057,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Functional residual capacity (FRC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given instrument is a hand held spirometer. Spirometry can measure airflow during forced maneuvers and can estimate FVC, FEV1, and peak expiratory flow rate (PEFR). Spirometry cannot measure residual volume and the associated capacities (like TLC/FRC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Tidal volume (TV):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The volume of air inhaled or exhaled during normal breathing. Can be measured in Spirometry</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vital capacity (VC):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The maximum volume of air that can be exhaled after a maximal inhalation. Can be measured in Spirometry</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Forced expiratory volume in 1 second (FEV1):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The volume of air exhaled in the first second of a forced exhalation. Can be measured in Spirometry</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spirometry can measure FVC, FEV1, and TV, but it cannot measure RV or FRC.</span></span></span></p>",
    "correct_choice_id": 80379,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InstrumentsBased"
    ]
  },
  {
    "id": 20105,
    "choices": [
      {
        "id": 80381,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal lung function </span></span></span></p>"
      },
      {
        "id": 80382,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive lung disease </span></span></span></p>"
      },
      {
        "id": 80383,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper airway obstruction </span></span></span></p>"
      },
      {
        "id": 80384,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive lung disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient&#39;s flow-volume (FV) loop demonstrates the following (red line in the image is the patients actual FV loop, background blue line is the predicted normal). What does this finding indicate?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/picture2.jpg\" style=\"height:298px; width:300px\" /></span></span></p>",
    "unique_key": "Q7284834",
    "question_audio": null,
    "question_video": null,
    "map_id": 20058,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Obstructive lung disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The concave shape with scooped appearance of expiratory limb and reduced PEFR on the expiratory limb are classic for obstructive lung diseases like COPD and asthma, indicating airflow limitation during exhalation. The patient also has a near normal FVC, further strengthening the diagnosis of obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Normal lung function:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Normal flow-volume loops are relatively linear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Restrictive lung disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Usually shows a smaller loop with normal shape.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Upper airway obstruction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically shows flattening on the inspiratory limb of the flow-volume loop.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></u></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A concave, scooped expiratory flow-volume loop with reduced PEFR is indicative of obstructive lung disease such as COPD or asthma.</span></span></p>",
    "correct_choice_id": 80384,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 20106,
    "choices": [
      {
        "id": 80385,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trachea</span></span></span></p>"
      },
      {
        "id": 80386,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mainstem bronchi</span></span></span></p>"
      },
      {
        "id": 80387,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medium-sized bronchi</span></span></span></p>"
      },
      {
        "id": 80388,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Small airways (bronchioles)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with wheezing and shortness of breath undergoes spirometry. A decreased maximum mid-expiratory flow rate (MMEF or FEF25-75%) is observed. Which airways are most likely affected?</span></span></p>",
    "unique_key": "Q7733235",
    "question_audio": null,
    "question_video": null,
    "map_id": 20059,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Small airways (bronchioles)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MMEF, also known as FEF25-75%, reflects airflow in the small airways (bronchioles). A decrease in MMEF suggests obstruction in these airways, which is a common finding in conditions like asthma and COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Option</strong>&nbsp;<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. Trachea:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Obstruction here would cause stridor, a high-pitched sound on inspiration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></span></strong>&nbsp;<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Mainstem bronchi:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Obstruction here would cause more severe symptoms and a different flow-volume loop pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></span></strong>&nbsp;<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Medium-sized bronchi:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While potentially affected, these airways are not the primary site of obstruction reflected by a decreased MMEF</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A decreased MMEF (FEF25-75%) indicates obstruction in the small airways (bronchioles), which is common in asthma and COPD.</span></span></p>",
    "correct_choice_id": 80388,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 20107,
    "choices": [
      {
        "id": 80389,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthma </span></span></span></p>"
      },
      {
        "id": 80390,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Main bronchus obstruction </span></span></span></p>"
      },
      {
        "id": 80391,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Large airway tumor </span></span></span></p>"
      },
      {
        "id": 80392,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a history of heavy smoking presents with a new onset of stridor and progressive dyspnea. His flow-volume loop is shown. What is the most likely cause?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/picture3.jpg\" style=\"height:302px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7212603",
    "question_audio": null,
    "question_video": null,
    "map_id": 20060,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Main bronchus obstruction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This patient has a unilateral mainstem bronchus obstruction. The flow-volume loop shows both an end-inspiratory and end-expiratory tail and is most commonly known as a biphasic flow-volume curve. This finding has also been described as &ldquo;two compartments.&rdquo;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Asthma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically shows a concave expiratory limb without biphasic flattening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Large airway tumor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While it can cause fixed obstruction with flattening of both limbs, a biphasic pattern is more indicative of a main bronchus obstruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. COPD:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Shows a concave expiratory limb and does not typically cause a biphasic pattern in the flow-volume loop.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A biphasic flow-volume loop indicates a main bronchus obstruction, often presenting with both end-inspiratory and end-expiratory tailing.</span></span></p>",
    "correct_choice_id": 80390,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 20108,
    "choices": [
      {
        "id": 80393,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spontaneous breathing </span></span></span></p>"
      },
      {
        "id": 80394,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Positive pressure ventilation </span></span></span></p>"
      },
      {
        "id": 80395,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Airway obstruction </span></span></span></p>"
      },
      {
        "id": 80396,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung collapse</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is in ICU and you are noticing the flow-volume loop as shown. What is the most likely explanation for this finding?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/picture4.jpg\" style=\"height:224px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q8835258",
    "question_audio": null,
    "question_video": null,
    "map_id": 20061,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Positive pressure ventilation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this FV loop expiration precedes inspiration and this is opposite to normal spontaneous respiration. This is due to positive pressure ventilation, where air is forced into the lungs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spontaneous breathing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Would show a normal pattern with inspiration preceding expiration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Airway obstruction</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Would cause a concave shape on the expiratory limb.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Lung collapse</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Would result in a smaller loop with decreased flows.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A flow-volume loop where expiration precedes inspiration indicates positive pressure ventilation, commonly seen in patients receiving mechanical ventilation in the ICU.</span></span></span></p>",
    "correct_choice_id": 80394,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 20109,
    "choices": [
      {
        "id": 80397,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthma </span></span></span></p>"
      },
      {
        "id": 80398,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congestive heart failure </span></span></span></p>"
      },
      {
        "id": 80399,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary hemorrhage </span></span></span></p>"
      },
      {
        "id": 80400,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of rheumatoid arthritis presents with progressive shortness of breath. Pulmonary function tests reveal a decreased diffusing capacity of the lung for carbon monoxide (DLCO). Which of the following conditions is the most likely cause of her decreased DLCO?</span></span></span></p>",
    "unique_key": "Q2978486",
    "question_audio": null,
    "question_video": null,
    "map_id": 20062,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Interstitial lung disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease, a known complication of rheumatoid arthritis, leads to thickening and fibrosis of the alveolar-capillary membrane, reducing gas diffusion and causing a decrease in DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Asthma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While asthma can cause a reduced DLCO due to air trapping, it is not the most likely cause in this clinical scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Congestive heart failure</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Can cause a reduced DLCO due to pulmonary edema, but the patient&#39;s history of rheumatoid arthritis makes ILD more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pulmonary hemorrhage</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Can cause a<em> transient increase</em> in DLCO due to the presence of blood in the alveoli.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></u></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with rheumatoid arthritis and progressive shortness of breath, a decreased DLCO is most likely due to interstitial lung disease, a common pulmonary complication associated with rheumatoid arthritis.</span></span></span></p>",
    "correct_choice_id": 80400,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20110,
    "choices": [
      {
        "id": 80401,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia</span></span></span></p>"
      },
      {
        "id": 80402,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease (ILD) </span></span></span></p>"
      },
      {
        "id": 80403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alveolar hemorrhage </span></span></span></p>"
      },
      {
        "id": 80404,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pleural effusion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with systemic lupus erythematosus (SLE) presents with sudden onset of hemoptysis and shortness of breath. Her DLCO is 163%. What underlying pathology is most likely responsible for this finding?</span></span></span></p>",
    "unique_key": "Q1726064",
    "question_audio": null,
    "question_video": null,
    "map_id": 20063,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Alveolar hemorrhage</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with systemic lupus erythematosus (SLE) presenting with hemoptysis and an increased DLCO, alveolar hemorrhage is the most likely cause. The presence of blood in the alveoli increases the binding capacity for carbon monoxide, thereby increasing DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pneumonia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically associated with normal or decreased DLCO due to inflammation and consolidation, not an increase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Interstitial lung disease (ILD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Usually associated with a decreased DLCO due to fibrosis and thickening of the alveolar-capillary membrane.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pleural effusion</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Does not typically affect DLCO in the same manner; it might decrease lung volumes but not directly increase DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased DLCO in a patient with SLE and sudden hemoptysis suggested alveolar hemorrhage, where the presence of blood in the alveoli elevates carbon monoxide binding capacity.</span></span></span></p>",
    "correct_choice_id": 80403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20111,
    "choices": [
      {
        "id": 80405,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased DLCO </span></span></span></p>"
      },
      {
        "id": 80406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal DLCO </span></span></span></p>"
      },
      {
        "id": 80407,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased DLCO </span></span></span></p>"
      },
      {
        "id": 80408,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased FEV1/FVC ratio</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a history of systemic sclerosis presents with progressive dyspnea. Which of the following pulmonary function test results would be most consistent with her underlying condition?</span></span></span></p>",
    "unique_key": "Q1148208",
    "question_audio": null,
    "question_video": null,
    "map_id": 20064,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>C) Decreased DLCO</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Systemic sclerosis can cause interstitial lung disease (ILD), a condition that decreases the diffusing capacity of the lung for carbon monoxide (DLCO) due to fibrosis and thickening of the alveolar-capillary membrane.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Increased DLCO:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in conditions like asthma, pulmonary hemorrhage, or polycythemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Normal DLCO:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Unlikely in ILD, which typically causes a reduced DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increased FEV1/FVC ratio:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Not characteristic of ILD, which is a restrictive pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Systemic sclerosis can lead to interstitial lung disease (ILD), characterized by a decreased DLCO due to fibrosis and thickening of the alveolar-capillary membrane.</span></span></p>",
    "correct_choice_id": 80407,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20112,
    "choices": [
      {
        "id": 80409,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emphysema </span></span></span></p>"
      },
      {
        "id": 80410,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asbestosis </span></span></span></p>"
      },
      {
        "id": 80411,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia </span></span></span></p>"
      },
      {
        "id": 80412,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchogenic carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old former naval ship worker with a 40-pack-year smoking history presents with progressive dyspnea, dry cough, bilateral end-inspiratory crackles, and no clubbing. PFT is given below.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total lung capacity&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67% of predicted</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Residual volume&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;72% of predicted</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FVC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65% of predicted</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEVI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;75% of predicted</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV I/FVC ratio&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;89% (Normal)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DLCO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;52% of predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chest X-ray reveals bilateral lower zone predominant lesions. Which diagnosis is most likely?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "unique_key": "Q8065336",
    "question_audio": null,
    "question_video": null,
    "map_id": 20065,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Asbestosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The history of asbestos exposure (naval ship worker), progressive dyspnea, dry cough, restrictive PFT pattern, and bilateral lower zone opacities are consistent with asbestosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Emphysema:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically causes obstructive pattern on PFTs, upper lobe predominant changes, and may present with wheezing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pneumonia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Usually acute onset with fever and consolidation on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Bronchogenic carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Often associated with a history of smoking but usually presents as a mass or nodule on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asbestosis is characterized by a history of asbestos exposure, restrictive PFT pattern, progressive dyspnea, and bilateral lower zone opacities on imaging.</span></span></span></p>",
    "correct_choice_id": 80410,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20113,
    "choices": [
      {
        "id": 80413,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive lung disease </span></span></span></p>"
      },
      {
        "id": 80414,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive lung disease </span></span></span></p>"
      },
      {
        "id": 80415,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal lung function </span></span></span></p>"
      },
      {
        "id": 80416,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Combined obstructive and restrictive lung disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">65-year-old man undergoes pulmonary function testing (PFT) as part of a routine medical health check (MHC). He has no pulmonary issues and is a lifelong non-smoker. The PFT results are shown below. Which of the following findings is most likely consistent with the observed data?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-194313.jpg\" style=\"height:332px; width:700px\" /></p>",
    "unique_key": "Q3239652",
    "question_audio": null,
    "question_video": null,
    "map_id": 20066,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Normal lung function</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The PFT results show normal FVC (102% predicted), FEV1 (95% predicted), FEV1/FVC ratio (73%) and DLCO (84% of predicted)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No significant change post-bronchodilator indicates no reversible obstruction.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Obstructive lung disease</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically has an FEV1/FVC ratio &lt; 70%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Restrictive lung disease</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically shows a reduced TLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Combined obstructive and restrictive lung disease</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Would show both a reduced FEV1/FVC ratio and reduced TLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal PFT results include an FEV1/FVC ratio around 75-80%, no significant change post-bronchodilator, and normal predicted values for FVC, FEV1, and DLCO.</span></span></span></p>",
    "correct_choice_id": 80415,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 49815,
    "choices": [
      {
        "id": 198823,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthma </span></span></span></p>"
      },
      {
        "id": 198824,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD) </span></span></span></p>"
      },
      {
        "id": 198825,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive lung disease </span></span></span></p>"
      },
      {
        "id": 198826,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 41-year-old smoker presents with shortness of breath (SOB). His pulmonary function test (PFT) results are shown below. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/screenshot-2024-06-19-113621.jpg\" style=\"height:323px; width:1000px\" /></span></span></span></p>",
    "unique_key": "Q4290331",
    "question_audio": null,
    "question_video": null,
    "map_id": 24837,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Chronic obstructive pulmonary disease (COPD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The PFT results indicate severe obstruction:</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1 is markedly reduced (19% predicted).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC ratio is significantly decreased (54%), consistent with obstructive lung disease.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RV is increased (257% predicted), indicating air trapping.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TLC is within normal limits (108% predicted), ruling out restrictive lung disease.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DLCO is severely reduced (3% predicted), consistent with emphysema, a common cause of COPD.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Asthma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically shows reversible airflow obstruction with significant improvement post-bronchodilator, which is not seen here (FEV1 change of -10%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Restrictive lung disease</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically shows a reduced TLC, which is not present in these results.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pulmonary embolism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Generally does not present with such a pronounced obstructive pattern and reduced DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD is characterized by reduced FEV1 and FEV1/FVC ratio, increased RV indicating air trapping, and a reduced DLCO, particularly in cases of emphysema.</span></span></span></p>",
    "correct_choice_id": 198824,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49817,
    "choices": [
      {
        "id": 198831,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD) </span></span></span></p>"
      },
      {
        "id": 198832,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myasthenia gravis </span></span></span></p>"
      },
      {
        "id": 198833,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypersensitivity pneumonitis </span></span></span></p>"
      },
      {
        "id": 198834,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman presents for evaluation of shortness of breath on exertion for 2 months. She is a non-smoker and has no prior history of asthma or other pulmonary problems. She works as a receptionist in a hotel and has two cats and three parakeets at home. Her pulmonary function test (PFT) results are shown below. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/screenshot-2024-06-19-113701.jpg\" style=\"height:321px; width:1000px\" /></span></span></span></p>",
    "unique_key": "Q1249973",
    "question_audio": null,
    "question_video": null,
    "map_id": 24839,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Hypersensitivity pneumonitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The PFT results indicate a restrictive pattern:</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1 is significantly reduced (43% predicted).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FVC is significantly reduced (40% predicted) suggesting a restrictive pattern.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC ratio is increased (91%), consistent with a restrictive pattern.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total Lung Capacity (TLC) is reduced (44% predicted), confirming a restrictive pattern.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DLCO is severely reduced (16% predicted), which is suggestive of intrinsic restriction (ILD) </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s exposure to birds (parakeets) is a common cause of hypersensitivity pneumonitis, leading to lung inflammation and fibrosis (ILD)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Chronic obstructive pulmonary disease (COPD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically shows a reduced FEV1/FVC ratio and increased TLC due to air trapping, not a restrictive pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Myasthenia gravis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Can cause a restrictive pattern but typically presents with muscle weakness rather than severe reductions in lung volumes and DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pulmonary embolism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Generally does not present with a restrictive pattern on PFT and primarily affects DLCO if significant, but not the overall lung volumes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypersensitivity pneumonitis is characterized by a restrictive pattern on PFTs, decreased TLC, and significantly reduced DLCO. Bird exposure, particularly to parakeets, is a common cause.</span></span></span></p>",
    "correct_choice_id": 198833,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 50318,
    "choices": [
      {
        "id": 200827,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD) </span></span></span></p>"
      },
      {
        "id": 200828,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myasthenia gravis </span></span></span></p>"
      },
      {
        "id": 200829,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease (ILD) </span></span></span></p>"
      },
      {
        "id": 200830,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old woman presents with worsening shortness of breath on exertion and exercise limitation. She is a lifelong non-smoker and has no significant past medical history. Her pulmonary function test (PFT) results are shown below. What is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/26/screenshot-2024-06-26-102120.jpg\" style=\"height:319px; width:700px\" /></span></span></p>",
    "unique_key": "Q9864707",
    "question_audio": null,
    "question_video": null,
    "map_id": 25022,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Myasthenia gravis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The PFT results indicate a restrictive pattern:</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1 is significantly reduced (30% predicted).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC ratio is normal (99%)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FVC is significantly reduced (26% predicted) suggesting a restrictive pattern.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Total Lung Capacity (TLC) is reduced (53% predicted), confirming a restrictive pattern.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RV/TLC ratio is increased (65%), which can be seen in conditions that affect muscle strength.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DLCO is relatively normal (84% predicted), which typically occurs in extrinsic restriction.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Chronic obstructive pulmonary disease (COPD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Typically shows a reduced FEV1/FVC ratio and increased TLC due to air trapping, not a restrictive pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Interstitial lung disease (ILD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Causes intrinsic restriction hence presents with significant diffusion impairment, often with very low DLCO values.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pulmonary embolism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Generally does not present with a restrictive pattern on PFT and primarily affects DLCO if significant enough, not the overall lung volumes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myasthenia gravis can present with a restrictive pattern on PFTs characterized by reduced FEV1 and FVC with a normal FEV1/FVC ratio, reduced TLC, and an increased RV/TLC ratio.</span></span></p>",
    "correct_choice_id": 200828,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 7145,
    "choices": [
      {
        "id": 28548,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor V Leiden mutation </span></span></span></p>"
      },
      {
        "id": 28549,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral contraceptive use </span></span></span></p>"
      },
      {
        "id": 28550,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Active malignancy&nbsp;</span></span></span></p>"
      },
      {
        "id": 28551,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prior history of DVT</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a history of deep vein thrombosis (DVT) six months ago. She is concerned about her risk of recurrence. Which of the following factors is the strongest predictor of recurrent venous thromboembolism (VTE)?</span></span></span></p>",
    "unique_key": "Q8138011",
    "question_audio": null,
    "question_video": null,
    "map_id": 20095,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Prior history of DVT</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A prior history of VTE, whether DVT or pulmonary embolism (PE), is the strongest predictor of recurrent events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor V Leiden mutation:</span></strong><span style=\"font-size:12.0pt\"> While a significant risk factor for VTE, it is not the strongest predictor of recurrence compared to a prior VTE event.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral contraceptive use:</span></strong><span style=\"font-size:12.0pt\"> This is a transient risk factor that decreases after discontinuation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Active malignancy:</span></strong><span style=\"font-size:12.0pt\"> Increases VTE risk but is less predictive of recurrence than a prior VTE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A prior history of venous thromboembolism (VTE) is the strongest predictor of recurrent events.</span></span></span></p>",
    "correct_choice_id": 28551,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7146,
    "choices": [
      {
        "id": 28552,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a benign condition with low risk of complications</span></span></span></p>"
      },
      {
        "id": 28553,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a surgical emergency requiring immediate intervention</span></span></span></p>"
      },
      {
        "id": 28554,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is typically managed with anticoagulation alone</span></span></span></p>"
      },
      {
        "id": 28555,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is associated with a low risk of pulmonary embolism.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old man with a recent left leg fracture presents with sudden severe pain, swelling, and bluish discoloration as shown in the picture. Doppler ultrasound confirms non compressible femoral, popliteal, and saphenous veins. Which of the following statements is TRUE regarding this condition?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture4.jpg\" style=\"height:169px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7312892",
    "question_audio": null,
    "question_video": null,
    "map_id": 20096,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It is a surgical emergency requiring immediate intervention.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non compressible femoral, popliteal, and saphenous veins confirms extensive DVT and the presentation here describes phlegmasia cerulea dolens, a rare and severe form of DVT with massive venous outflow obstruction. It requires urgent thrombectomy/fasciotomy to prevent limb ischemia and gangrene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>It is a benign condition with low risk of complications:</strong></span><span style=\"font-size:12.0pt\"> It is a serious condition with high risk of limb loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong> <strong><span style=\"font-size:12.0pt\">It is typically managed with anticoagulation alone:</span></strong><span style=\"font-size:12.0pt\"> Anticoagulation alone is insufficient; surgical intervention is necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">It is associated with a low risk of pulmonary embolism:</span></strong><span style=\"font-size:12.0pt\"> It carries a high risk of pulmonary embolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phlegmasia cerulea dolens is a surgical emergency requiring immediate intervention to prevent limb ischemia and gangrene.</span></span></p>",
    "correct_choice_id": 28553,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 7147,
    "choices": [
      {
        "id": 28556,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">McConnell&#39;s sign </span></span></span></p>"
      },
      {
        "id": 28557,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">D sign </span></span></span></p>"
      },
      {
        "id": 28558,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">60/60 sign </span></span></span></p>"
      },
      {
        "id": 28559,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">RV strain pattern</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with suspected acute pulmonary embolism (PE) undergoes transthoracic echocardiography (TTE). 2D Echo shows akinesia of the right ventricle (RV) mid-free wall with preserved contraction of the RV apex. What is this characteristic finding called?</span></span></span></p>",
    "unique_key": "Q8373432",
    "question_audio": null,
    "question_video": null,
    "map_id": 20097,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>A)</strong> <strong>McConnell&#39;s sign</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">McConnell&#39;s sign is a specific echocardiographic finding in PE, representing regional RV dysfunction due to increased pressure from the embolus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. D sign:</span></strong><span style=\"font-size:12.0pt\"> Indicates RV dilation in PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 60/60 sign:</span></strong><span style=\"font-size:12.0pt\"> Refers to specific Doppler findings in pulmonary hypertension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. RV strain pattern:</span></strong><span style=\"font-size:12.0pt\"> A more general term for RV dysfunction, not specific to PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">McConnell&#39;s sign is a specific echocardiographic finding in acute pulmonary embolism, indicating regional right ventricular dysfunction.</span></span></p>",
    "correct_choice_id": 28556,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 7148,
    "choices": [
      {
        "id": 28560,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Massive PE </span></span></span></p>"
      },
      {
        "id": 28561,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sub-massive PE </span></span></span></p>"
      },
      {
        "id": 28562,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low risk PE&nbsp;</span></span></span></p>"
      },
      {
        "id": 28563,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unclassified</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman on chronic steroid therapy presents with sudden-onset shortness of breath and syncope. CT pulmonary angiography (CTPA) confirms a large saddle Pulmonary Embolism (PE). She is normotensive, but echocardiogram shows moderate right ventricular (RV) dysfunction and elevated brain natriuretic peptide (BNP). Which of the following classifies her Pulmonary Embolism?</span></span></span></p>",
    "unique_key": "Q6805166",
    "question_audio": null,
    "question_video": null,
    "map_id": 20098,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Sub-massive PE </span></strong></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This classification is for patients who are normotensive (systolic BP &ge; 90 mmHg) but have evidence of right ventricular (RV) dysfunction or myocardial injury. In this case, the patient has moderate RV dysfunction and elevated BNP, which are indicative of RV strain, classifying her condition as submassive PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Massive PE:</span></strong><span style=\"font-size:12.0pt\"> Characterized by sustained hypotension (systolic BP &lt; 90 mmHg for at least 15 minutes), shock, or requiring inotropic support. This is not applicable here as the patient is normotensive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Low Risk PE:</span></strong><span style=\"font-size:12.0pt\"> Patients are normotensive and do not have evidence of RV dysfunction or myocardial injury. This is incorrect because the patient has RV dysfunction and elevated BNP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. <strong>Unclassified:</strong> Not a standard clinical classification for PE. PE cases are typically classified as massive, submassive, or low risk based on hemodynamic stability and RV function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Submassive PE is characterized by normotension with evidence of right ventricular dysfunction or myocardial injury.</span></span></span></p>",
    "correct_choice_id": 28561,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 7149,
    "choices": [
      {
        "id": 28564,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deep vein thrombosis (DVT) </span></span></span></p>"
      },
      {
        "id": 28565,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism (PE) </span></span></span></p>"
      },
      {
        "id": 28566,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis </span></span></span></p>"
      },
      {
        "id": 28567,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron-deficiency anemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with a history of recent surgery presents with swelling and pain in his right calf. Which of the following conditions would NOT be associated with an elevated D-dimer level?</span></span></span></p>",
    "unique_key": "Q9066785",
    "question_audio": null,
    "question_video": null,
    "map_id": 20099,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Iron-deficiency anemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron-deficiency anemia does not typically activate the coagulation system or fibrinolysis, which are the processes that lead to elevated D-dimer levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Causes of elevated D-dimer levels</span><em><span style=\"font-size:12.0pt\">:</span></em><span style=\"font-size:12.0pt\"> Venous or arterial thrombosis, DIC, Advanced age, Recent surgery or trauma, Cancer, Pregnancy or puerperium, Infection/sepsis, Chronic inflammation, Liver/renal disease, thrombolytic therapy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. DVT:</span></strong><span style=\"font-size:12.0pt\"> DVT leads to clot formation and breakdown, resulting in elevated D-dimer levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PE:</span></strong><span style=\"font-size:12.0pt\"> PE is often preceded by DVT, leading to elevated D-dimer levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sepsis:</span></strong><span style=\"font-size:12.0pt\"> Sepsis can cause systemic inflammation and activation of coagulation, leading to elevated D-dimer levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron-deficiency anemia does not typically lead to elevated D-dimer levels, unlike conditions that activate the coagulation system or fibrinolysis.</span></span></span></p>",
    "correct_choice_id": 28567,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7152,
    "choices": [
      {
        "id": 28576,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT Pulmonary angiogram </span></span></span></p>"
      },
      {
        "id": 28577,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECG </span></span></span></p>"
      },
      {
        "id": 28578,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram </span></span></span></p>"
      },
      {
        "id": 28579,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MRI&nbsp;</span></span></span><span style=\"font-family:&quot;Segoe UI&quot;,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">of infont of thorax</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old patient with allergic bronchopulmonary aspergillosis (ABPA) on chronic steroids presents to the ER with swelling and pain in the left lower limb and sudden onset breathlessness. On arrival, the patient is hemodynamically stable but the shock index is &gt;1. Compression ultrasound showed a left lower limb DVT. Which of the following tests would be the most definitive to confirm the probable diagnosis?</span></span></p>",
    "unique_key": "Q7319869",
    "question_audio": null,
    "question_video": null,
    "map_id": 20100,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CT Pulmonary angiogram (CTPA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Given the clinical findings, the patient is likely to be having Pulmonary Embolism (PE). CTPA is the gold standard for diagnosing PE. It provides a detailed visualization of the pulmonary vasculature, allowing for the detection of filling defects indicative of emboli. This is especially important in patients with underlying lung disease like ABPA, where other tests might be less reliable.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ECG:</span></strong><span style=\"font-size:12.0pt\"> Might show nonspecific signs like sinus tachycardia or right heart strain but cannot definitively diagnose PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Echocardiogram:</span></strong><span style=\"font-size:12.0pt\"> Can detect right ventricular dysfunction, a common finding in PE, but not always diagnostic, especially in patients with pre-existing cardiac conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. MRI&nbsp;</span></strong></span></span><strong><span style=\"font-family:&quot;Segoe UI&quot;,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">of infont of thorax</span></span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Less readily available and not as sensitive or specific as CTPA for diagnosing PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT Pulmonary Angiogram (CTPA) is the gold standard for diagnosing pulmonary embolism, providing detailed visualization of the pulmonary vasculature to detect emboli.</span></span></p>",
    "correct_choice_id": 28576,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 7154,
    "choices": [
      {
        "id": 28584,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LMWH (Low Molecular Weight Heparin) </span></span></span></p>"
      },
      {
        "id": 28585,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warfarin </span></span></span></p>"
      },
      {
        "id": 28586,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bivalirudin </span></span></span></p>"
      },
      {
        "id": 28587,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alteplase</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old male with prostate cancer presents with worsening breathlessness, chest pain, and syncope. He is tachycardic and CTPA confirms pulmonary embolism (PE). Cardiac troponins and BNP levels are normal, but echocardiogram shows reduced RV function. Which of the following is the most appropriate in-hospital treatment for this patient?</span></span></span></p>",
    "unique_key": "Q4395249",
    "question_audio": null,
    "question_video": null,
    "map_id": 20101,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) LMWH (Low Molecular Weight Heparin)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a cancer patient with intermediate-low risk PE (no hemodynamic instability but with RV dysfunction), LMWH is the preferred initial anticoagulant due to its efficacy and lower bleeding risk compared to thrombolytics.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Warfarin:</span></strong><span style=\"font-size:12.0pt\"> Requires close INR monitoring, has a delayed onset of action and has numerous drug interactions. Hence, not appropriate for in-hospital management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bivalirudin:</span></strong><span style=\"font-size:12.0pt\"> A direct thrombin inhibitor typically used primarily in patients with heparin-induced thrombocytopenia (HIT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Alteplase:</span></strong><span style=\"font-size:12.0pt\"> A thrombolytic agent reserved for high-risk PE with hemodynamic instability.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cancer patients with intermediate-low risk pulmonary embolism (PE), Low Molecular Weight Heparin (LMWH) is preferred due to its efficacy and lower bleeding risk.</span></span></p>",
    "correct_choice_id": 28584,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7156,
    "choices": [
      {
        "id": 28592,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus tachycardia is the most common finding&nbsp;</span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in PE</span></span></p>"
      },
      {
        "id": 28593,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S1Q3T3 is pathognomonic of Pulmonary Embolism </span></span></span></p>"
      },
      {
        "id": 28594,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">T-wave inversion in the anterior leads can be a sign of right heart strain </span></span></span></p>"
      },
      {
        "id": 28595,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ECG findings in this patient are suggestive of Pulmonary embolism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old gentleman with a family history of colorectal cancer presents with pleuritic chest pain, breathlessness and syncope. On examination he has a swollen right leg. His ECG is shown. Which of the following statements regarding the condition is NOT true?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-101539.jpg\" style=\"height:179px; width:350px\" /></span></span></span></p>",
    "unique_key": "Q6730359",
    "question_audio": null,
    "question_video": null,
    "map_id": 20102,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) S1Q3T3 is pathognomonic of Pulmonary Embolism </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></span>B.</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While the S1Q3T3 pattern (deep S in lead I, Q wave in lead III, inverted T in lead III) is highly suggestive of PE, it is not pathognomonic (specific) and can occur in other conditions causing acute right heart strain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sinus tachycardia is the most common ECG finding in PE:</span></strong><span style=\"font-size:12.0pt\"> True.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. T-wave inversions in the anterior leads can be a sign of right heart strain:</span></strong><span style=\"font-size:12.0pt\"> True.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The ECG findings in this patient are suggestive of PE:</span></strong><span style=\"font-size:12.0pt\"> Patient has the classic S1Q3T3 pattern along with T inversions in anterior leads and RBBB. ECG also shows a borderline right axis deviation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The S1Q3T3 pattern is highly suggestive of pulmonary embolism (PE) but is not pathognomonic, as it can occur in other conditions causing acute right heart strain.</span></span></span></p>",
    "correct_choice_id": 28593,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 7158,
    "choices": [
      {
        "id": 28600,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat thrombolysis with a higher dose of alteplase </span></span></span></p>"
      },
      {
        "id": 28601,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer anticoagulation with heparin </span></span></span></p>"
      },
      {
        "id": 28602,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proceed with surgical embolectomy </span></span></span></p>"
      },
      {
        "id": 28603,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue supportive care and monitor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with massive pulmonary embolism and shock undergoes thrombolysis with alteplase, but their blood pressure remains low despite aggressive fluid resuscitation, and oxygen saturation does not improve. What is the next most appropriate step in management?</span></span></p>",
    "unique_key": "Q9426546",
    "question_audio": null,
    "question_video": null,
    "map_id": 20103,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Proceed with surgical embolectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></span></strong><strong>C.</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cases of massive PE with hemodynamic instability where thrombolysis fails, surgical or catheter-directed embolectomy is the next step to remove the clot and restore blood flow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Repeat thrombolysis with a higher dose of alteplase</span></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Not recommended due to increased bleeding risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\"><strong>Administer anticoagulation with heparin</strong></span><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Indicated after successful thrombolysis or embolectomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><strong><span style=\"font-size:12.0pt\">Continue supportive care and monitor:</span></strong><span style=\"font-size:12.0pt\"> Not sufficient in a patient with persistent shock and hypoxemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cases of massive PE with hemodynamic instability where thrombolysis fails, surgical or catheter-directed embolectomy is the next step to remove the clot and restore blood flow.</span></span></span></p>",
    "correct_choice_id": 28602,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 7160,
    "choices": [
      {
        "id": 28608,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SBP &le; 90 mm Hg </span></span></span></p>"
      },
      {
        "id": 28609,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent immobilization </span></span></span></p>"
      },
      {
        "id": 28610,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of DVT or PE </span></span></span></p>"
      },
      {
        "id": 28611,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart rate &gt; 100 beats/minute</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman with no significant past medical history presents with pleuritic chest pain and shortness of breath after a long flight. Her heart rate is 110 beats per minute. Which of the following would NOT increase her Wells probability score for pulmonary embolism (PE)?</span></span></p>",
    "unique_key": "Q5183437",
    "question_audio": null,
    "question_video": null,
    "map_id": 20104,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) SBP &le; 90 mm Hg</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemoptysis, while a possible symptom of PE, is not a criterion in the modified Wells score for PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Recent immobilization:</span></strong><span style=\"font-size:12.0pt\"> Increased risk of DVT and PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. History of DVT or PE:</span></strong><span style=\"font-size:12.0pt\"> Increases the likelihood of recurrent events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Heart rate &gt; 100 beats/minute:</span></strong><span style=\"font-size:12.0pt\"> A sign of tachycardia, which can be seen in PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective :</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemoptysis, while a possible symptom of PE, is not a criterion in the modified Wells score for PE.</span></span></p>",
    "correct_choice_id": 28608,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 7162,
    "choices": [
      {
        "id": 28616,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hamptoms Hump</span></span></p>"
      },
      {
        "id": 28617,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palla sign</span></span></p>"
      },
      {
        "id": 28618,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Westermark sig</span></span></p>"
      },
      {
        "id": 28619,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Split pleura sign</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presented with sudden onset chest pain and syncope. ECG showed sinus tachycardia. CTPA confirmed Pulmonary embolism. Chest radiograph given below. Identify the sign found on CXR?</span></span></p>\r\n\r\n<p><br />\r\n<br />\r\n<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/whatsapp-image-2024-06-20-at-103358-am.jpeg\" style=\"height:265px; width:300px\" /></p>",
    "unique_key": "Q8527459",
    "question_audio": null,
    "question_video": null,
    "map_id": 20105,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Palla sign</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enlargement of right descending pulmonary artery is termed Palla sign. Image shows enlargement mimicking right hilar mass.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option A.&nbsp;Hamptons hump:</strong> refers to wedge shaped opacity due to pulmonary infarct.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/24/whatsapp-image-2024-06-24-at-55611-pm.jpeg\" style=\"height:320px; width:400px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Westermark sign:</strong> Refers to focal oligemia due to cutoff of blood supply</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture3.jpg\" style=\"height:297px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Split pleura sign</strong>: refers to thickening and separation of pleura with enhancement occurring in empyema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective :</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Enlargement of right descending pulmonary artery is termed Palla sign.</span></span></span></p>",
    "correct_choice_id": 28617,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 7163,
    "choices": [
      {
        "id": 28620,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the dose of anticoagulants </span></span></span></p>"
      },
      {
        "id": 28621,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Place an inferior vena cava (IVC) filter </span></span></span></p>"
      },
      {
        "id": 28622,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch to a different anticoagulant </span></span></span></p>"
      },
      {
        "id": 28623,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perform an embolectomy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man presents with acute pulmonary embolism (PE). He is currently on anticoagulation therapy but has developed a major gastrointestinal bleed. Which of the following is the best next step?</span></span></span></p>",
    "unique_key": "Q3604217",
    "question_audio": null,
    "question_video": null,
    "map_id": 20106,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Place an inferior vena cava (IVC) filter</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">An IVC filter is recommended for patients with PE who cannot continue anticoagulation therapy due to major bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase the dose of anticoagulants</span></strong><span style=\"font-size:12.0pt\">: This would exacerbate the bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Switch to a different anticoagulant</span></strong><span style=\"font-size:12.0pt\">: This is not advisable in the context of active major bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Perform an embolectomy</span></strong><span style=\"font-size:12.0pt\">: This is an invasive procedure not typically indicated as a primary step when an IVC filter can effectively prevent further emboli.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective </span></strong><span style=\"font-size:12.0pt\">:</span></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An IVC filter is recommended for patients with PE who cannot continue anticoagulation therapy due to major bleeding.</span></span></p>",
    "correct_choice_id": 28621,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49912,
    "choices": [
      {
        "id": 199207,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral antibiotics </span></span></span></p>"
      },
      {
        "id": 199208,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warm compresses and NSAIDs </span></span></span></p>"
      },
      {
        "id": 199209,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heparin therapy </span></span></span></p>"
      },
      {
        "id": 199210,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical removal of the affected vein</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old female presents with redness, swelling, and tenderness along a superficial vein in her upper arm following an IV catheter placement. There is no fever or signs of systemic infection. What is the initial treatment?</span></span></span></p>",
    "unique_key": "Q3982621",
    "question_audio": null,
    "question_video": null,
    "map_id": 24884,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Warm compresses and NSAIDs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial treatment for catheter-associated superficial thrombophlebitis includes conservative measures like warm compresses and NSAIDs to relieve symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oral antibiotics</span></strong><span style=\"font-size:12.0pt\">: Not necessary unless there are signs of infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Heparin therapy</span></strong><span style=\"font-size:12.0pt\">: Anticoagulation is not needed unless there is extension into deep veins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Surgical removal of the affected vein</span></strong><span style=\"font-size:12.0pt\">: Surgery is not indicated for initial treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective </span></strong><span style=\"font-size:12.0pt\">: </span></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial treatment for catheter-associated superficial thrombophlebitis includes conservative measures like warm compresses and NSAIDs.</span></span></span></p>",
    "correct_choice_id": 199208,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49913,
    "choices": [
      {
        "id": 199211,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Superficial femoral vein</span></span></p>"
      },
      {
        "id": 199212,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Great saphenous vein</span></span></p>"
      },
      {
        "id": 199213,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Common femoral vein</span></span></p>"
      },
      {
        "id": 199214,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Popliteal vein</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombosis in which of the following is least likely to cause pulmonary embolism? </span></span></p>",
    "unique_key": "Q2736659",
    "question_audio": null,
    "question_video": null,
    "map_id": 24885,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Great saphenous vein</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Great saphenous vein is part of the superficial venous system of the lower limb along with great saphenous vein and very unlikely to cause pulmonary embolism</span></span></span></p>\r\n\r\n<p><br />\r\n<strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A.</strong>&nbsp;</span><strong><span style=\"font-size:12.0pt\">Superficial femoral vein:</span></strong><span style=\"font-size:12.0pt\"> Although termed superficial, SFV is part of deep venous system</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C</strong></span><span style=\"font-size:12.0pt\"><strong>. Common femoral vein</strong> <strong>and</strong> <strong>D.</strong> <strong>Popliteal vein:</strong> are veins of the deep venous system and thrombus propagation can cause pulmonary embolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombosis in great saphenous vein is least likely to cause pulmonary embolism.</span></span></span></p>",
    "correct_choice_id": 199212,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49914,
    "choices": [
      {
        "id": 199215,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT pulmonary angiography (CTPA) </span></span></span></p>"
      },
      {
        "id": 199216,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">V/Q scan </span></span></span></p>"
      },
      {
        "id": 199217,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">D-dimer assay </span></span></span></p>"
      },
      {
        "id": 199218,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old male with chronic kidney disease (CKD) stage 4 presents to the emergency department with acute onset shortness of breath and pleuritic chest pain. His D-dimer test is elevated, and clinical examination raises suspicion for pulmonary embolism (PE). What is the preferred diagnostic test in this scenario?</span></span></span></p>",
    "unique_key": "Q4707439",
    "question_audio": null,
    "question_video": null,
    "map_id": 24886,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) V/Q scan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with advanced chronic kidney disease, a V/Q scan is preferred for diagnosing PE because it does not require the use of iodinated contrast agents, which are nephrotoxic and can worsen renal function. A V/Q scan assesses the ventilation/perfusion mismatch in the lungs and is a reliable alternative for patients with contraindications to contrast agents.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT pulmonary angiography (CTPA)</span></strong><span style=\"font-size:12.0pt\">: Although CTPA is the gold standard for PE diagnosis, it requires iodinated contrast, which can cause contrast-induced nephropathy in patients with CKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. D-dimer assay</span></strong><span style=\"font-size:12.0pt\">: While useful as an initial screening test, a positive D-dimer is not definitive for diagnosing PE and must be followed by imaging studies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: This can identify right heart strain, a secondary effect of PE, but is not sufficient for primary diagnosis of PE and does not provide direct visualization of pulmonary emboli.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with advanced chronic kidney disease, a V/Q scan is preferred for diagnosing PE.</span></span></span></p>",
    "correct_choice_id": 199216,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 49916,
    "choices": [
      {
        "id": 199223,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term anticoagulation </span></span></span></p>"
      },
      {
        "id": 199224,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Compression therapy </span></span></span></p>"
      },
      {
        "id": 199225,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical vein stripping </span></span></span></p>"
      },
      {
        "id": 199226,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic corticosteroids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 62-year-old woman with a history of deep vein thrombosis (DVT) treated one year ago presents with complaints of persistent leg swelling, pain, and hyperpigmentation around her ankles. What is the recommended initial management for her condition?</span></span></span></p>",
    "unique_key": "Q3238818",
    "question_audio": null,
    "question_video": null,
    "map_id": 24888,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Compression therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post-thrombotic syndrome (PTS) is a long-term complication of DVT characterized by chronic leg pain, swelling, and skin changes due to venous insufficiency. It occurs as a result of damage to the venous valves and obstruction of blood flow following a DVT. Compression therapy is the mainstay of treatment for post-thrombotic syndrome (PTS). It helps to reduce swelling, improve venous return, and alleviate symptoms of pain and discomfort.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Long-term anticoagulation</span></strong><span style=\"font-size:12.0pt\">: Prevents new clots but does not treat the chronic symptoms of PTS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Surgical vein stripping</span></strong><span style=\"font-size:12.0pt\">: Not typically indicated for PTS; it&#39;s more for varicose veins without significant post-thrombotic changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Systemic corticosteroids</span></strong><span style=\"font-size:12.0pt\">: Not a treatment for PTS and do not address the underlying venous insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Compression therapy is the mainstay of treatment for post-thrombotic syndrome (PTS).</span></span></span></p>",
    "correct_choice_id": 199224,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20162,
    "choices": [
      {
        "id": 80609,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MRI angiogram of the thorax </span></span></span></p>"
      },
      {
        "id": 80610,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT pulmonary angiogram (CTPA) </span></span></span></p>"
      },
      {
        "id": 80611,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography </span></span></span></p>"
      },
      {
        "id": 80612,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start prostacyclin therapy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old banker with a history of DVT presents with progressive dyspnea, chest tightness, and syncope. PFTs are normal, but DLCO is reduced. ECHO shows elevated Right Ventricular Systolic Pressure (RVSP). What is the next BEST step?</span></span></p>",
    "unique_key": "Q7968353",
    "question_audio": null,
    "question_video": null,
    "map_id": 20107,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans. B)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>CT pulmonary angiogram</strong> <strong>CTPA</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The history, symptoms, and elevated RVSP raise strong suspicion for <strong>chronic thromboembolic pulmonary hypertension (CTEPH).</strong> CTPA is the primary imaging modality to identify chronic thromboembolic obstructions in pulmonary arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MRI angiogram of the thorax:</span></strong><span style=\"font-size:12.0pt\"> While useful for some vascular imaging, not as sensitive or readily available as CTPA for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Coronary angiography:</span></strong><span style=\"font-size:12.0pt\"> This assesses coronary arteries, not pulmonary circulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Start prostacyclin therapy:</span></strong><span style=\"font-size:12.0pt\"> This is a treatment option for PAH, but not the initial step in diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CTPA is the primary imaging modality for diagnosing chronic thromboembolic pulmonary hypertension (CTEPH).</span></span></span></p>",
    "correct_choice_id": 80610,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20163,
    "choices": [
      {
        "id": 80613,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riociguat </span></span></span></p>"
      },
      {
        "id": 80614,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sildenafil </span></span></span></p>"
      },
      {
        "id": 80615,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macitentan </span></span></span></p>"
      },
      {
        "id": 80616,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epoprostenol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with a history of pulmonary embolism (PE) has undergone pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH) but continues to experience exertional dyspnea and fatigue. Which of the following is an approved medication for treatment of CTEPH?</span></span></span></p>",
    "unique_key": "Q7162526",
    "question_audio": null,
    "question_video": null,
    "map_id": 20108,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Riociguat</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riociguat is a soluble guanylate cyclase stimulator specifically approved for the treatment of persistent/recurrent CTEPH after pulmonary endarterectomy, improving exercise capacity and hemodynamics.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sildenafil:</span></strong><span style=\"font-size:12.0pt\"> Primarily used in pulmonary arterial hypertension (PAH), not CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Macitentan:</span></strong><span style=\"font-size:12.0pt\"> An endothelin receptor antagonist, not specifically indicated for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Espoprostenol:</span></strong><span style=\"font-size:12.0pt\"> </span><span style=\"font-size:12.0pt\">Espoprostenol is a PGI2 analog used in PAAH but not approved for CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Riociguat is an approved medication for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy.</span></strong></span></span></p>",
    "correct_choice_id": 80613,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20164,
    "choices": [
      {
        "id": 80617,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brain Natriuretic Peptide (BNP) levels </span></span></span></p>"
      },
      {
        "id": 80618,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WHO functional class </span></span></span></p>"
      },
      {
        "id": 80619,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mean pulmonary artery pressure (mPAP) </span></span></span></p>"
      },
      {
        "id": 80620,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac index (CI)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with idiopathic pulmonary arterial hypertension (PAH) is being evaluated for disease progression. Which hemodynamic parameter is the LEAST reliable predictor of survival in PAH patients?</span></span></p>",
    "unique_key": "Q3780879",
    "question_audio": null,
    "question_video": null,
    "map_id": 20109,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Mean pulmonary artery pressure (mPAP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While mean pulmonary artery pressure (mPAP) is important for the diagnosis and monitoring of PAH, it is not the most reliable predictor of survival. Other parameters such as cardiac index (CI), WHO functional class, and BNP levels are more closely associated with patient outcomes and survival rates in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Poor prognostic markers in PAH: Features of RVF (ex., </span>&nbsp;<span style=\"font-size:12.0pt\">&nbsp;RAP), WHO class IV, 6MWT &lt; 300m, VO2max &lt; 10.4 mL/kg/min, CI &lt; 2L/min/m2, &uarr; BNP, &uarr; PVR</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Brain Natriuretic Peptide (BNP) levels</span></strong><span style=\"font-size:12.0pt\">: Elevated BNP levels correlate with right ventricular dysfunction and are a strong predictor of morbidity and mortality in PAH patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. WHO functional class</span></strong><span style=\"font-size:12.0pt\">: The functional classification of patients based on symptoms and exercise capacity is a well-established predictor of survival in PAH.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiac index (CI)</span></strong><span style=\"font-size:12.0pt\">: A measure of cardiac output relative to body size, CI is a critical parameter in assessing the severity and prognosis of PAH. A lower CI is associated with worse outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mean pulmonary artery pressure (mPAP) is not the most reliable predictor of survival in PAH compared to parameters such as cardiac index (CI), WHO functional class, and BNP levels.</span></span></span></p>",
    "correct_choice_id": 80619,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20165,
    "choices": [
      {
        "id": 80621,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;15 mmHg </span></span></span></p>"
      },
      {
        "id": 80622,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;20 mmHg </span></span></span></p>"
      },
      {
        "id": 80623,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;25 mmHg </span></span></span></p>"
      },
      {
        "id": 80624,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;30 mmHg</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 48-year-old man with systemic sclerosis undergoes right heart catheterization. What is the threshold value of mean pulmonary arterial pressure (mPAP) that confirms the diagnosis of pulmonary hypertension (PH)?</span></span></span></p>",
    "unique_key": "Q8149968",
    "question_audio": null,
    "question_video": null,
    "map_id": 20110,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) &gt;20 mmHg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PH is defined as mPAP &gt; 20 mmHg at rest. Values above this threshold indicate increased pressure in the pulmonary circulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. &gt;15 mmHg:</span></strong><span style=\"font-size:12.0pt\"> Current cut off is &gt; 20 mm Hg for diagnosing PH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &gt;25 mmHg:</span></strong><span style=\"font-size:12.0pt\"> Old recommendation, not followed now.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &gt;30 mmHg:</span></strong><span style=\"font-size:12.0pt\"> False</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary hypertension is defined as mPAP &gt; 20 mmHg at rest</span></span></p>",
    "correct_choice_id": 80622,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20166,
    "choices": [
      {
        "id": 80625,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 </span></span></span></p>"
      },
      {
        "id": 80626,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFTR </span></span></span></p>"
      },
      {
        "id": 80627,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BMPR2 </span></span></span></p>"
      },
      {
        "id": 80628,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">KCNH2</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a family history of early-onset pulmonary hypertension presents with exertional dyspnea. Genetic testing is being considered. Which gene is most commonly associated with hereditary pulmonary arterial hypertension?</span></span></p>",
    "unique_key": "Q2722021",
    "question_audio": null,
    "question_video": null,
    "map_id": 20111,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) BMPR2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the BMPR2 gene are the most frequent cause of hereditary PAH, leading to dysregulation of pulmonary vascular growth and remodeling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BRCA1:</span></strong><span style=\"font-size:12.0pt\"> Associated with breast and ovarian cancer susceptibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CFTR:</span></strong><span style=\"font-size:12.0pt\"> Associated with cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. KCNH2:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Associated with long QT syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the BMPR2 gene are the most frequent cause of hereditary pulmonary arterial hypertension (PAH), leading to dysregulation of pulmonary vascular growth and remodeling.</span></span></span></p>",
    "correct_choice_id": 80627,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20167,
    "choices": [
      {
        "id": 80629,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial Pulmonary artery hypertension (FPAH)</span></span></span></p>"
      },
      {
        "id": 80630,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic thromboembolic pulmonary hypertension (CTEPH)</span></span></span></p>"
      },
      {
        "id": 80631,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) </span></span></span></p>"
      },
      {
        "id": 80632,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Associated Pulmonary artery hypertension (APAH)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman presents with progressive dyspnea. Initial CXR, CT, and PFT are normal. However, echocardiography reveals an elevated RVSP of 55 mmHg. Right heart catheterization reveals normal PCWP and mPAP of 35 mmHg. What is the most likely cause of her dyspnea?</span></span></p>",
    "unique_key": "Q5624830",
    "question_audio": null,
    "question_video": null,
    "map_id": 20112,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C)&nbsp;Idiopathic pulmonary arterial hypertension (IPAH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) is diagnosed in the absence of known familial, associated, or secondary causes of PAH. The findings of elevated RVSP, normal PCWP, and elevated mPAP (&ge; 25 mmHg) on right heart catheterization are consistent with PAH. Given the normal initial imaging and PFTs, IPAH is the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Familial Pulmonary artery hypertension (FPAH):</span></strong><span style=\"font-size:12.0pt\"> While this is a possible cause, there is no indication of a family history provided in the case, making it less likely compared to IPAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chronic thromboembolic pulmonary hypertension (CTEPH):</span></strong><span style=\"font-size:12.0pt\"> Typically, patients have a history of thromboembolic events, and CT may show chronic thromboembolic disease. The normal CT in this case makes CTEPH less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Associated Pulmonary artery hypertension (APAH):</span></strong><span style=\"font-size:12.0pt\"> This refers to PAH associated with other conditions (e.g., connective tissue disease, HIV, portal hypertension). There is no mention of such associated conditions in the patient&#39;s history, making IPAH more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary arterial hypertension (IPAH) is diagnosed in the absence of known familial, associated, or secondary causes of PAH, and is characterized by elevated RVSP, normal PCWP, and elevated mPAP (&ge; 25 mmHg).</span></span></p>",
    "correct_choice_id": 80631,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20168,
    "choices": [
      {
        "id": 80633,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 1</span></span></span></p>"
      },
      {
        "id": 80634,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 2</span></span></span></p>"
      },
      {
        "id": 80635,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 3</span></span></span></p>"
      },
      {
        "id": 80636,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Group 4</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old smoker with progressive breathlessness for one year presents with hyperinflated lungs on chest X-ray and moderate airflow obstruction on PFTs. Echocardiogram reveals an RVSP of 60 mmHg. According to the WHO classification, which group of pulmonary hypertension (PH) does this patient most likely belong to?</span></span></p>",
    "unique_key": "Q1445748",
    "question_audio": null,
    "question_video": null,
    "map_id": 20113,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Group 3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history of smoking, hyperinflated lungs on X-ray, and obstructive PFTs point towards an underlying lung disease (COPD), which is a common cause of Group 3 PH (PH due to Lung Diseases and/or Hypoxemia)1`</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Group 1: PAH -&nbsp;</span></strong><span style=\"font-size:12.0pt\">Typically occurs in younger individuals without significant lung disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Group 2:</span></strong><span style=\"font-size:12.0pt\"> Would be caused by left heart disease, not supported by the clinical picture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Group 4: CTEPH -&nbsp;</span></strong><span style=\"font-size:12.0pt\">While possible in smokers, the absence of a prior PE history makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history of smoking, hyperinflated lungs on X-ray, and obstructive PFTs point towards an underlying lung disease (COPD), which is a common cause of Group 3 PH (PH due to Lung Diseases and/or Hypoxemia).</span></span></span></p>",
    "correct_choice_id": 80635,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20169,
    "choices": [
      {
        "id": 80637,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension </span></span></span></p>"
      },
      {
        "id": 80638,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post-capillary pulmonary hypertension </span></span></span></p>"
      },
      {
        "id": 80639,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Combined post- and pre-capillary pulmonary hypertension</span></span></span></p>"
      },
      {
        "id": 80640,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient undergoes right heart catheterization (RHC) for evaluation of pulmonary hypertension. The results show:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP: 50 mmHg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PCWP: 40 mmHg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PVR: 2 Wood units</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the likely type of pulmonary hypertension this patient is suffering from?</span></span></span></p>",
    "unique_key": "Q5371019",
    "question_audio": null,
    "question_video": null,
    "map_id": 20114,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Post-capillary pulmonary hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The elevated mPAP and PCWP (which reflects left atrial pressure) with normal PVR are characteristic of post-capillary pulmonary hypertension, often caused by left heart disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><strong><span style=\"font-size:12.0pt\">. Pre-capillary pulmonary hypertension</span></strong><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Would show elevated PVR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12pt\">Combined post- and pre-capillary pulmonary hypertension:</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><span style=\"font-size:12pt\">Would show elevated mPAP, PCWP, and PVR.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12pt\">Idiopathic pulmonary arterial hypertension (IPAH):</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><span style=\"font-size:12pt\">A type of pre-capillary PH, would have elevated PVR.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The elevated mPAP and PCWP (which reflects left atrial pressure) with normal PVR are characteristic of post-capillary pulmonary hypertension, often caused by left heart disease.</span></span></span></p>",
    "correct_choice_id": 80638,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20170,
    "choices": [
      {
        "id": 80641,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nifedipine </span></span></span></p>"
      },
      {
        "id": 80642,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ambrisentan </span></span></span></p>"
      },
      {
        "id": 80643,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epoprostenol </span></span></span></p>"
      },
      {
        "id": 80644,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tadalafil</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old woman with Pulmonary arterial hypertension (PAH) undergoes a vasoreactivity test during right heart catheterization. The test is positive, showing a significant decrease in mPAP with vasodilators. Which medication would be the most appropriate initial treatment for this patient?</span></span></p>",
    "unique_key": "Q2899499",
    "question_audio": null,
    "question_video": null,
    "map_id": 20115,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Nifedipine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive vasoreactivity testing suggests that the patient&#39;s pulmonary vasculature is responsive to vasodilators. High-dose calcium channel blockers (CCBs) like nifedipine are the first-line therapy for vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ambrisentan:</span></strong><span style=\"font-size:12.0pt\"> Endothelin receptor antagonist, used in non-vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Epoprostenol:</span></strong><span style=\"font-size:12.0pt\"> Prostacyclin analog, used in severe PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tadalafil:</span></strong><span style=\"font-size:12.0pt\"> PDE5 inhibitor, used in non-vasoreactive PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Positive vasoreactivity testing suggests that the patient&#39;s pulmonary vasculature is responsive to vasodilators. High-dose calcium channel blockers (CCBs) like nifedipine are the first-line therapy for vasoreactive PAH.</span></span></p>",
    "correct_choice_id": 80641,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20171,
    "choices": [
      {
        "id": 80645,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept </span></span></span></p>"
      },
      {
        "id": 80646,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Luspatercept </span></span></span></p>"
      },
      {
        "id": 80647,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Selexipag</span></span></span></p>"
      },
      {
        "id": 80648,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macitentan</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with pulmonary arterial hypertension (PAH) is being considered for a novel therapy that targets the activin signaling pathway to reduce pulmonary vascular remodeling. Which medication is an activin receptor fusion protein that has been shown to improve cardiopulmonary function in PAH?</span></span></span></p>",
    "unique_key": "Q2472379",
    "question_audio": null,
    "question_video": null,
    "map_id": 20116,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Sotatercept</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept is an activin receptor type IIA fusion protein that binds and inhibits members of the TGF-&beta; superfamily, including activins, leading to improved hemodynamics and exercise capacity in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Luspatercept:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Activin receptor type IIB fusion protein that binds and inhibits members of the TGF-&beta; superfamily. This reduces SMAD signalling and increases erythroid maturation. Used to treat anemia in MDS and thalassemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Selexipag:</span></strong><span style=\"font-size:12.0pt\"> Prostacyclin receptor agonist used in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Macitentan:</span></strong><span style=\"font-size:12.0pt\"> Endothelin receptor antagonist used in PAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sotatercept is an activin receptor type IIA fusion protein that binds and inhibits members of the TGF-&beta; superfamily, including activins, leading to improved hemodynamics and exercise capacity in PAH.</span></span></span></p>",
    "correct_choice_id": 80645,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 20172,
    "choices": [
      {
        "id": 80649,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term anticoagulation </span></span></span></p>"
      },
      {
        "id": 80650,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy </span></span></span></p>"
      },
      {
        "id": 80651,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Balloon pulmonary angioplasty </span></span></span></p>"
      },
      {
        "id": 80652,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung transplantation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old female presents with progressive dyspnea and exercise intolerance. She has a history of recurrent pulmonary embolisms. Right heart catheterization confirms pulmonary hypertension, and imaging studies show organized thrombi within the pulmonary arteries. Which of the following is considered the best treatment option for her condition?</span></span></span></p>",
    "unique_key": "Q8377250",
    "question_audio": null,
    "question_video": null,
    "map_id": 20120,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary endarterectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy is the best treatment for chronic thromboembolic pulmonary hypertension (CTEPH). It is a surgical procedure that removes organized thrombi from the pulmonary arteries, improving hemodynamics and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Long-term anticoagulation</span></strong><span style=\"font-size:12.0pt\">: Essential for preventing new clots but does not address the existing organized thrombi causing CTEPH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Balloon pulmonary angioplasty</span></strong><span style=\"font-size:12.0pt\">: An option for patients who are not candidates for surgery or have residual disease post-endarterectomy, but not considered the first-line treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung transplantation</span></strong><span style=\"font-size:12.0pt\">: Considered for patients with advanced disease who are not candidates for other treatments, but pulmonary endarterectomy is preferred if feasible.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary endarterectomy is the best treatment for chronic thromboembolic pulmonary hypertension (CTEPH) as it removes organized thrombi from the pulmonary arteries, improving hemodynamics and symptoms.</span></span></span></p>",
    "correct_choice_id": 80650,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 7143,
    "choices": [
      {
        "id": 28540,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diuretics are given to reduce peripheral edema </span></span></span></p>"
      },
      {
        "id": 28541,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen supplementation is given if PO2 is reduced </span></span></span></p>"
      },
      {
        "id": 28542,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For patients with persistent right heart failure, lung transplantation may be considered </span></span></span></p>"
      },
      {
        "id": 28543,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary arterial hypertension is more common in males</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old male presents to the OPD with exertional dyspnea, fatigue, syncope, and peripheral edema. On examination, JVP is raised and a loud P2 is noted. ECHO shows right atrial and right ventricular enlargement with a mean pulmonary artery pressure of 30 mmHg. Which of the following statements is false regarding the condition?</span></span></span></p>",
    "unique_key": "Q5913936",
    "question_audio": null,
    "question_video": null,
    "map_id": 20117,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pulmonary arterial hypertension is more common in males</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic Pulmonary arterial hypertension (IPAH) is actually more common in females than in males. The female-to-male ratio is approximately 3:1 and tend to </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">present in the fourth and fifth decades. Major presenting symptom is dyspnea, which is often insidious. Mean survival of IPAH is 5-6 years, even with therapy. Prognosis is slightly better in males compared to females. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diuretics are given to reduce peripheral edema</span></strong><span style=\"font-size:12.0pt\">: True. Diuretics are commonly used to manage symptoms of right heart failure, including peripheral edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oxygen supplementation is given if PO2 is reduced</span></strong><span style=\"font-size:12.0pt\">: True. Oxygen therapy is used to maintain adequate oxygenation and prevent hypoxemia in PAH patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. For patients with persistent right heart failure, lung transplantation may be considered</span></strong><span style=\"font-size:12.0pt\">: True. Lung transplantation is a treatment option for patients with advanced PAH and right heart failure that is refractory to medical therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic Pulmonary arterial hypertension (IPAH) is more common in females than in males, with a female-to-male ratio of approximately 3:1.</span></span></p>",
    "correct_choice_id": 28543,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7144,
    "choices": [
      {
        "id": 28544,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;20 mm Hg, PCWP &gt; 15 mm Hg </span></span></span></p>"
      },
      {
        "id": 28545,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;25 mm Hg, PCWP &gt; 15 mm Hg </span></span></span></p>"
      },
      {
        "id": 28546,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;20 mm Hg, PCWP &lt; 15 mm Hg</span></span></span></p>"
      },
      {
        "id": 28547,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mPAP &gt;25 mm Hg, PCWP &lt; 15 mm Hg</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old male presents with chronic progressive breathlessness. On examination, his JVP is elevated, there is a loud 2nd heart sound, and bilateral pedal edema. Right heart catheterization reveals pulmonary hypertension. Pre-capillary pulmonary hypertension is defined as:</span></span></p>",
    "unique_key": "Q2643322",
    "question_audio": null,
    "question_video": null,
    "map_id": 20118,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) mPAP &gt;20 mm Hg, PCWP &lt; 15 mm Hg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to updated recommendations, pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. mPAP &gt;20 mm Hg, PCWP &gt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This describes post-capillary pulmonary hypertension, indicating elevated pressures due to left heart disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. mPAP &gt;25 mm Hg, PCWP &gt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This was the previous threshold for post-capillary pulmonary hypertension but has been updated to mPAP &gt;20 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mPAP &gt;25 mm Hg, PCWP &lt; 15 mm Hg</span></strong><span style=\"font-size:12.0pt\">: This was the previous threshold for pre-capillary pulmonary hypertension but has been updated to mPAP &gt;20 mm Hg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>",
    "correct_choice_id": 28546,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7166,
    "choices": [
      {
        "id": 28632,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic obstructive pulmonary disease (COPD) </span></span></span></p>"
      },
      {
        "id": 28633,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary arterial hypertension (IPAH) </span></span></span></p>"
      },
      {
        "id": 28634,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Schistosomiasis </span></span></span></p>"
      },
      {
        "id": 28635,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left heart disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male from an endemic region presents with signs of pulmonary hypertension (PH). He has a history of hepatosplenic disease and portal hypertension. Which of the following is the most likely cause of his pulmonary hypertension?</span></span></span></p>",
    "unique_key": "Q1216890",
    "question_audio": null,
    "question_video": null,
    "map_id": 20119,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Schistosomiasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Globally, schistosomiasis is a common cause of pulmonary hypertension (PH), particularly in individuals with hepatosplenic disease and portal hypertension. The inflammation from the infection triggers maladaptive pulmonary vascular changes. Diagnosis is confirmed by finding the parasite ova in the urine or stool of symptomatic patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic obstructive pulmonary disease (COPD)</span></strong><span style=\"font-size:12.0pt\">: Typically associated with a history of smoking and different clinical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Idiopathic pulmonary arterial hypertension (IPAH)</span></strong><span style=\"font-size:12.0pt\">: A diagnosis of exclusion when other causes of PH are ruled out.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Left heart disease</span></strong><span style=\"font-size:12.0pt\">: Causes post-capillary pulmonary hypertension, typically with elevated PCWP, which is not the scenario here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-capillary pulmonary hypertension is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mm Hg and a pulmonary capillary wedge pressure (PCWP) less than 15 mm Hg.</span></span></span></p>",
    "correct_choice_id": 28634,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 11218,
    "choices": [
      {
        "id": 44838,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC &lt;0.7 and FEV1 &lt; 30%</span></span></span></span></p>"
      },
      {
        "id": 44839,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC &lt;0.7 and FEV1 &lt;70%</span></span></span></span></p>"
      },
      {
        "id": 44840,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC&lt;0.7 and FEV1&lt; 50%</span></span></span></span></p>"
      },
      {
        "id": 44841,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both A and C</span></span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Gold&#39;s criteria for very severe COPD is:</span></span> <span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></p>",
    "unique_key": "Q4486056",
    "question_audio": null,
    "question_video": null,
    "map_id": 20076,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) FEV1/FVC &lt;0.7 and FEV1 &lt; 30%</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for staging chronic obstructive pulmonary disease (COPD), very severe COPD is classified as Stage IV. This stage is defined by a FEV1/FVC ratio (forced expiratory volume in one second/forced vital capacity) less than 0.7, which indicates the presence of airflow limitation, and a FEV1 less than 30% of the predicted value. This level of FEV1 signifies a very severe reduction in lung function and typically corresponds with significant symptoms and health status impairment.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-164040.jpg\" style=\"height:335px; width:992px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Currently Class C+D have been combined and called Class E</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Classification of types have been updated.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference: GOLD 2023 guidelines</span></span></em></strong></p>",
    "correct_choice_id": 44838,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "OlderNEETPG"
    ]
  },
  {
    "id": 20114,
    "choices": [
      {
        "id": 80417,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exposure to cat dander</span></span></span></p>"
      },
      {
        "id": 80418,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent URI with rhinovirus </span></span></span></p>"
      },
      {
        "id": 80419,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Using beta-blocker for hypertension </span></span></span></p>"
      },
      {
        "id": 80420,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consuming large amounts of alcohol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 48-year-old man with a history of asthma presents to the clinic with worsening wheezing, cough, and shortness of breath. Which of the following is the LEAST likely trigger for his current exacerbation?</span></span></span></p>",
    "unique_key": "Q4775977",
    "question_audio": null,
    "question_video": null,
    "map_id": 20067,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>D)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Consuming large amounts of alcohol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While excessive alcohol consumption can indirectly worsen asthma symptoms through dehydration or disrupted sleep, it is not a direct trigger for bronchoconstriction and airway inflammation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Triggers for airway narrowing in asthma: 1. Allergens 2. Irritants 3. Viral infections 4. Exercise and cold, dry air 5. Air pollution 6. Drugs 7. Occupational exposures 8. Hormonal changes 9. Pregnancy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Exposure to cat dander:</span></strong><span style=\"font-size:12.0pt\"> Animal dander is a common allergen and a well-known trigger for asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options B. Recent URI with rhinovirus:</span></strong><span style=\"font-size:12.0pt\"> Viral respiratory infections are among the most common triggers of asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options C. Using a beta-blocker for hypertension:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Beta-blockers can worsen asthma symptoms due to their bronchoconstrictive effects by blocking beta-2 receptors in the airways.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcohol consumption is not a direct trigger for bronchoconstriction and airway inflammation in asthma.</span></span></span></p>",
    "correct_choice_id": 80420,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20115,
    "choices": [
      {
        "id": 80421,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFTR </span></span></span></p>"
      },
      {
        "id": 80422,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 </span></span></span></p>"
      },
      {
        "id": 80423,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ORMDL3 </span></span></span></p>"
      },
      {
        "id": 80424,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">KCNH2</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old boy with a family history of asthma and allergies presents with recurrent wheezing, coughing, and shortness of breath. Genetic testing is being considered to assess his risk of developing persistent asthma. Which of the following genes is MOST consistently associated with asthma susceptibility?</span></span></p>",
    "unique_key": "Q3653607",
    "question_audio": null,
    "question_video": null,
    "map_id": 20068,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) ORMDL3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ORMDL3 is one of the most consistently identified genes associated with asthma susceptibility, particularly in early-onset disease. It is involved in airway remodeling and inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Asssociated genes in asthma:</span></strong> <em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">The most consistently identified include&nbsp;</span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">ORMDL3/GSDMB </span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">(in the 17q21 chromosomal region),&nbsp;</span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">ADAM33</span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">, DPP-10, </span></em><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">TSLP</span></strong><em><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">, IL-12, IL-33, ST2, HLA-DQB1, HLA-DQB2, TLR1, and IL6R.</span></em></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. CFTR:</span></strong><span style=\"font-size:12.0pt\"> Associated with cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options B. BRCA1:</span></strong><span style=\"font-size:12.0pt\"> Associated with breast and ovarian cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options D. KCNH2:</span></strong><span style=\"font-size:12.0pt\"> Associated with long QT syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ORMDL3 is the most <strong>&nbsp;</strong>consistently associated gene with asthma susceptibility. </span></span></p>",
    "correct_choice_id": 80423,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20116,
    "choices": [
      {
        "id": 80425,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised serum IgE levels </span></span></span></p>"
      },
      {
        "id": 80426,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive skin test for inhaled allergens </span></span></span></p>"
      },
      {
        "id": 80427,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nasal polyps </span></span></span></p>"
      },
      {
        "id": 80428,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A type of extrinsic asthma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old woman experiences recurrent episodes of wheezing and nasal congestion after taking aspirin for a headache. Which of the following is most likely associated with her condition?</span></span></p>",
    "unique_key": "Q4909850",
    "question_audio": null,
    "question_video": null,
    "map_id": 20069,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Nasal polyps</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of asthma, aspirin sensitivity, and nasal polyps is characteristic of aspirin-exacerbated respiratory disease (AERD) &ndash; previously called as Samters triad. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Raised serum IgE levels:</span></strong><span style=\"font-size:12.0pt\"> Associated with allergic asthma, not AERD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Positive skin test for inhaled allergens:</span></strong><span style=\"font-size:12.0pt\"> Also associated with allergic asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. A type of extrinsic asthma:</span></strong><span style=\"font-size:12.0pt\"> AERD is a type of intrinsic (non-allergic) asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nasal polyps are characteristic of aspirin-exacerbated respiratory disease (AERD) in patients with asthma and aspirin sensitivity.</span></span></span></p>",
    "correct_choice_id": 80427,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20118,
    "choices": [
      {
        "id": 80433,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest X-ray </span></span></span></p>"
      },
      {
        "id": 80434,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin prick test </span></span></span></p>"
      },
      {
        "id": 80435,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FEV1 measurement </span></span></span></p>"
      },
      {
        "id": 80436,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demonstration of reversible obstruction on PFT</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient experiences recurrent episodes of wheezing, cough, and shortness of breath. Which test is most reliable in confirming the diagnosis of bronchial asthma?</span></span></span></p>",
    "unique_key": "Q3520325",
    "question_audio": null,
    "question_video": null,
    "map_id": 20070,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Demonstration of reversible obstruction on PFT</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A significant improvement in FEV1 after bronchodilator administration on PFTs is the most reliable indicator of reversible airflow obstruction, the hallmark of asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chest X-ray:</span></strong><span style=\"font-size:12.0pt\"> Typically normal in asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Skin prick test:</span></strong><span style=\"font-size:12.0pt\"> Identifies allergic triggers, but not diagnostic of asthma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. FEV1 measurement:</span></strong><span style=\"font-size:12.0pt\"> May show obstruction, but reversibility is key for diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demonstration of reversible obstruction on PFTs is the most reliable test for confirming the diagnosis of bronchial asthma.</span></span></span></p>",
    "correct_choice_id": 80436,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 20119,
    "choices": [
      {
        "id": 80437,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 minutes </span></span></p>"
      },
      {
        "id": 80438,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">15 minutes </span></span></p>"
      },
      {
        "id": 80439,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30 minutes </span></span></span></p>"
      },
      {
        "id": 80440,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">60 minutes</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After administering a short-acting beta-agonist (SABA) inhaler like salbutamol for suspected asthma, how long should you wait before repeating spirometry to assess for reversibility?</span></span></p>",
    "unique_key": "Q7995772",
    "question_audio": null,
    "question_video": null,
    "map_id": 20071,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 15 minutes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The bronchodilator effect of SABAs like salbutamol typically peaks around 15 minutes after administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>5 minutes:</strong> Too soon; the full effect of the bronchodilator may not yet be evident.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"><strong>&nbsp;30 minutes and,&nbsp;</strong></span><strong><span style=\"font-size:12.0pt\">D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>60 minutes</strong>: Waiting longer may lead to the bronchodilator effect wearing off, giving a false negative result.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wait 15 minutes after administering a SABA inhaler like salbutamol before repeating spirometry to assess for reversibility.</span></span></p>",
    "correct_choice_id": 80438,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 20122,
    "choices": [
      {
        "id": 80449,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Improved survival </span></span></p>"
      },
      {
        "id": 80450,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced pulmonary vascular resistance </span></span></p>"
      },
      {
        "id": 80451,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased hematocrit </span></span></p>"
      },
      {
        "id": 80452,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Improved V/Q mismatch</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with stable COPD and resting oxygen saturation of 88% on room air is started on long-term oxygen therapy (LTOT). Which of the following is NOT a known benefit of LTOT in COPD?</span></span></span></p>",
    "unique_key": "Q3337231",
    "question_audio": null,
    "question_video": null,
    "map_id": 20072,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased hematocrit</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term oxygen therapy (LTOT) in COPD patients with chronic hypoxemia (resting SpO2 &le; 88%) has several established benefits:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Improved survival:</span></strong><span style=\"font-size:12.0pt\"> LTOT has been shown to increase survival in patients with severe resting hypoxemia (PaO2 &le; 55 mmHg).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reduced pulmonary vascular resistance:</span></strong><span style=\"font-size:12.0pt\"> LTOT helps reduce pulmonary hypertension by improving oxygenation and decreasing hypoxic vasoconstriction.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Improved V/Q mismatch:</span></strong><span style=\"font-size:12.0pt\"> By increasing alveolar oxygen tension, LTOT can help correct the ventilation-perfusion mismatch often seen in COPD.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Decreased hematocrit (polycythemia):</span></strong><span style=\"font-size:12.0pt\"> Chronic hypoxemia can trigger an increase in red blood cell production (polycythemia). LTOT can reverse this effect</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long-term oxygen therapy (LTOT) in COPD improves survival, reduces pulmonary vascular resistance, and improves V/Q mismatch, but it does not increase hematocrit.</span></span></p>",
    "correct_choice_id": 80451,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20130,
    "choices": [
      {
        "id": 80481,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 of 54 mmHg and evidence of cor pulmonale </span></span></span></p>"
      },
      {
        "id": 80482,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 88% on room air and a history of two COPD exacerbations in the past year </span></span></span></p>"
      },
      {
        "id": 80483,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 of 58 mmHg and a hematocrit of 55% </span></span></span></p>"
      },
      {
        "id": 80484,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 89% and a normal 6-minute walk distance</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old man with severe emphysema secondary to alpha-1 antitrypsin deficiency is being evaluated for long-term oxygen therapy (LTOT). Which of the following scenarios would NOT meet the criteria for LTOT in this patient?</span></span></span></p>",
    "unique_key": "Q3286144",
    "question_audio": null,
    "question_video": null,
    "map_id": 20073,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Resting SpO2 of 89% and a normal 6-minute walk distance</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The current guidelines for LTOT in COPD recommend it for patients with:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting PaO2 &le; 55 mmHg OR SaO2 &le; 88% on room air</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">OR PaO2 56-59 mmHg or SaO2 89% with evidence of:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cor pulmonale</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycythemia (Hct &gt; 55%)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hypertension</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D.</strong>&nbsp;does not meet these criteria as the patient&#39;s oxygen saturation is above 88% and there&#39;s no evidence of end-organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Resting PaO2 of 54 mmHg and evidence of cor pulmonale:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria for LTOT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Resting SpO2 of 88% and a history of two COPD exacerbations:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria due to low SpO2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Resting PaO2 of 58 mmHg and a hematocrit of 55%:</span></strong><span style=\"font-size:12.0pt\"> Meets the criteria due to low PaO2 and high hematocrit</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting SpO2 of 89% and a normal 6-minute walk distance do not meet the criteria for long-term oxygen therapy (LTOT) in COPD.</span></span></span></p>",
    "correct_choice_id": 80484,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20134,
    "choices": [
      {
        "id": 80497,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tiotropium </span></span></span></p>"
      },
      {
        "id": 80498,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Salmeterol </span></span></span></p>"
      },
      {
        "id": 80499,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Roflumilast </span></span></span></p>"
      },
      {
        "id": 80500,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with severe COPD and chronic bronchitis presents with a history of frequent exacerbations despite optimal bronchodilator therapy. He has a 50-pack-year smoking history and continues to smoke 1 pack per day. Which of the following medications is most likely to reduce the frequency of his exacerbations?</span></span></span></p>",
    "unique_key": "Q4280509",
    "question_audio": null,
    "question_video": null,
    "map_id": 20074,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Roflumilast&nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roflumilast is specifically indicated for severe COPD with chronic bronchitis and frequent exacerbations despite optimized bronchodilator therapy. It works by reducing inflammation and mucus production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tiotropium:</span></strong><span style=\"font-size:12.0pt\"> While a LAMA improves lung function and symptoms, it doesn&#39;t have the same impact on exacerbation frequency as roflumilast.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Salmeterol:</span></strong><span style=\"font-size:12.0pt\"> LABAs improve lung function but don&#39;t specifically target exacerbations like roflumilast.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisolone:</span></strong><span style=\"font-size:12.0pt\"> Oral steroids are used for acute exacerbations, not long-term prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Roflumilast (PDE4 inhibitor) is indicated for severe COPD with chronic bronchitis and frequent exacerbations, reducing inflammation and mucus production.</span></span></span></p>",
    "correct_choice_id": 80499,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20139,
    "choices": [
      {
        "id": 80517,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD A </span></span></span></p>"
      },
      {
        "id": 80518,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD B </span></span></span></p>"
      },
      {
        "id": 80519,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD C </span></span></span></p>"
      },
      {
        "id": 80520,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD E</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old smoker with a history of COPD presents to the clinic with a COPD Assessment Test (CAT) score of 15 and two hospitalizations for COPD exacerbations in the past year. Which GOLD category does he belong to based on the 2023 GOLD guidelines?</span></span></span></p>",
    "unique_key": "Q8846498",
    "question_audio": null,
    "question_video": null,
    "map_id": 20075,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) GOLD E</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The 2023 GOLD guidelines have replaced categories C and D with category E. Group E patients have a high symptom burden (CAT score &ge;10) or history of exacerbations, regardless of airflow limitation severity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture41.jpg\" style=\"height:392px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GOLD A:</span></strong><span style=\"font-size:12.0pt\"> Low risk, low symptoms</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GOLD B:</span></strong><span style=\"font-size:12.0pt\"> Low risk, high symptoms</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GOLD C:</span></strong><span style=\"font-size:12.0pt\"> No longer used in the 2023 guidelines</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with a high symptom burden (CAT score &ge;10) or a history of exacerbations belong to GOLD category E according to the 2023 GOLD guidelines.</span></span></p>",
    "correct_choice_id": 80520,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 20145,
    "choices": [
      {
        "id": 80541,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased total lung capacity (TLC) </span></span></span></p>"
      },
      {
        "id": 80542,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased FEV1/FVC ratio </span></span></span></p>"
      },
      {
        "id": 80543,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased diffusing capacity of the lung for carbon monoxide (DLCO) </span></span></span></p>"
      },
      {
        "id": 80544,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased vital capacity (VC)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with a long history of smoking and progressive dyspnea presents with a barrel chest and expiratory wheezing. Which of the following pulmonary function test (PFT) findings is NOT typically seen in emphysema?</span></span></p>",
    "unique_key": "Q5255031",
    "question_audio": null,
    "question_video": null,
    "map_id": 20078,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Increased diffusing capacity of the lung for carbon monoxide (DLCO)</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Emphysema destroys alveoli, leading to decreased gas exchange surface area and a <em>reduced</em> DLCO.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased total lung capacity (TLC)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Common in emphysema due to air trapping and hyperinflation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased FEV1/FVC ratio:</span></strong><span style=\"font-size:12.0pt\"> Hallmark of obstructive lung disease like emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased vital capacity (VC):</span></strong><span style=\"font-size:12.0pt\"> Often seen in emphysema due to severe air trapping - also called as &lsquo;pseudo-restriction&rsquo;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased DLCO is not typically seen in emphysema, as this condition reduces gas exchange surface area, leading to decreased DLCO.</span></span></span></p>",
    "correct_choice_id": 80543,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20147,
    "choices": [
      {
        "id": 80549,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 1 (Mild) </span></span></span></p>"
      },
      {
        "id": 80550,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 2 (Moderate) </span></span></span></p>"
      },
      {
        "id": 80551,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 3 (Severe) </span></span></span></p>"
      },
      {
        "id": 80552,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GOLD 4 (Very Severe)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with severe COPD undergoes spirometry after bronchodilator administration. His FEV1 is 28% of the predicted value. Which GOLD stage does he belong to?</span></span></span></p>",
    "unique_key": "Q3867532",
    "question_audio": null,
    "question_video": null,
    "map_id": 20080,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) GOLD 4 (Very Severe)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Very severe COPD (GOLD 4) is defined by a post-bronchodilator FEV1 less than 30% of the predicted value.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u>Explanation</u>:</strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GOLD 1&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Mild)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">FEV1 &ge; 80% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GOLD 2 (</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Moderate)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>:&nbsp;</strong>50% &le; FEV1 &lt; 80% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GOLD 3 </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Severe)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">30% &le; FEV1 &lt; 50% predicted</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Very severe COPD (GOLD 4) is defined by a post-bronchodilator FEV1 less than 30% of the predicted value.</span></span></span></p>",
    "correct_choice_id": 80552,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20149,
    "choices": [
      {
        "id": 80557,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 0 </span></span></span></p>"
      },
      {
        "id": 80558,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 1 </span></span></span></p>"
      },
      {
        "id": 80559,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 2 </span></span></span></p>"
      },
      {
        "id": 80560,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mMRC 3</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 62-year-old woman with COPD reports that she becomes short of breath when walking at her own pace on level ground, and sometimes has to stop for breath. Based on the modified Medical Research Council (mMRC) dyspnea scale, what is her dyspnea grade?</span></span></span></p>",
    "unique_key": "Q2675997",
    "question_audio": null,
    "question_video": null,
    "map_id": 20082,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) mMRC 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s description matches the mMRC grade 2 criterion: &quot;Short of breath when hurrying on the level or walking up a slight hill.&quot;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. mMRC 0:</span></strong><span style=\"font-size:12.0pt\">&nbsp;No breathlessness except with strenuous exercise.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. mMRC 1:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Breathlessness when hurrying or walking up a slight hill.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mMRC 3:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Walks slower than others of same age due to breathlessness or stops for breath at own pace.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s description matches the mMRC grade 2 criterion: &quot;Short of breath when hurrying on the level or walking up a slight hill.&quot;</span></span></p>",
    "correct_choice_id": 80559,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20150,
    "choices": [
      {
        "id": 80561,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Body mass index (BMI) </span></span></span></p>"
      },
      {
        "id": 80562,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Airflow obstruction (FEV1) </span></span></span></p>"
      },
      {
        "id": 80563,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dyspnea (mMRC grade) </span></span></span></p>"
      },
      {
        "id": 80564,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exacerbation frequency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT a component of the BODE index, a prognostic tool in COPD that incorporates the mMRC dyspnea scale?</span></span></span></p>",
    "unique_key": "Q8742861",
    "question_audio": null,
    "question_video": null,
    "map_id": 20083,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Exacerbation frequency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BODE index includes BMI, airflow obstruction (FEV1), dyspnea (mMRC grade), and exercise capacity (6-minute walk distance). Exacerbation frequency, while important, is not included in the BODE index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BMI:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Lower BMI is associated with worse prognosis in COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Airflow obstruction (FEV1):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Lower FEV1 indicates worse lung function and prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dyspnea (mMRC grade):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Higer mMRC grade indicates more severe dyspnea and worse prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exacerbation frequency, while important, is not included in the BODE index, which incorporates BMI, FEV1, mMRC dyspnea grade, and 6-minute walk distance.</span></span></span></p>",
    "correct_choice_id": 80564,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 20151,
    "choices": [
      {
        "id": 80565,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asthma </span></span></span></p>"
      },
      {
        "id": 80566,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD (Chronic Obstructive Pulmonary Disease) </span></span></span></p>"
      },
      {
        "id": 80567,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allergic Bronchopulmonary Aspergillosis (ABPA) </span></span></span></p>"
      },
      {
        "id": 80568,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary Langerhans Cell Histiocytosis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a 20-pack-year smoking history presents with progressive shortness of breath and chronic cough. Spirometry reveals an FEV1 of 62% predicted and an FEV1/FVC ratio of 39%. After administration of a bronchodilator (BD), the FEV1 improves to 75% predicted, and the FEV1/FVC ratio improves to 73%. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q2168756",
    "question_audio": null,
    "question_video": null,
    "map_id": 20084,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Asthma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post BD FEV1/FVC &gt; 70% rules out COPD and establishes the diagnosis of asthma. Note that this patient also has a significant improvement in FEV1 post bronchodilator (FEV1 &ge; 12%/200mL)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. COPD&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Chronic Obstructive Pulmonary Disease)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Although COPD can also cause airflow obstruction, it is typically less reversible with bronchodilators.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Allergic Bronchopulmonary Aspergillosis (ABPA)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> While ABPA can cause asthma-like symptoms, it is usually associated with elevated IgE levels and positive Aspergillus serology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pulmonary Langerhans Cell Histiocytosis:</span></strong><span style=\"font-size:12.0pt\"> Primarily seen in smokers and associated with cystic lung lesions on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-bronchodilator FEV1/FVC &gt; 70% rules out COPD and establishes the diagnosis of asthma, with significant improvement in FEV1 indicating reversibility.</span></span></span></p>",
    "correct_choice_id": 80565,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20152,
    "choices": [
      {
        "id": 80569,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Irreversible airflow limitation </span></span></span></p>"
      },
      {
        "id": 80570,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased residual volume (RV) </span></span></span></p>"
      },
      {
        "id": 80571,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Affects small airways </span></span></span></p>"
      },
      {
        "id": 80572,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can occur due to protease-antiprotease imbalance</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old smoker with a long-standing history of dyspnea and a scanty cough experiences relief with bronchodilator therapy. Pulmonary function tests reveal an FEV1/FVC 54% and FEV1 50% predicted. Post Bronchodilator neb his FEV1/FVC improved to 65% and FEV1 improved to 57%. Which of the following is NOT a typical feature of this patient&#39;s likely diagnosis?</span></span></p>",
    "unique_key": "Q2333856",
    "question_audio": null,
    "question_video": null,
    "map_id": 20085,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Decreased residual volume (RV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD is characterized by air trapping, which leads to an <em>increased</em> residual volume (RV).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Irreversible airflow limitation:</span></strong><span style=\"font-size:12.0pt\"> This is the hallmark of COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Affects small airways:</span></strong><span style=\"font-size:12.0pt\"> Small airway inflammation and narrowing contribute to COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Can occurs due to protease-antiprotease imbalance:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This imbalance contributes to the destruction of lung tissue in emphysema, which is a major cause of COPD</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD is characterized by air trapping, leading to an increased residual volume (RV), not decreased.</span></span></p>",
    "correct_choice_id": 80570,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 20153,
    "choices": [
      {
        "id": 80573,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Centrilobular emphysema </span></span></span></p>"
      },
      {
        "id": 80574,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Paraseptal emphysema </span></span></span></p>"
      },
      {
        "id": 80575,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panacinar emphysema </span></span></span></p>"
      },
      {
        "id": 80576,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bullous emphysema</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with alpha-1 antitrypsin deficiency is found to have emphysema predominantly affecting the lower lobes of the lungs. Which type of emphysema is this most consistent with?</span></span></p>",
    "unique_key": "Q6189477",
    "question_audio": null,
    "question_video": null,
    "map_id": 20086,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Panacinar emphysema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panacinar emphysema involves uniform destruction of the acinus (respiratory bronchiole, alveolar ducts, and alveoli) and is typically seen in the lower lobes of patients with alpha-1 antitrypsin deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Centrilobular emphysema:</span></strong><span style=\"font-size:12.0pt\"> Predominantly affects the respiratory bronchioles and is more common in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Paraseptal emphysema:</span></strong><span style=\"font-size:12.0pt\"> Occurs adjacent to pleural surfaces and interlobular septa.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bullous emphysema:</span></strong><span style=\"font-size:12.0pt\"> Refers to large bullae formation, not a distinct type.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Panacinar emphysema involves uniform destruction of the acinus and is typically seen in the lower lobes of patients with alpha-1 antitrypsin deficiency.</span></span></p>",
    "correct_choice_id": 80575,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20154,
    "choices": [
      {
        "id": 80577,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce mortality in COPD </span></span></span></p>"
      },
      {
        "id": 80578,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the frequency of COPD exacerbations. </span></span></span></p>"
      },
      {
        "id": 80579,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the rate of decline of FEV1 in COPD</span></span></span></p>"
      },
      {
        "id": 80580,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICS reduce the incidence of pneumonia in COPD.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with moderate to severe COPD is being considered for treatment with inhaled corticosteroids (ICS). Which of the following statements is TRUE regarding the use of ICS in COPD?</span></span></span></p>",
    "unique_key": "Q6084969",
    "question_audio": null,
    "question_video": null,
    "map_id": 20087,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) ICS reduce the frequency of COPD exacerbations.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While ICS don&#39;t reduce mortality or slow FEV1 decline in COPD, they have been shown to reduce the frequency of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ICS reduce mortality in COPD</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Not true. But recently, triple combinations (LABA + LAMA + ICS) in selected patients (Group E) has shown to reduce mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ICS reduce the rate of decline of FEV1 in COPD</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Not true.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ICS reduce the incidence of pneumonia in COPD</strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Actually, ICS may slightly increase the risk of pneumonia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhaled corticosteroids (ICS) reduce the frequency of COPD exacerbations.</span></span></p>",
    "correct_choice_id": 80578,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20155,
    "choices": [
      {
        "id": 80581,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daily azithromycin 500mg </span></span></span></p>"
      },
      {
        "id": 80582,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous oxygen at 2 L/min </span></span></span></p>"
      },
      {
        "id": 80583,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nocturnal BiPAP (bilevel positive airway pressure) </span></span></span></p>"
      },
      {
        "id": 80584,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled corticosteroids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 69-year-old smoker with COPD has had three hospitalizations for exacerbations in the past year. He is already on LABA(long acting beta 2 agonist), LAMA long acting muscarinic antagonist) and ICS (inhaled corticosteroids). Which of the following treatments is most likely to decrease the frequency of his exacerbations?</span></span></span></p>",
    "unique_key": "Q2999796",
    "question_audio": null,
    "question_video": null,
    "map_id": 20088,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Daily azithromycin 500mg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has severe COPD with frequent exacerbations despite being on triple therapy(LABA, LAMA, and ICS). In such cases, studies have shown that daily azithromycin 250mg or 500mg can significantly reduce the frequency of exacerbations due to its anti-inflammatory and immunomodulatory effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Continuous oxygen at 2 L/min:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While oxygen therapy is crucial for patients with chronic hypoxemia,&nbsp;it doesn&#39;t directly reduce the frequency of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nocturnal BiPAP (bilevel positive airway pressure)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is indicated for COPD patients with hypercapnic respiratory failure or nocturnal desaturation,&nbsp;not as a primary prevention for exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhaled corticosteroids:</span></strong><span style=\"font-size:12.0pt\">&nbsp;The patient is already on ICS,&nbsp;and further increasing the dose is unlikely to provide additional benefit in preventing exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Daily azithromycin 500mg can significantly reduce the frequency of exacerbations in severe COPD patients already on LABA, LAMA, and ICS therapy.</span></span></span></p>",
    "correct_choice_id": 80581,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20156,
    "choices": [
      {
        "id": 80585,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoxemia (PaO2 &lt; 60 mmHg on room air) </span></span></span></p>"
      },
      {
        "id": 80586,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypercapnia (PaCO2 &gt; 50 mmHg) </span></span></span></p>"
      },
      {
        "id": 80587,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Respiratory acidosis (pH &lt; 7.35) </span></span></span></p>"
      },
      {
        "id": 80588,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inability to protect airway</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with an acute exacerbation of COPD presents with respiratory distress, tachypnea, and altered mental status. Which of the following would be an absolute contraindication to initiating non-invasive ventilation (NIV)?</span></span></span></p>",
    "unique_key": "Q7093952",
    "question_audio": null,
    "question_video": null,
    "map_id": 20089,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Inability to protect airway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired consciousness and inability to protect the airway are absolute contraindications to NIV, as they increase the risk of aspiration and respiratory arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypoxemia (PaO2 &lt; 60 mmHg on room air):</span></strong><span style=\"font-size:12.0pt\"> NIV can be used to improve oxygenation in COPD exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><strong><span style=\"font-size:12.0pt\"> Hypercapnia (PaCO2 &gt; 50 mmHg):</span></strong><span style=\"font-size:12.0pt\"> NIV can improve ventilation and reduce CO2 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Respiratory acidosis (pH &lt; 7.35):</span></strong><span style=\"font-size:12.0pt\"> NIV can help correct acidosis caused by hypercapnia.</span></span></span></p>\r\n\r\n<div>\r\n<div>\r\n<div class=\"msocomtxt\" id=\"_com_1\">\r\n<p>&nbsp;</p>\r\n</div>\r\n</div>\r\n</div>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inability to protect the airway is an absolute contraindication to initiating non-invasive ventilation (NIV) in patients with acute exacerbation of COPD.</span></span></span></p>",
    "correct_choice_id": 80588,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20157,
    "choices": [
      {
        "id": 80589,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asthma </span></span></span></p>"
      },
      {
        "id": 80590,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">COPD (Chronic Obstructive Pulmonary Disease) </span></span></span></p>"
      },
      {
        "id": 80591,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Preserved Ratio Impaired Spirometry (PRISm) </span></span></span></p>"
      },
      {
        "id": 80592,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal lung function</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old occasional smoker presents with a chronic cough and dyspnea on exertion. Physical examination is unremarkable, and chest X-ray is normal. Spirometry reveals an FEV1 of 60% predicted and an FEV1/FVC ratio of 80%. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q8218879",
    "question_audio": null,
    "question_video": null,
    "map_id": 20090,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Preserved Ratio Impaired Spirometry (PRISm)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PRISm is characterized by reduced FEV1 but a normal FEV1/FVC ratio. It&#39;s a potential precursor to COPD, particularly in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Asthma:</span></strong><span style=\"font-size:12.0pt\"> Usually shows a reduced FEV1/FVC ratio with reversibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">COPD (Chronic Obstructive Pulmonary Disease)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> Requires an FEV1/FVC &lt; 0.70.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Normal lung function:</span></strong><span style=\"font-size:12.0pt\"> Not possible with reduced FEV1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRISm (Preserved Ratio Impaired Spirometry) is characterized by a reduced FEV1 with a normal FEV1/FVC ratio, often seen as a potential precursor to COPD.</span></span></p>",
    "correct_choice_id": 80591,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20158,
    "choices": [
      {
        "id": 80593,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, epinephrine is indicated for all asthma exacerbations. </span></span></span></p>"
      },
      {
        "id": 80594,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, but only if she fails to respond to inhaled bronchodilators. </span></span></span></p>"
      },
      {
        "id": 80595,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, epinephrine is only indicated for asthma associated with anaphylaxis or angioedema. </span></span></span></p>"
      },
      {
        "id": 80596,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, epinephrine should only be used in patients with severe asthma exacerbations requiring hospitalization.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a history of asthma presents with worsening wheezing, cough, and shortness of breath. There is no associated angioedema or urticaria. Her vital signs are stable, and her oxygen saturation is 94% on room air. Would intramuscular epinephrine be indicated in this scenario? </span></span></p>",
    "unique_key": "Q9753285",
    "question_audio": null,
    "question_video": null,
    "map_id": 20091,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">C) No, epinephrine is only indicated for asthma associated with anaphylaxis or angioedema.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intramuscular epinephrine is primarily reserved for asthma exacerbations that are accompanied by anaphylaxis or angioedema (severe allergic reactions). In this patient with no signs of anaphylaxis or angioedema, standard asthma treatment with bronchodilators and corticosteroids would be appropriate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Yes, epinephrine is indicated for all asthma exacerbations:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;Epinephrine is a potent drug reserved for life-threatening situations like anaphylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Yes, but only if she fails to respond to inhaled bronchodilators:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;While epinephrine may be used in refractory cases,&nbsp;it&#39;s not the initial therapy for most asthma exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No, epinephrine should only be used in patients with severe asthma exacerbations requiring hospitalization:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect.&nbsp;While epinephrine is often used in severe cases,&nbsp;it&#39;s indicated for any asthma exacerbation with anaphylaxis or angioedema,&nbsp;regardless of severity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intramuscular epinephrine is only indicated for asthma exacerbations associated with anaphylaxis or angioedema.</span></span></p>",
    "correct_choice_id": 80595,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20159,
    "choices": [
      {
        "id": 80597,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Short-acting beta-agonist (SABA) alone </span></span></span></p>"
      },
      {
        "id": 80598,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Short-acting muscarinic antagonist (SAMA) alone </span></span></span></p>"
      },
      {
        "id": 80599,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose ICS + SABA combination </span></span></span></p>"
      },
      {
        "id": 80600,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose ICS + LABA (long-acting beta-agonist) combination</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman with mild persistent asthma is well-controlled on a low-dose inhaled corticosteroid (ICS) as maintenance therapy. She experiences occasional wheezing and shortness of breath, especially after exercise. According to current asthma guidelines, which of the following is the preferred reliever medication for her symptoms?</span></span></span></p>",
    "unique_key": "Q7268981",
    "question_audio": null,
    "question_video": null,
    "map_id": 20092,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Low-dose ICS + LABA (long-acting beta-agonist) combination</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Current guidelines recommend using a combination inhaler containing both low-dose ICS and a LABA as the preferred reliever medication for ALL patients with asthma, regardless of severity. This approach provides both rapid symptom relief (LABA) and anti-inflammatory effects (ICS), reducing the risk of exacerbations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Short-acting beta-agonist (SABA) alone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Although SABAs provide quick relief,&nbsp;they don&#39;t address underlying inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Short-acting muscarinic antagonist (SAMA) alone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Less effective than SABAs in most cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Low-dose ICS + SABA combination</span></strong><span style=\"font-size:12.0pt\">: Not preferred as the LABA component is short-acting and doesn&#39;t provide sustained bronchodilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The preferred reliever medication for mild persistent asthma is a combination inhaler containing both low-dose ICS and a LABA.</span></span></span></p>",
    "correct_choice_id": 80600,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 20160,
    "choices": [
      {
        "id": 80601,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled short-acting beta-agonists (SABA) as needed </span></span></span></p>"
      },
      {
        "id": 80602,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial thermoplasty </span></span></span></p>"
      },
      {
        "id": 80603,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-IgE therapy (e.g., omalizumab) </span></span></span></p>"
      },
      {
        "id": 80604,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral corticosteroids at higher doses</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 20-year-old man with severe asthma remains symptomatic despite high-dose inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA), and long-acting beta-agonists (LABA). He is also on oral steroids and montelukast. Further evaluation reveals elevated IgE levels and FeNO (fractional exhaled nitric oxide) of 55 ppb. Which therapy is most likely to be effective for this patient?</span></span></span></p>",
    "unique_key": "Q4471855",
    "question_audio": null,
    "question_video": null,
    "map_id": 20093,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-IgE therapy (e.g., omalizumab)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated IgE and FeNO suggest atype 2 inflammatory response. Anti-IgE therapy targets this pathway and is indicated in severe allergic asthma not controlled with standard therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><strong><span style=\"font-size:12.0pt\">Inhaled short-acting beta-agonists (SABA) as needed: &nbsp;</span></strong><span style=\"font-size:12.0pt\">Used for quick relief, not long-term control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bronchial thermoplasty:</span></strong><span style=\"font-size:12.0pt\"> Considered for severe refractory asthma but not the first-line option in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Oral corticosteroids at higher doses:</span></strong><span style=\"font-size:12.0pt\"> Already on high doses, increasing further may lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-IgE therapy (e.g., omalizumab) is indicated for severe allergic asthma not controlled with standard therapy, especially in the presence of elevated IgE and FeNO levels.</span></span></p>",
    "correct_choice_id": 80603,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20161,
    "choices": [
      {
        "id": 80605,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen therapy to maintain SpO2 &ge; 94% </span></span></span></p>"
      },
      {
        "id": 80606,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeated doses of nebulized salbutamol</span></span></span></p>"
      },
      {
        "id": 80607,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral prednisolone </span></span></span></p>"
      },
      {
        "id": 80608,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhaled Formeterol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old boy with a history of mild persistent asthma is brought to the ER with an acute exacerbation. His symptoms include wheezing, shortness of breath, and cough. He is using accessory muscles to breathe, and his peak flow is 50% of his personal best. Which of the following is NOT recommended as part of his initial management?</span></span></p>",
    "unique_key": "Q1042199",
    "question_audio": null,
    "question_video": null,
    "map_id": 20094,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Inhaled Formeterol</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LABAs (formeterol) are not used in the acute management of asthma exacerbations. They are long-term control medications and have a delayed onset of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oxygen therapy to maintain SpO2 &ge; 94%:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Essential to correct hypoxemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Repeated doses of nebulized salbutamol:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Mainstay of acute bronchodilator therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oral prednisolone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Oral corticosteroids reduce airway inflammation and are important in exacerbation management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LABAs like formoterol are not used in the acute management of asthma exacerbations due to their delayed onset of action.</span></span></span></p>",
    "correct_choice_id": 80608,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49955,
    "choices": [
      {
        "id": 199379,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nasal congestion</span></span></p>"
      },
      {
        "id": 199380,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Difficulty inhaling</span></span></p>"
      },
      {
        "id": 199381,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Claustrophobia</span></span></p>"
      },
      {
        "id": 199382,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aerophagia</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are complications of CPAP therapy in OSA except:</span></span></p>",
    "unique_key": "Q5871836",
    "question_audio": null,
    "question_video": null,
    "map_id": 24909,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B)&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Difficulty inhaling</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) can have several common complications, including nasal congestion, claustrophobia, aerophagia, bruised nose and difficulty exhaling. However, difficulty inhaling is not typically associated with CPAP therapy, as the therapy is designed to provide continuous positive pressure to keep the airways open, which should facilitate, rather than impede, inspiration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nasal congestion:</span></strong><span style=\"font-size:12.0pt\"> Common due to the air pressure and can be mitigated with humidification or steroid/saline nasal sprays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Claustrophobia:</span></strong><span style=\"font-size:12.0pt\"> A common issue due to the mask, which can make some patients feel confined. Can mitigate by changing mask interface (e.g., nasal prongs)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Aerophagia:</span></strong><span style=\"font-size:12.0pt\"> Swallowing air, which can lead to bloating and discomfort, is a known side effect of CPAP therapy. Can mitigate to some extent by administering antacids</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Difficulty inhaling is not a typical complication of CPAP therapy; common issues include nasal congestion, claustrophobia, and aerophagia.</span></span></span></p>",
    "correct_choice_id": 199380,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49934,
    "choices": [
      {
        "id": 199295,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate noninvasive positive pressure ventilation (NIPPV) </span></span></span></p>"
      },
      {
        "id": 199296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start intravenous (IV) methylprednisolone </span></span></span></p>"
      },
      {
        "id": 199297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer a nebulized bronchodilator </span></span></span></p>"
      },
      {
        "id": 199298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proceed with endotracheal intubation (ETT) and mechanical ventilation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a history of severe COPD presents to the emergency department with an acute exacerbation. He is tachypneic, using accessory muscles of respiration, and his oxygen saturation is 88% on room air. Arterial blood gas analysis shows a pH of 7.28 and PaCO2 of 65 mmHg. Which of the following is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q6167798",
    "question_audio": null,
    "question_video": null,
    "map_id": 24889,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Initiate noninvasive positive pressure ventilation (NIPPV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is experiencing an acute exacerbation of COPD with significant hypercapnia and respiratory acidosis. NIPPV is the preferred initial management strategy in this scenario, as it can improve ventilation, reduce work of breathing, and potentially avoid the need for invasive mechanical ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Start IV methylprednisolone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Corticosteroids are indicated in COPD exacerbations,&nbsp;but NIPPV should be prioritized in patients with respiratory failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer a nebulized bronchodilator:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Bronchodilators are important for symptom relief,&nbsp;but they won&#39;t address the primary issue of hypercapnia and acidosis.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Proceed with endotracheal intubation (ETT) and mechanical ventilation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While intubation may be necessary if NIPPV fails or the patient deteriorates,&nbsp;it is not the first-line treatment due to its associated risks and complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate noninvasive positive pressure ventilation (NIPPV) for patients with acute COPD exacerbation and respiratory failure to improve ventilation and avoid invasive mechanical ventilation.</span></span></p>",
    "correct_choice_id": 199295,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InstrumentsBased"
    ]
  },
  {
    "id": 49935,
    "choices": [
      {
        "id": 199299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peak flow meter </span></span></span></p>"
      },
      {
        "id": 199300,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spirometer </span></span></span></p>"
      },
      {
        "id": 199301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Body plethysmograph </span></span></span></p>"
      },
      {
        "id": 199302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Incentive spirometer</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young patient with asthma is given a device to monitor his asthma. What is the device?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture5.jpg\" style=\"height:182px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q6447540",
    "question_audio": null,
    "question_video": null,
    "map_id": 24890,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Peak flow meter</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A peak flow meter is a portable device used by asthmatics to measure how fast they can forcefully exhale, providing a quick assessment of airway obstruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Spirometer:</span></strong><span style=\"font-size:12.0pt\"> Measures lung volumes and flow rates during forced exhalation and inhalation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-left:24px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture6.jpg\" style=\"height:285px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Body plethysmograph:</span></strong><span style=\"font-size:12.0pt\"> Measures total lung capacity and airway resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture7.jpg\" style=\"height:410px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Incentive spirometer:</span></strong><span style=\"font-size:12.0pt\"> Helps improve lung function by encouraging deep breaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-left:24px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture8.jpg\" style=\"height:321px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dveice shown in the image is a peak flow meter used by asthmatics to measure how fast they can forcefully exhale, providing a quick assessment of airway obstruction.</span></span></span></p>",
    "correct_choice_id": 199299,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 49936,
    "choices": [
      {
        "id": 199303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amoxicillin </span></span></span></p>"
      },
      {
        "id": 199304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azithromycin </span></span></span></p>"
      },
      {
        "id": 199305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Piperacillin-tazobactam </span></span></span></p>"
      },
      {
        "id": 199306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxycycline</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old patient with known bronchiectasis is hospitalized with acute worsening of cough, sputum production, and fever. Which antibiotic regimen is most appropriate for this exacerbation?</span></span></p>",
    "unique_key": "Q6980077",
    "question_audio": null,
    "question_video": null,
    "map_id": 24891,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Piperacillin-tazobactam</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><em><span style=\"font-size:12.0pt\">Pseudomonas aeruginosa</span></em><span style=\"font-size:12.0pt\"> is a common pathogen in bronchiectasis exacerbations. Piperacillin-tazobactam is a broad-spectrum antibiotic with activity against Pseudomonas and other gram-negative organisms, making it the preferred initial therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amoxicillin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Not effective against&nbsp;<em>Pseudomonas</em>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Azithromycin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;May be used in chronic management but not first-line for acute exacerbations with Pseudomonas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Doxycycline:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Not effective against Pseudomonas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Piperacillin-tazobactam is the preferred antibiotic for acute exacerbations of bronchiectasis due to its broad-spectrum activity against Pseudomonas aeruginosa and other gram-negative organisms.</span></span></p>",
    "correct_choice_id": 199305,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 49937,
    "choices": [
      {
        "id": 199307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cylindrical bronchiectasis </span></span></span></p>"
      },
      {
        "id": 199308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Varicose bronchiectasis </span></span></span></p>"
      },
      {
        "id": 199309,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cystic bronchiectasis </span></span></span></p>"
      },
      {
        "id": 199310,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Traction bronchiectasis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with chronic cough and sputum production undergoes bronchoscopy, which reveals dilated airways and nodular lesions. Bronchial washings culture positive for <em>Mycobacterium avium complex</em> (MAC). Which type of bronchiectasis is most likely associated?</span></span></p>",
    "unique_key": "Q6067357",
    "question_audio": null,
    "question_video": null,
    "map_id": 24892,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Varicose bronchiectasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Varicose bronchiectasis, with irregular airway dilation and constriction, is commonly seen in NTM infections like MAC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cylindrical bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This type of bronchiectasis is characterized by uniformly dilated airways, typically seen in post-infectious bronchiectasis or bronchiectasis associated with bronchial obstruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cystic bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is the most severe form of bronchiectasis, with large, balloon-like dilations of the airways. While it can be seen in NTM infections, it&#39;s less common than varicose bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Traction bronchiectasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This type is caused by fibrosis pulling on the airways, often seen in conditions like tuberculosis or sarcoidosis. It presents with irregular dilations and distortions of the airways but is less common in NTM infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key Point:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Varicose bronchiectasis is the most common type seen in NTM infections, particularly <em>Mycobacterium avium</em> complex (MAC). The irregular dilations and constrictions of the airways resemble varicose veins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Varicose bronchiectasis, with irregular airway dilation and constriction, is commonly seen in NTM infections like Mycobacterium avium complex (MAC).</span></span></span></p>",
    "correct_choice_id": 199308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49938,
    "choices": [
      {
        "id": 199311,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchiectasis</span></span></p>"
      },
      {
        "id": 199312,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic bronchitis</span></span></p>"
      },
      {
        "id": 199313,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration pneumonia</span></span></p>"
      },
      {
        "id": 199314,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emphysema</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 66-year-old man presented after coughing up copious amounts of blood-tinged sputum at his nursing home Physical examination shows digital clubbing and cyanosis of the lips. Coarse crackles are heard throughout the lung fields and his SpO2 is 95%. A chest X-ray reveals increased translucency and tram-track opacities in the right lower lung field. What is the likely diagnosis?</span></span></span></p>",
    "unique_key": "Q1729612",
    "question_audio": null,
    "question_video": null,
    "map_id": 24893,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Bronchiectasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with typical symptoms of bronchiectasis, including chronic cough with copious amounts of sputum, hemoptysis, and coarse crackles on auscultation. The presence of tram-track opacities on the chest X-ray is characteristic of bronchiectasis, indicating thickened bronchial walls. Digital clubbing and cyanosis are also associated with chronic hypoxia commonly seen in bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Chronic bronchitis:</span></strong><span style=\"font-size:12.0pt\"> Typically seen in patients with a history of smoking and characterized by a chronic, productive cough. However, copious amounts of blood-tinged sputum and signs of chronic hypoxia (e.g., digital clubbing, lip cyanosis) are less typical.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Aspiration pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Common in patients with a history of stroke, which may result in dysphagia. Patients with aspiration pneumonia may present with dyspnea, cough, and hypoxemia, but would not typically show the tram-track opacities seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Emphysema:</span></strong><span style=\"font-size:12.0pt\"> Usually presents with a history of a chronic cough that is characteristically worse in the mornings, production of small amounts of sputum, and dyspnea. Chest X-rays typically show hyperinflation rather than tram-track opacities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchiectasis presents with chronic cough, copious sputum, hemoptysis, coarse crackles, and tram-track opacities on X-ray, along with digital clubbing and cyanosis due to chronic hypoxia.</span></span></span></p>",
    "correct_choice_id": 199311,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49939,
    "choices": [
      {
        "id": 199315,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cirrhosis</span></span></p>"
      },
      {
        "id": 199316,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypothyroidism</span></span></p>"
      },
      {
        "id": 199317,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Panacinar emphysema</span></span></p>"
      },
      {
        "id": 199318,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancreatitis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 4-year-old girl presents with productive cough, high fever, poor weight gain, and frequent respiratory infections. Exam reveals crackles in the left lower lung. Chest X-ray shows dilated bronchi and infiltrates. Sputum culture: pink rods on Gram stain, non-lactose fermenting, oxidase positive. She is at increased risk for which condition?</span></span></span></p>",
    "unique_key": "Q3080617",
    "question_audio": null,
    "question_video": null,
    "map_id": 24894,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pancreatitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms and findings suggest cystic fibrosis (CF), which is characterized by thick mucus secretions that lead to chronic respiratory infections and bronchiectasis. The bacteria identified, likely Pseudomonas aeruginosa, is common in CF patients. CF also affects the pancreas, leading to an increased risk of pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cirrhosis:</span></strong><span style=\"font-size:12.0pt\"> &nbsp;Although CF can lead to liver disease, pancreatitis is a more immediate and common complication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Not typically associated with CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Panacinar emphysema:</span></strong><span style=\"font-size:12.0pt\"> More commonly related to alpha-1 antitrypsin deficiency, not CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystic fibrosis, characterized by chronic respiratory infections and bronchiectasis, increases the risk of pancreatitis due to thick mucus secretions affecting the pancreas.</span></span></p>",
    "correct_choice_id": 199318,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 49940,
    "choices": [
      {
        "id": 199319,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemoptysis</span></span></p>"
      },
      {
        "id": 199320,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rhizopus infections</span></span></p>"
      },
      {
        "id": 199321,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumothorax</span></span></p>"
      },
      {
        "id": 199322,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old man complains of cough, shortness of breath, and daily copious sputum production. He has a history of frequent lung infections. His SpO2 is 95%. Diffuse crackles and wheezing are heard on auscultation throughout the lung fields. A CT scan is shown. The patient is at greatest risk for which of the following complications?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/picture9.jpg\" style=\"height:264px; width:300px\" /></span></span></p>",
    "unique_key": "Q1126361",
    "question_audio": null,
    "question_video": null,
    "map_id": 24895,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hemoptysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history and CT findings suggest bronchiectasis, characterized by chronic productive cough and recurrent lung infections. One of the most significant complications of bronchiectasis is hemoptysis due to damage and dilation of the bronchial arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Rhizopus infections:</span></strong><span style=\"font-size:12.0pt\"> Causes Mucormycosis. Uncommon in bronchiectasis. More common in patients with DKA or COVID19</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pneumothorax:</span></strong><span style=\"font-size:12.0pt\"> While possible, it is less common in bronchiectasis. More common in Emphysema</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung cancer:</span></strong><span style=\"font-size:12.0pt\"> Bronchiectasis is not a risk factor for lung cancer </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchiectasis, characterized by chronic productive cough and recurrent lung infections, significantly increases the risk of hemoptysis due to damage and dilation of the bronchial arteries.</span></span></span></p>",
    "correct_choice_id": 199319,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 49941,
    "choices": [
      {
        "id": 199323,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cells with multilobular nuclei and enzyme-filled granules</span></span></span></p>"
      },
      {
        "id": 199324,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Collagen &alpha;-chains in triplets</span></span></p>"
      },
      {
        "id": 199325,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heavy and light protein chains linked by disulfide bonds</span></span></p>"
      },
      {
        "id": 199326,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tubular arrangements of linked heavy chains that slide against one another</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old man with a history of upper respiratory tract infections presents with four other respiratory infections this year and frequent bouts of otitis media. He was diagnosed with bronchiectasis as a child. Which structure is most likely defective in this patient?</span></span></span></p>",
    "unique_key": "Q4223105",
    "question_audio": null,
    "question_video": null,
    "map_id": 24896,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tubular arrangements of linked heavy chains that slide against one another</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms suggest primary ciliary dyskinesia (Kartagener syndrome), where the defect is in the cilia&#39;s dynein arms. These are tubular arrangements of linked heavy chains that slide against one another to facilitate movement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cells with multilobular nuclei and enzyme-filled granules:</span></strong><span style=\"font-size:12.0pt\"> Refers to neutrophils, not related to this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Collagen &alpha;-chains in triplets:</span></strong><span style=\"font-size:12.0pt\"> Related to collagen structure, not relevant here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Heavy and light protein chains linked by disulfide bonds:</span></strong><span style=\"font-size:12.0pt\"> Refers to immunoglobulins, not relevant here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s symptoms suggest primary ciliary dyskinesia (Kartagener syndrome), where the defect is in the cilia&#39;s dynein arms, which are tubular arrangements of linked heavy chains that slide against one another to facilitate movement.</span></span></span></p>",
    "correct_choice_id": 199326,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 49942,
    "choices": [
      {
        "id": 199327,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudomonas aeruginosa</span></span></p>"
      },
      {
        "id": 199328,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Staphylococcus aureus</span></span></p>"
      },
      {
        "id": 199329,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Haemophilus influenzae</span></span></p>"
      },
      {
        "id": 199330,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Streptococcus pneumoniae</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child with cystic fibrosis presents with a persistent cough and frequent respiratory infections over the past year. Sputum cultures have consistently grown a specific pathogen. Given the patient&#39;s age and clinical history, which pathogen is most likely responsible for these early respiratory infections?</span></span></p>",
    "unique_key": "Q1707191",
    "question_audio": null,
    "question_video": null,
    "map_id": 24897,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Staphylococcus aureus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Staphylococcus aureus is the primary pathogen responsible for early respiratory infections in cystic fibrosis patients. It frequently colonizes the respiratory tract of young children with cystic fibrosis and can cause persistent and recurrent infections, leading to inflammation and damage in the lungs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pseudomonas aeruginosa:</span></strong><span style=\"font-size:12.0pt\"> This pathogen typically becomes more prevalent in the respiratory tracts of cystic fibrosis patients as they get older and is associated with chronic lung infections and a more rapid decline in lung function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Haemophilus influenzae:</span></strong><span style=\"font-size:12.0pt\"> This bacterium can cause respiratory infections but is less common and less significant than Staphylococcus aureus in the early stages of cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Streptococcus pneumoniae:</span></strong><span style=\"font-size:12.0pt\"> Although it can cause respiratory infections, it is not the primary pathogen in early cystic fibrosis respiratory infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Staphylococcus aureus is the primary pathogen responsible for early respiratory infections in young children with cystic fibrosis, frequently causing persistent and recurrent infections.</span></span></span></p>",
    "correct_choice_id": 199328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 49943,
    "choices": [
      {
        "id": 199331,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of liver dysfunction post-transplant</span></span></p>"
      },
      {
        "id": 199332,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced success rates of lung transplantation</span></span></span></p>"
      },
      {
        "id": 199333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Higher likelihood of developing diabetes post-transplant</span></span></span></p>"
      },
      {
        "id": 199334,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of gastrointestinal complications</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 16-year-old patient with cystic fibrosis, who has been colonized with Burkholderia cepacia complex (BCC), is scheduled for a lung transplant evaluation. What is a major concern related to BCC colonization in this context?</span></span></span></p>",
    "unique_key": "Q6352765",
    "question_audio": null,
    "question_video": null,
    "map_id": 24898,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Reduced success rates of lung transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colonization with Burkholderia cepacia complex (BCC) is a significant concern in cystic fibrosis patients undergoing lung transplantation due to the increased risk of post-transplant complications and reduced success rates. BCC is highly resistant to antibiotics and can lead to severe infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased risk of liver dysfunction post-transplant:</span></strong><span style=\"font-size:12.0pt\"> This is not specifically related to BCC colonization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Higher likelihood of developing diabetes post-transplant:</span></strong><span style=\"font-size:12.0pt\"> Diabetes can occur post-transplant but is not specifically linked to BCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increased risk of gastrointestinal complications:</span></strong><span style=\"font-size:12.0pt\"> Gastrointestinal issues are common in cystic fibrosis but not specifically related to BCC colonization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkholderia cepacia complex (BCC) colonization in cystic fibrosis patients is a significant concern due to the reduced success rates and increased risk of severe infections post-lung transplantation.</span></span></span></p>",
    "correct_choice_id": 199332,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49944,
    "choices": [
      {
        "id": 199335,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10-15 mL per year</span></span></p>"
      },
      {
        "id": 199336,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20-30 mL per year</span></span></p>"
      },
      {
        "id": 199337,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50-55 mL per year</span></span></span></p>"
      },
      {
        "id": 199338,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">70-80 mL per year</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old patient with a history of non-CF bronchiectasis presents for a routine follow-up. The patient has experienced a noticeable decline in lung function over the past few years. What is the typical annual decline in FEV1 for patients with non-CF bronchiectasis?</span></span></p>",
    "unique_key": "Q6850362",
    "question_audio": null,
    "question_video": null,
    "map_id": 24899,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 50-55 mL per year</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with non-CF bronchiectasis typically experience a decline in FEV1 of about 50-55 mL per year, which is significantly higher than the decline observed in healthy individuals (20-30 mL per year). This rapid decline highlights the progressive nature of bronchiectasis and the importance of regular monitoring and management to slow disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">. <strong>10-15 mL per year:</strong> This rate is too low and more typical of normal aging in healthy individuals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 20-30 mL per year:</span></strong><span style=\"font-size:12.0pt\"> This is the decline seen in healthy controls, not in bronchiectasis patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 70-80 mL per year:</span></strong><span style=\"font-size:12.0pt\"> This rate is higher than what is typically observed in non-CF bronchiectasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with non-CF bronchiectasis typically experience an annual decline in FEV1 of about 50-55 mL, highlighting the progressive nature of the disease.</span></span></p>",
    "correct_choice_id": 199337,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49945,
    "choices": [
      {
        "id": 199339,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obstruction of the epididymis</span></span></span></p>"
      },
      {
        "id": 199340,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Complete involution of the vas deferens</span></span></p>"
      },
      {
        "id": 199341,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defective spermatogenesis</span></span></p>"
      },
      {
        "id": 199342,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal imbalances</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A male patient with cystic fibrosis is found to be infertile despite having normal spermatogenesis. What is the most likely cause of this infertility?</span></span></span></p>",
    "unique_key": "Q7265437",
    "question_audio": null,
    "question_video": null,
    "map_id": 24900,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Complete involution of the vas deferens</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cystic fibrosis, nearly 99% of males are infertile due to the complete involution of the vas deferens, despite having normal spermatogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Obstruction of the epididymis:</span></strong><span style=\"font-size:12.0pt\"> Not the primary cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Defective spermatogenesis:</span></strong><span style=\"font-size:12.0pt\"> Spermatogenesis is typically normal in CF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hormonal imbalances:</span></strong><span style=\"font-size:12.0pt\"> Infertility in CF is primarily due to anatomical defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cystic fibrosis, nearly 99% of males are infertile due to the complete involution of the vas deferens, despite having normal spermatogenesis.</span></span></p>",
    "correct_choice_id": 199340,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49946,
    "choices": [
      {
        "id": 199343,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Appendicitis </span></span></span></p>"
      },
      {
        "id": 199344,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crohn&#39;s disease </span></span></span></p>"
      },
      {
        "id": 199345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal intestinal obstruction syndrome (DIOS) </span></span></span></p>"
      },
      {
        "id": 199346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intussusception</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old with cystic fibrosis presents with right lower quadrant abdominal pain, nausea, vomiting, and obstipation. Abdominal X-ray reveals a mass in the ileocecal region with dilated bowel loops. Which of the following is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q2444842",
    "question_audio": null,
    "question_video": null,
    "map_id": 24901,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Distal Intestinal Obstruction Syndrome (DIOS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal Intestinal Obstruction Syndrome (DIOS): This is a common complication in cystic fibrosis patients, caused by the buildup of thick, sticky stools in the distal ileum and cecum. The symptoms described (abdominal pain, nausea, vomiting, obstipation) and the radiological finding of a mass in the ileocecal region with dilated bowel loops are classic for DIOS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Appendicitis:</span></strong><span style=\"font-size:12.0pt\"> While appendicitis can present with similar symptoms, the presence of a mass in the ileocecal region and the patient&#39;s history of cystic fibrosis make DIOS a more likely diagnosis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Crohn&#39;s disease:</span></strong><span style=\"font-size:12.0pt\"> Crohn&#39;s disease is an inflammatory bowel disease that can cause abdominal pain and bowel obstruction. However, it is less common in cystic fibrosis patients and typically presents with a different clinical picture and radiological findings</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intussusception:</span></strong><span style=\"font-size:12.0pt\"> Intussusception is the telescoping of one segment of the intestine into another. While it can cause bowel obstruction, it is more common in children and usually presents with a sausage-shaped mass on palpation, which is not seen in this case.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal Intestinal Obstruction Syndrome (DIOS) is a common complication in cystic fibrosis, characterized by the buildup of thick, sticky stools in the distal ileum and cecum, leading to abdominal pain, nausea, vomiting, and obstipation.</span></span></span></p>",
    "correct_choice_id": 199345,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49947,
    "choices": [
      {
        "id": 199347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired synthesis of the CFTR protein</span></span></span></p>"
      },
      {
        "id": 199348,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defective chloride channel function at the cell surface</span></span></p>"
      },
      {
        "id": 199349,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased degradation of the CFTR protein in the endoplasmic reticulum</span></span></p>"
      },
      {
        "id": 199350,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abnormal post-translational modification of the CFTR protein</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old female patient with cystic fibrosis is found to have the most common mutation seen in these patients. What is the primary defect caused by this mutation?</span></span></span></p>",
    "unique_key": "Q1636120",
    "question_audio": null,
    "question_video": null,
    "map_id": 24902,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased degradation of the CFTR protein in the endoplasmic reticulum</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common mutation in cystic fibrosis is delta F508 mutation&nbsp; and this results in the misfolding of the CFTR protein, leading to its increased degradation in the endoplasmic reticulum. As a result, the defective CFTR protein fails to reach the cell surface, causing impaired chloride and water transport, which characterizes cystic fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Impaired synthesis of the CFTR protein:</span></strong><span style=\"font-size:12.0pt\"> The delta F508 mutation affects protein folding, not synthesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Defective chloride channel function at the cell surface</span></strong><span style=\"font-size:12.0pt\">: This is a consequence, but the primary issue is the degradation before reaching the cell surface.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Abnormal post-translational modification of the CFTR protein</span></strong><span style=\"font-size:12.0pt\">: This is not the main issue with the delta F508 mutation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common mutation in cystic fibrosis, delta F508, leads to increased degradation of the CFTR protein in the endoplasmic reticulum, preventing it from reaching the cell surface and causing impaired chloride and water transport.</span></span></p>",
    "correct_choice_id": 199349,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 49948,
    "choices": [
      {
        "id": 199351,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivacaftor monotherapy</span></span></p>"
      },
      {
        "id": 199352,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumacaftor/Ivacaftor combination</span></span></p>"
      },
      {
        "id": 199353,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tezacaftor/Ivacaftor combination</span></span></p>"
      },
      {
        "id": 199354,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elexacaftor/Tezacaftor/Ivacaftor combination</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old patient with cystic fibrosis has a homozygous F508del mutation in the CFTR gene. What is the most appropriate treatment regimen?</span></span></p>",
    "unique_key": "Q3804434",
    "question_audio": null,
    "question_video": null,
    "map_id": 24903,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Elexacaftor/Tezacaftor/Ivacaftor combination&nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Elexacaftor/Tezacaftor/Ivacaftor combination, known as Trikafta, is the most advanced and effective treatment for patients with the F508del mutation in the CFTR gene. This triple therapy works by correcting the folding defect (Elexacaftor and Tezacaftor) and enhancing the function of the CFTR protein at the cell surface (Ivacaftor), leading to significant improvements in lung function and other clinical outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ivacaftor monotherapy:</span></strong><span style=\"font-size:12.0pt\"> Effective for certain gating mutations but not sufficient for the F508del mutation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lumacaftor/Ivacaftor combination:</span></strong><span style=\"font-size:12.0pt\"> Provides benefit for F508del mutation but is less effective than the triple therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tezacaftor/Ivacaftor combination:</span></strong><span style=\"font-size:12.0pt\"> An improvement over Lumacaftor/Ivacaftor but still not as effective as the triple therapy for the F508del mutation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Elexacaftor/Tezacaftor/Ivacaftor combination (Trikafta) is the most advanced and effective treatment for patients with the F508del mutation in the CFTR gene.</span></span></span></p>",
    "correct_choice_id": 199354,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49949,
    "choices": [
      {
        "id": 199355,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class I mutation leading to no CFTR protein production</span></span></p>"
      },
      {
        "id": 199356,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II mutation causing defective protein processing</span></span></p>"
      },
      {
        "id": 199357,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class III mutation resulting in defective channel regulation</span></span></p>"
      },
      {
        "id": 199358,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class IV mutation causing decreased conductance</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old cystic fibrosis patient is found to have a CFTR mutation that results in defective protein processing and impaired channel function. Which type of CFTR defect is most effectively treated with a combination of potentiators and correctors?</span></span></p>",
    "unique_key": "Q2566399",
    "question_audio": null,
    "question_video": null,
    "map_id": 24904,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Class II mutation causing defective protein processing</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II CFTR mutations, such as the F508del mutation, result in defective protein processing that leads to misfolded CFTR proteins that are degraded before reaching the cell surface. This type of defect benefits from a combination of correctors and potentiators. Correctors, such as Lumacaftor or Tezacaftor, improve the folding and trafficking of the CFTR protein to the cell surface, while potentiators, such as Ivacaftor, enhance the function of the CFTR protein at the cell surface.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Class I mutation leading to no CFTR protein production:</span></strong><span style=\"font-size:12.0pt\"> These mutations produce little to no CFTR protein, making correctors and potentiators ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Class III mutation resulting in defective channel regulation</span></strong><span style=\"font-size:12.0pt\">: Typically treated effectively with potentiators alone, as the CFTR protein is present but dysfunctional.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Class IV mutation causing decreased conductance:</span></strong><span style=\"font-size:12.0pt\"> Potentiators may help, but the primary defect involves reduced channel function rather than misprocessing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II CFTR mutations causing defective protein processing are most effectively treated with a combination of correctors and potentiators.</span></span></p>",
    "correct_choice_id": 199356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49950,
    "choices": [
      {
        "id": 199359,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoid Endotracheal intubation</span></span></p>"
      },
      {
        "id": 199360,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective intubation of the bleeding lung to remove blood clots</span></span></p>"
      },
      {
        "id": 199361,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insert a single-lumen endotracheal tube</span></span></p>"
      },
      {
        "id": 199362,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Position the patient with the bleeding side down</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old man presents with massive hemoptysis and is desaturating. Which of the following is incorrect according to AAFP guidelines?</span></span></span></p>",
    "unique_key": "Q7879192",
    "question_audio": null,
    "question_video": null,
    "map_id": 24905,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Selective intubation of the bleeding lung to remove blood clots</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B :</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to AAFP guidelines, selective intubation should be performed on the nonbleeding lung, not the bleeding lung. This helps protect the nonbleeding lung from contamination and allows effective ventilation. Avoiding endotracheal intubation is recommended unless truly necessary, and positioning the patient with the bleeding side down helps keep blood out of the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Avoid Endotracheal intubation:</span></strong><span style=\"font-size:12.0pt\"> Recommended unless absolutely necessary, to use the cough reflex for blood removal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insert a single-lumen endotracheal tube:</span></strong><span style=\"font-size:12.0pt\"> Incorrect as it does not allow for selective ventilation and protection of the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Position the patient with the bleeding side down</span></strong><span style=\"font-size:12.0pt\">: Correct as it uses gravitational advantage to prevent blood from entering the nonbleeding lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to AAFP guidelines, selective intubation should be performed on the nonbleeding lung, not the bleeding lung, to protect the nonbleeding lung from contamination and ensure effective ventilation.</span></span></span></p>",
    "correct_choice_id": 199360,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49951,
    "choices": [
      {
        "id": 199363,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberculosis</span></span></p>"
      },
      {
        "id": 199364,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Viral bronchitis</span></span></p>"
      },
      {
        "id": 199365,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer</span></span></p>"
      },
      {
        "id": 199366,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old lady presents with non-massive hemoptysis. What is the most common cause?</span></span></p>",
    "unique_key": "Q7296196",
    "question_audio": null,
    "question_video": null,
    "map_id": 24906,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Viral bronchitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Viral bronchitis is the most common cause of non-massive hemoptysis, typically resulting from inflammation and irritation of the airways. It often presents with a productive cough and blood-tinged sputum, especially in the context of a recent or ongoing respiratory infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tuberculosis:</span></strong><span style=\"font-size:12.0pt\"> It is one of the most common causes in developing countries like India.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lung cancer:</span></strong><span style=\"font-size:12.0pt\"> A significant cause but not the most common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pulmonary embolism:</span></strong><span style=\"font-size:12.0pt\"> Can cause hemoptysis, but it is not the most common cause of non-massive hemoptysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective</u>: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Viral bronchitis is the most common cause of non-massive hemoptysis, typically resulting from inflammation and irritation of the airways.</span></span></span></p>",
    "correct_choice_id": 199364,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 49952,
    "choices": [
      {
        "id": 199367,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchoscopy</span></span></p>"
      },
      {
        "id": 199368,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchial artery embolization</span></span></p>"
      },
      {
        "id": 199369,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Surgical resection</span></span></p>"
      },
      {
        "id": 199370,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous antibiotic therapy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old male presents with massive hemoptysis. What is the procedure of choice for controlling the bleeding?</span></span></span></p>",
    "unique_key": "Q5313482",
    "question_audio": null,
    "question_video": null,
    "map_id": 24907,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bronchial artery embolization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial artery embolization is the procedure of choice for controlling bleeding in life-threatening cases of hemoptysis as most massive bleeds originate from the bronchial circulation. This interventional radiology technique effectively targets and stops the source of bleeding, providing rapid control and stabilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bronchoscopy:</span></strong><span style=\"font-size:12.0pt\"> Useful for diagnosis and initial management but not primarily for controlling severe bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Surgical resection:</span></strong><span style=\"font-size:12.0pt\"> Considered when embolization fails or is not feasible, but it is more invasive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intravenous antibiotic therapy:</span></strong><span style=\"font-size:12.0pt\"> Used to treat underlying infections but not effective for immediate control of severe bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchial artery embolization is the procedure of choice for controlling bleeding in life-threatening cases of massive hemoptysis.</span></span></span></p>",
    "correct_choice_id": 199368,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49953,
    "choices": [
      {
        "id": 199371,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></p>"
      },
      {
        "id": 199372,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stroke</span></span></p>"
      },
      {
        "id": 199373,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis</span></span></p>"
      },
      {
        "id": 199374,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiovascular disease</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are complications of obstructive sleep apnea (OSA) except:</span></span></p>",
    "unique_key": "Q1273527",
    "question_audio": null,
    "question_video": null,
    "map_id": 24908,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pulmonary fibrosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">OPtion C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obstructive sleep apnea (OSA) is associated with several complications, including hypertension, stroke, and cardiovascular disease, due to repeated episodes of hypoxia and increased sympathetic activity. Pulmonary fibrosis, however, is not a typical complication of OSA and is more commonly associated with other conditions such as chronic exposure to lung irritants or autoimmune diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Hypertension:</span></strong><span style=\"font-size:12.0pt\"> Common in OSA due to repeated hypoxic episodes and increased sympathetic activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Stroke:</span></strong><span style=\"font-size:12.0pt\"> Increased risk due to the association of OSA with hypertension and other cardiovascular risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiovascular disease:</span></strong><span style=\"font-size:12.0pt\"> Strongly linked with OSA, including conditions such as heart failure and arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis is not a typical complication of obstructive sleep apnea (OSA); common complications include hypertension, stroke, and cardiovascular disease.</span></span></p>",
    "correct_choice_id": 199373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20283,
    "choices": [
      {
        "id": 81093,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transudative</span></span></p>"
      },
      {
        "id": 81094,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exudative</span></span></p>"
      },
      {
        "id": 81095,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignant</span></span></p>"
      },
      {
        "id": 81096,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemorrhagic</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with dyspnea and pleuritic chest pain. A chest X-ray reveals a pleural effusion. Diagnostic thoracentesis is performed, and pleural fluid analysis shows the following: pleural fluid protein/serum protein ratio of 0.7. How would this pleural effusion be classified?</span></span></p>",
    "unique_key": "Q6826751",
    "question_audio": null,
    "question_video": null,
    "map_id": 20231,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Exudative</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to Light&#39;s criteria, a pleural effusion is classified as exudative if one or more of the following criteria are met:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pleural fluid protein/serum protein ratio &gt; 0.5</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pleural fluid LDH/serum LDH ratio &gt; 0.6</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pleural fluid LDH is greater than two-thirds of the upper limit of normal for serum LDH.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the pleural fluid protein/serum protein ratio is 0.7, the pleural fluid LDH/serum LDH ratio is 0.8, and the pleural fluid LDH is greater than two-thirds of the upper limit of normal for serum LDH, fulfilling all criteria for an exudative effusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Transudative</span></strong><span style=\"font-size:12.0pt\">: Transudative effusions do not meet Light&#39;s criteria for exudative effusions and are typically due to systemic factors such as heart failure or cirrhosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Malignant</span></strong><span style=\"font-size:12.0pt\">: While malignancy can cause exudative effusions, this classification is based on Light&#39;s criteria, not etiology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hemorrhagic</span></strong><span style=\"font-size:12.0pt\">: Refers to the presence of blood in the pleural fluid, which is a descriptive term rather than a classification based on Light&#39;s criteria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A pleural effusion is classified as exudative if one or more of Light&#39;s criteria are met, such as a pleural fluid protein/serum protein ratio &gt; 0.5. In this case, the pleural fluid protein/serum protein ratio is 0.7, classifying it as exudative.</span></span></span></p>",
    "correct_choice_id": 81094,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49956,
    "choices": [
      {
        "id": 199383,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loculated pleural fluid</span></span></span></p>"
      },
      {
        "id": 199384,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pleural fluid pH &lt; 7.2</span></span></span></p>"
      },
      {
        "id": 199385,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pleural fluid glucose &lt; 60 mg/dL</span></span></span></p>"
      },
      {
        "id": 199386,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of gross pus in the pleural space</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with dyspnea and pleuritic chest pain. Thoracentesis reveals loculated pleural fluid, pH of 7.15, glucose of 2.8 mmol/L (50 mg/dL), and gross pus in the pleural space. Which of the following is not an indication for chest drain placement?</span></span></p>",
    "unique_key": "Q1105899",
    "question_audio": null,
    "question_video": null,
    "map_id": 24910,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pleural fluid glucose &lt;60 mg/dL)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While low pleural fluid glucose (&lt;3.3 mmol/L or &lt;60 mg/dL) suggests a complicated effusion, it is not an absolute indication for chest drain placement. The other conditions&mdash;loculated fluid, low pH (&lt;7.20), and gross pus&mdash;definitely indicate the need for drainage to prevent or treat empyema or complicated parapneumonic effusions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Loculated pleural fluid</span></strong><span style=\"font-size:12.0pt\">: Indicates complicated effusion that often requires drainage</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pleural fluid pH &lt;7.2</span></strong><span style=\"font-size:12.0pt\">: Suggests a more severe infection or inflammation needing drainage</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Presence of gross pus in the pleural space:</span></strong><span style=\"font-size:12.0pt\"> Clearly indicates empyema, which requires drainage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While low pleural fluid glucose (&lt;3.3 mmol/L or &lt;60 mg/dL) suggests a complicated effusion, it is not an absolute indication for chest drain placement. However, loculated pleural fluid, pleural fluid pH &lt;7.2, and the presence of gross pus in the pleural space are definite indications for chest drain placement to prevent or treat empyema or complicated parapneumonic effusions.</span></span></span></p>",
    "correct_choice_id": 199385,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 49957,
    "choices": [
      {
        "id": 199387,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intrapleural fibrinolytic agents alone</span></span></p>"
      },
      {
        "id": 199388,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)</span></span></span></p>"
      },
      {
        "id": 199389,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Repeat thoracostomy</span></span></p>"
      },
      {
        "id": 199390,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-dose corticosteroids</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with loculated pleural effusion has been treated with antibiotics and tube thoracostomy. Despite treatment, the patient continues to have fever, leukocytosis, and anorexia. Which of the following treatments should be considered next to improve clinical outcomes ?</span></span></span></p>",
    "unique_key": "Q8254107",
    "question_audio": null,
    "question_video": null,
    "map_id": 24911,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) has been shown in controlled trials to improve clinical outcomes, including increased drainage, decreased length of stay, and decreased surgical referral, compared with placebo or either agent alone. This treatment should be considered when fever, leukocytosis, or anorexia persist despite antibiotics and tube thoracostomy, or when the lung fails to re-expand.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intrapleural fibrinolytic agents alone</span></strong><span style=\"font-size:12.0pt\">: Controlled trials have not shown improvement in drainage with fibrinolytic agents alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Repeat thoracostomy</span></strong><span style=\"font-size:12.0pt\">: Not typically the next step when combination therapy of tPA and DNase can be more effective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High-dose corticosteroids</span></strong><span style=\"font-size:12.0pt\">: Not indicated for improving drainage or treating persistent symptoms in pleural effusion</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) should be considered when fever, leukocytosis, or anorexia persist despite antibiotics and tube thoracostomy, as this combination has been shown to improve clinical outcomes, including increased drainage, decreased length of stay, and decreased surgical referral.</span></span></span></p>",
    "correct_choice_id": 199388,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 49958,
    "choices": [
      {
        "id": 199391,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uncomplicated parapneumonic effusion </span></span></span></p>"
      },
      {
        "id": 199392,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignancy </span></span></span></p>"
      },
      {
        "id": 199393,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Esophageal rupture </span></span></span></p>"
      },
      {
        "id": 199394,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tuberculosis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of alcoholism presents with acute onset of left-sided chest pain and shortness of breath. Chest X-ray reveals a left-sided pleural effusion and pneumothorax. Thoracentesis yields turbid, red-brown fluid with a pH of 5.5. Which of the following is the most likely diagnosis ? </span></span></p>",
    "unique_key": "Q9677121",
    "question_audio": null,
    "question_video": null,
    "map_id": 24912,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Esophageal rupture</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of pleural effusion, pneumothorax, red-brown fluid, and low pH is strongly suggestive of esophageal rupture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Uncomplicated parapneumonic effusions</span></strong><span style=\"font-size:12.0pt\"> typically have clear to turbid fluid with a near normal pH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Malignant</span></strong><span style=\"font-size:12.0pt\"> effusions are rarely associated with pneumothorax or a low pH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tuberculosis</span></strong><span style=\"font-size:12.0pt\"> effusions are usually serous to serosanguineous &nbsp;and have a near normal pH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of pleural effusion, pneumothorax, red-brown fluid, and low pH strongly suggests esophageal rupture.</span></span></span></p>",
    "correct_choice_id": 199393,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 49959,
    "choices": [
      {
        "id": 199395,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary infarction </span></span></p>"
      },
      {
        "id": 199396,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Esophageal rupture </span></span></p>"
      },
      {
        "id": 199397,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignancy </span></span></p>"
      },
      {
        "id": 199398,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parapneumonic effusion</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 70-year-old male presents with sudden onset of pleuritic chest pain and dyspnea. On examination he had an irregularly irregular pulse. X ray showed a wedge shaped opacity with effusion in the left lung. Which of the following is the most likely cause of the effusion ? </span></span></span></p>",
    "unique_key": "Q7581700",
    "question_audio": null,
    "question_video": null,
    "map_id": 24913,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pulmonary infarction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of sudden-onset pleuritic chest pain, dyspnea, irregularly irregular pulse (suggesting atrial fibrillation), and a wedge-shaped opacity on chest X-ray is highly suggestive of pulmonary embolism with subsequent pulmonary infarction. The infarction causes localized tissue damage and inflammation, leading to the pleural effusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Esophageal rupture:</span></strong><span style=\"font-size:12.0pt\"> This would present with severe chest pain, often radiating to the back, and may be associated with subcutaneous emphysema or mediastinal air.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Malignancy:</span></strong><span style=\"font-size:12.0pt\"> While malignancy can cause pleural effusions, they are typically more indolent in onset and not associated with the acute presentation or wedge-shaped opacity seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Parapneumonic effusion:</span></strong><span style=\"font-size:12.0pt\"> This is an effusion associated with pneumonia and would likely present with fever, cough, and a more diffuse consolidation on chest X-ray.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of sudden-onset pleuritic chest pain, dyspnea, irregularly irregular pulse (suggesting atrial fibrillation), and a wedge-shaped opacity on chest X-ray is highly suggestive of pulmonary embolism with subsequent pulmonary infarction, which can cause pleural effusion.</span></span></span></p>",
    "correct_choice_id": 199395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 49960,
    "choices": [
      {
        "id": 199399,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Empyema </span></span></p>"
      },
      {
        "id": 199400,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chylothorax </span></span></p>"
      },
      {
        "id": 199401,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemothorax </span></span></p>"
      },
      {
        "id": 199402,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pseudochylous effusion</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old male with a history of lymphoma presents with dyspnea and a large pleural effusion. Pleural fluid analysis reveals a milky white appearance and an elevated triglyceride level. Which of the following is the most likely diagnosis ? </span></span></p>",
    "unique_key": "Q2477492",
    "question_audio": null,
    "question_video": null,
    "map_id": 24914,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Chylothorax</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The milky white appearance and elevated triglyceride level are characteristic of chylothorax, which is caused by a disruption of the thoracic duct.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Empyema</span></strong><span style=\"font-size:12.0pt\"> presents with purulent fluid and a low glucose level. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hemothorax</span></strong><span style=\"font-size:12.0pt\"> presents with bloody fluid. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pseudochylothorax</span></strong><span style=\"font-size:12.0pt\"> has a milky white appearance but normal triglyceride levels</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A milky white appearance and elevated triglyceride level in pleural fluid are characteristic of chylothorax, which results from the disruption of the thoracic duct.</span></span></span></p>",
    "correct_choice_id": 199400,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 49961,
    "choices": [
      {
        "id": 199403,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 mm </span></span></p>"
      },
      {
        "id": 199404,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10 mm </span></span></span></p>"
      },
      {
        "id": 199405,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">15 mm </span></span></p>"
      },
      {
        "id": 199406,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 mm</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old male presents with a gradual onset of dyspnea and a non-productive cough. Ultrasound confirms the presence of pleural effusion. Which of the following minimum fluid pocket depths on ultrasound would be considered adequate for a safe diagnostic thoracentesis?</span></span></span></p>",
    "unique_key": "Q4171499",
    "question_audio": null,
    "question_video": null,
    "map_id": 24915,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 10 mm</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A minimum pleural fluid pocket depth of 10 mm on ultrasound is generally considered adequate for a safe diagnostic thoracentesis. This depth allows for sufficient space to insert the needle and aspirate fluid without risking lung injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 5 mm:</span></strong><span style=\"font-size:12.0pt\"> This is too shallow and increases the risk of puncturing the lung.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 15 mm and D. 20 mm:</span></strong><span style=\"font-size:12.0pt\"> While these depths are safe, they are not the minimum required. A 10 mm pocket is sufficient for a diagnostic thoracentesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A minimum pleural fluid pocket depth of 10 mm on ultrasound is considered adequate for a safe diagnostic thoracentesis, providing sufficient space to insert the needle and aspirate fluid without risking lung injury.</span></span></span></p>",
    "correct_choice_id": 199404,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 49962,
    "choices": [
      {
        "id": 199407,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is most likely a secondary spontaneous pneumothorax due to underlying lung disease</span></span></p>"
      },
      {
        "id": 199408,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of apical blebs is highly suggestive of Marfan syndrome</span></span></span></p>"
      },
      {
        "id": 199409,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Smoking is an important risk factor</span></span></p>"
      },
      {
        "id": 199410,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrence of pneumothorax is unlikely in this patient population.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 24-year-old tall, thin male presents with acute-onset left-sided chest pain and shortness of breath. He reports a 10-pack-year smoking history. Chest X-ray reveals a small apical pneumothorax. Which of the following statements is most accurate regarding his condition?</span></span></span></p>",
    "unique_key": "Q4683637",
    "question_audio": null,
    "question_video": null,
    "map_id": 24916,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) smoking is an important risk factor</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp; </strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>This is most likely a secondary spontaneous pneumothorax due to underlying lung disease</strong>:&nbsp;This is likely a primary, not secondary, spontaneous pneumothorax given the absence of underlying lung disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>The presence of apical blebs is highly suggestive of Marfan syndrome</strong>:&nbsp;Apical blebs are not specific to Marfan syndrome; they are common in Primary spontaneous pneumothorax</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Recurrence of pneumothorax is unlikely in this patient population</span></strong><span style=\"font-size:12.0pt\">:&nbsp;Recurrence of PSP is common, especially in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is an important risk factor for primary spontaneous pneumothorax, which is often associated with the rupture of subpleural apical blebs in young, tall, thin individuals. Recurrence is common, especially in smokers.</span></span></span></p>",
    "correct_choice_id": 199409,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 49963,
    "choices": [
      {
        "id": 199411,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia </span></span></p>"
      },
      {
        "id": 199412,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism </span></span></span></p>"
      },
      {
        "id": 199413,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary spontaneous pneumothorax </span></span></p>"
      },
      {
        "id": 199414,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tension pneumothorax</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old male with no significant past medical history presents to the emergency department with sudden onset of sharp, right-sided chest pain and shortness of breath. His JVP is normal and BP is 110/70 mm Hg. He denies any recent trauma or illness. X-ray is shown. What is the likely diagnosis ?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-160110.png\" style=\"height:332px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q3439190",
    "question_audio": null,
    "question_video": null,
    "map_id": 24917,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Primary spontaneous pneumothorax</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The chest X-ray demonstrates a visible visceral pleural line with no lung markings peripheral to it, which is diagnostic of a pneumothorax. Given the patient&#39;s young age, lack of underlying lung disease, and absence of trauma, the most likely diagnosis is a primary spontaneous pneumothorax. Primary spontaneous pneumothorax typically occurs due to the rupture of apical blebs in the lungs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pneumonia:</span></strong><span style=\"font-size:12.0pt\"> would typically present with consolidation or infiltrates on chest x-ray.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pulmonary embolism:</span></strong><span style=\"font-size:12.0pt\"> could present with chest pain and shortness of breath, but x-ray findings are usually normal or show subtle abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tension pneumothorax:</span></strong><span style=\"font-size:12.0pt\"> this is a life-threatening emergency where the patients would be having high JVP and hypotension and X rays usually show mediastinal shift and tracheal deviation, which are not seen in this image. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The chest X-ray shows a visible visceral pleural line with no lung markings peripheral to it, indicating a pneumothorax. Given the patient&#39;s young age, lack of underlying lung disease, and absence of trauma, the most likely diagnosis is a primary spontaneous pneumothorax, typically caused by the rupture of apical blebs in the lungs.</span></span></span></p>",
    "correct_choice_id": 199413,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 49964,
    "choices": [
      {
        "id": 199415,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chest X-ray to confirm the diagnosis </span></span></p>"
      },
      {
        "id": 199416,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Needle decompression in the second intercostal space, midclavicular line </span></span></p>"
      },
      {
        "id": 199417,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placement of a chest tube in the fourth intercostal space, anterior axillary line </span></span></p>"
      },
      {
        "id": 199418,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intubation and mechanical ventilation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male presents to the emergency department with sudden onset of shortness of breath, chest pain, and tachycardia. Upon examination, he has decreased breath sounds on the left side, jugular venous distention, and tracheal deviation to the right. The most appropriate immediate management of this patient is:</span></span></p>",
    "unique_key": "Q3121723",
    "question_audio": null,
    "question_video": null,
    "map_id": 24918,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Needle decompression in the second intercostal space, midclavicular line</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and physical exam findings are highly suggestive of a tension pneumothorax, a life-threatening condition. The immediate management of a tension pneumothorax is needle decompression to relieve the pressure in the pleural space. This is performed by inserting a large-bore needle in the second intercostal space, midclavicular line on the affected side.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">(Note that <em><u>ATLS 10<sup>th</sup> edition recommends needle thoracostomy to be done in the 5<sup>th</sup> ICS in the mid-axillary line</u></em>. But this is often difficult in obese individuals and has a higher failure rate as the chest wall is thicker at the 5<sup>th</sup> ICS. Also, it is difficult in pre-hospital settings as arm movements in the ambulance or by the patient can disrupt the catheters in place)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chest X-ray to confirm the diagnosis:</span></strong><span style=\"font-size:12.0pt\"> While a chest X-ray can confirm the diagnosis, it should not delay the immediate treatment of needle decompression in a suspected tension pneumothorax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Placement of a chest tube in the fourth intercostal space, anterior axillary line:</span></strong><span style=\"font-size:12.0pt\"> This is the definitive treatment for pneumothorax, but needle decompression is the immediate life-saving intervention in a tension pneumothorax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intubation and mechanical ventilation:</span></strong><span style=\"font-size:12.0pt\"> While intubation and mechanical ventilation may be necessary later in the management, needle decompression is the priority in stabilizing the patient&#39;s condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The immediate management of a tension pneumothorax is needle decompression in the second intercostal space, midclavicular line, to relieve the pressure in the pleural space and stabilize the patient&#39;s condition. This is a life-saving intervention that should be performed promptly based on clinical suspicion without waiting for imaging confirmation.</span></span></span></p>",
    "correct_choice_id": 199416,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20198,
    "choices": [
      {
        "id": 80754,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CFTR</span></span></p>"
      },
      {
        "id": 80755,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MUC5B</span></span></p>"
      },
      {
        "id": 80756,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1</span></span></p>"
      },
      {
        "id": 80757,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">KRAS</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 70-year-old man is diagnosed with idiopathic pulmonary fibrosis (IPF) after presenting with progressive dyspnea and a dry cough and he has a strong family history. Which gene mutation is most commonly associated with idiopathic pulmonary fibrosis?</span></span></span></p>",
    "unique_key": "Q5183321",
    "question_audio": null,
    "question_video": null,
    "map_id": 20146,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Ans. B)&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">MUC5B</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The MUC5B gene mutation is the most commonly associated genetic variant with idiopathic pulmonary fibrosis (IPF). This mutation is linked to the production of mucin, a component of mucus, and has been shown to influence the prognosis and progression of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. CFTR:</span></strong><span style=\"font-size:12.0pt\"> Associated with cystic fibrosis, not IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. BRCA1:</span></strong><span style=\"font-size:12.0pt\"> Associated with breast and ovarian cancer, not IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. KRAS:</span></strong><span style=\"font-size:12.0pt\"> Commonly associated with various cancers, including lung cancer, but not specifically IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The MUC5B gene mutation is the most commonly associated genetic variant with idiopathic pulmonary fibrosis (IPF).</span></span></span></p>",
    "correct_choice_id": 80755,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20202,
    "choices": [
      {
        "id": 80769,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-specific interstitial pneumonia</span></span></p>"
      },
      {
        "id": 80770,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desquamative interstitial pneumonia</span></span></p>"
      },
      {
        "id": 80771,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary fibrosis</span></span></p>"
      },
      {
        "id": 80772,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Respiratory bronchiolitis associated interstitial lung disease</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old woman presents with progressive shortness of breath and a dry cough. High-resolution CT of the chest reveals honeycombing and reticular opacities. Based on epidemiological data, which of the following is the most common interstitial lung disease?</span></span></span></p>",
    "unique_key": "Q2341871",
    "question_audio": null,
    "question_video": null,
    "map_id": 20149,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Ans. C)&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Idiopathic pulmonary fibrosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease, characterized by progressive scarring of the lung tissue leading to respiratory failure. It is often diagnosed in older adults and has a poor prognosis. The presence of honeycombing and reticular opacities on high-resolution CT is indicative of IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Non-specific interstitial pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Less common than IPF and has different radiographic and clinical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Desquamative interstitial pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Also less common and typically associated with smoking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Respiratory bronchiolitis associated interstitial lung disease:</span></strong><span style=\"font-size:12.0pt\"> Primarily seen in smokers but less common than IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The most common interstitial lung disease is idiopathic pulmonary fibrosis.</span></strong></span></span></p>",
    "correct_choice_id": 80771,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20216,
    "choices": [
      {
        "id": 80825,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic obstructive pulmonary disease (COPD)</span></span></span></p>"
      },
      {
        "id": 80826,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interstitial lung disease (ILD)</span></span></span></p>"
      },
      {
        "id": 80827,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic bronchitis</span></span></p>"
      },
      {
        "id": 80828,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old retired coal miner presents with progressive shortness of breath and chronic cough. He has a long history of working in coal mines. Which of the following conditions is least likely to be associated with his occupational history?</span></span></span></p>",
    "unique_key": "Q7588020",
    "question_audio": null,
    "question_video": null,
    "map_id": 20164,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Lung cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coal workers&#39; pneumoconiosis (CWP), also known as black lung disease, is associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and chronic bronchitis due to long-term inhalation of coal dust. These conditions lead to progressive lung damage and respiratory impairment. However, CWP is not directly associated with an increased risk of lung cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic obstructive pulmonary disease (COPD):</span></strong><span style=\"font-size:12.0pt\"> CWP can lead to the development of COPD due to long-term exposure to coal dust.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Interstitial lung disease (ILD):</span></strong><span style=\"font-size:12.0pt\"> CWP is a form of ILD caused by coal dust inhalation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chronic bronchitis: </span></strong><span style=\"font-size:12.0pt\">Chronic bronchitis is common in coal workers due to continuous exposure to coal dust.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coal workers&#39; pneumoconiosis (CWP), or black lung disease, is associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and chronic bronchitis due to long-term inhalation of coal dust. However, CWP is not directly associated with an increased risk of lung cancer.</span></span></span></p>",
    "correct_choice_id": 80828,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 20217,
    "choices": [
      {
        "id": 80829,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
      },
      {
        "id": 80830,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberculosis</span></span></p>"
      },
      {
        "id": 80831,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Caplan syndrome</span></span></p>"
      },
      {
        "id": 80832,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of working in the mining industry presents with chronic cough and joint pain. Chest X-ray shows multiple, rounded nodules in the lungs. He also has a known diagnosis of rheumatoid arthritis. Which of the following diagnoses best explains his clinical presentation?</span></span></p>",
    "unique_key": "Q8417243",
    "question_audio": null,
    "question_video": null,
    "map_id": 20165,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Caplan syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Caplan syndrome, also known as rheumatoid pneumoconiosis, occurs in patients with rheumatoid arthritis who are exposed to dust such as silica or coal dust. It is characterized by the presence of multiple, rounded nodules on chest X-ray in the setting of underlying pneumoconiosis and rheumatoid arthritis. This condition combines features of both rheumatoid arthritis and pneumoconiosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Characterized by bilateral hilar lymphadenopathy and non-caseating granulomas, not typically associated with rheumatoid arthritis and mining exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tuberculosis:</span></strong><span style=\"font-size:12.0pt\"> Typically presents with cavitary lesions or consolidations, not rounded nodules, and is not associated with rheumatoid arthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Interstitial lung disease (ILD):</span></strong><span style=\"font-size:12.0pt\"> Refers to a group of disorders causing fibrosis and scarring of the lung tissue, which can include conditions like idiopathic pulmonary fibrosis, but does not typically present with the specific combination of rheumatoid arthritis and mining exposure seen in Caplan syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Caplan syndrome, or rheumatoid pneumoconiosis, occurs in patients with rheumatoid arthritis who are exposed to dust such as silica or coal dust. It is characterized by multiple, rounded nodules on chest X-ray in the setting of pneumoconiosis and rheumatoid arthritis.</span></span></span></p>",
    "correct_choice_id": 80831,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20223,
    "choices": [
      {
        "id": 80853,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchoalveolar lavage (BAL) with CD4/CD8 ratio</span></span></p>"
      },
      {
        "id": 80854,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beryllium lymphocyte proliferation test (BeLPT)</span></span></span></p>"
      },
      {
        "id": 80855,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum angiotensin-converting enzyme (ACE) level</span></span></p>"
      },
      {
        "id": 80856,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HRCT of the chest</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 48-year-old man who works in an aerospace manufacturing plant presents with progressive dyspnea, cough, and fatigue. Chest X-ray showed bilateral hilar lymphadenopathy, and a transbronchial lung biopsy revealed non-caseating granulomas. Which diagnostic test is most appropriate for confirming the diagnosis?</span></span></span></p>",
    "unique_key": "Q5149994",
    "question_audio": null,
    "question_video": null,
    "map_id": 20171,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Beryllium lymphocyte proliferation test (BeLPT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Beryllium lymphocyte proliferation test (BeLPT) is the most appropriate diagnostic test for confirming chronic beryllium disease (CBD) in a patient with a history of beryllium exposure and findings of non-caseating granulomas on biopsy. The BeLPT measures the proliferation of lymphocytes in response to beryllium exposure and is specific for diagnosing beryllium sensitization and chronic beryllium disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bronchoalveolar lavage (BAL) with CD4/CD8 ratio</span></strong><span style=\"font-size:12.0pt\">: Useful in sarcoidosis but not specific for berylliosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Serum angiotensin-converting enzyme (ACE) level:</span></strong><span style=\"font-size:12.0pt\"> Elevated in sarcoidosis but not specific for berylliosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High-resolution CT scan of the chest:</span></strong><span style=\"font-size:12.0pt\"> Helps in identifying interstitial lung disease but does not confirm beryllium exposure or CBD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Beryllium lymphocyte proliferation test (BeLPT) is the most appropriate diagnostic test for confirming chronic beryllium disease (CBD) in a patient with a history of beryllium exposure and findings of non-caseating granulomas on biopsy. The BeLPT measures the proliferation of lymphocytes in response to beryllium exposure and is specific for diagnosing beryllium sensitization and chronic beryllium disease.</span></span></span></p>",
    "correct_choice_id": 80854,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20226,
    "choices": [
      {
        "id": 80865,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchoalveolar lavage (BAL) with lymphocyte count</span></span></p>"
      },
      {
        "id": 80866,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum angiotensin-converting enzyme (ACE) level</span></span></p>"
      },
      {
        "id": 80867,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum antigen-specific IgG testing</span></span></p>"
      },
      {
        "id": 80868,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-caseating granulomas in lung biopsy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with chronic cough, dyspnea, and fatigue. She keeps birds as pets, and high-resolution CT of the chest is done and shown. All are useful for diagnosis except:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-124749.png\" style=\"height:250px; width:300px\" /></span></span></p>",
    "unique_key": "Q5742722",
    "question_audio": null,
    "question_video": null,
    "map_id": 20174,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Serum angiotensin-converting enzyme (ACE) level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Based on her history of pets, presenting symptoms and CT (showing scattered regions of ground-glass infiltrates in a mosaic pattern (due to&nbsp; air trapping) - Diagnosis is certainly hypersensitivity pneumonitis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum angiotensin-converting enzyme (ACE) level is typically elevated in sarcoidosis but is not specific for hypersensitivity pneumonitis (HP). Therefore, it is not useful for diagnosing HP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bronchoalveolar lavage (BAL) with lymphocyte count</span></strong><span style=\"font-size:12.0pt\">: An increased lymphocyte count and CD4/CD8 ration of &lt; 1 in BAL fluid is indicative of HP and helps in the diagnosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Serum antigen-specific IgG testing</span></strong><span style=\"font-size:12.0pt\">: Identifies antibodies against specific antigens (such as bird proteins) that can cause HP, making it useful for diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Non-caseating granulomas in lung biopsy</span></strong><span style=\"font-size:12.0pt\">: The presence of non-caseating granulomas is a key histopathological feature of HP, supporting the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum angiotensin-converting enzyme (ACE) level is typically elevated in sarcoidosis but is not specific for hypersensitivity pneumonitis (HP). Therefore, it is not useful for diagnosing HP.</span></span></span></p>",
    "correct_choice_id": 80866,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 20228,
    "choices": [
      {
        "id": 80873,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Penicillium casei</span></span></p>"
      },
      {
        "id": 80874,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coffee bean dust</span></span></p>"
      },
      {
        "id": 80875,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saccharopolyspora rectivirgula</span></span></p>"
      },
      {
        "id": 80876,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Botrytis cinerea</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old agricultural worker presents with symptoms of chronic cough, dyspnea, and fatigue. He reports working with moldy hay and grain regularly. Based on the table, which pathogen is most likely responsible for his condition?</span></span></p>",
    "unique_key": "Q3473535",
    "question_audio": null,
    "question_video": null,
    "map_id": 20176,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong><strong><span style=\"font-size:12.0pt\">Ans. C) Saccharopolyspora rectivirgula</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The question is based on a table from Harrison&rsquo;s Principles of Internal Medicine (Pg 2160), hence may appear difficult to many.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s occupational exposure to moldy hay and grain is consistent with Farmer&#39;s lung, which is caused by inhaling thermophilic actinomycetes such as Saccharopolyspora rectivirgula. This pathogen is commonly associated with hypersensitivity pneumonitis in individuals who work in farming and food processing environments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></strong>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Penicillium casei:</span></strong><span style=\"font-size:12.0pt\"> Associated with Cheese washer&rsquo;s lung, not typically found in moldy hay or grain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coffee bean dust</span></strong><span style=\"font-size:12.0pt\">: Associated with Coffee worker&rsquo;s lung, not relevant to this patient&#39;s agricultural exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Botrytis cinerea:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Associated with Wine maker&rsquo;s lung, linked to grape exposure, not moldy hay or grain.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s occupational exposure to moldy hay and grain is consistent with Farmer&#39;s lung, caused by inhaling thermophilic actinomycetes such as Saccharopolyspora rectivirgula.</span></span></span></p>",
    "correct_choice_id": 80875,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20231,
    "choices": [
      {
        "id": 80885,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mikulicz syndrome</span></span></p>"
      },
      {
        "id": 80886,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heerfordt syndrome</span></span></p>"
      },
      {
        "id": 80887,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L&ouml;fgren syndrome</span></span></p>"
      },
      {
        "id": 80888,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blau syndrome</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with a known diagnosis of sarcoidosis presents with new-onset facial weakness and decreased tear production. She also reports episodes of dry mouth and swelling near her jawline. Which specific manifestation of sarcoidosis is most likely?</span></span></p>",
    "unique_key": "Q1412984",
    "question_audio": null,
    "question_video": null,
    "map_id": 20179,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Ans. B) Heerfordt syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heerfordt syndrome, also known as uveoparotid fever, is a rare manifestation of sarcoidosis characterized by parotid gland enlargement, uveitis, fever, and facial nerve palsy. The patient&rsquo;s symptoms of facial weakness, decreased tear production, dry mouth, and jaw swelling are consistent with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mikulicz syndrome</span></strong><span style=\"font-size:12.0pt\">: Characterized by chronic, painless enlargement of the parotid and lacrimal glands, often associated with Sj&ouml;gren&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. L&ouml;fgren syndrome</span></strong><span style=\"font-size:12.0pt\">: Characterized by bilateral hilar lymphadenopathy, erythema nodosum, and arthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Blau syndrome</span></strong><span style=\"font-size:12.0pt\">: A genetic disorder presenting with granulomatous arthritis, uveitis, and dermatitis, seen in children, not related to Heerfordt syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heerfordt syndrome, also known as uveoparotid fever, is a rare manifestation of sarcoidosis characterized by parotid gland enlargement, uveitis, fever, and facial nerve palsy.</span></span></span></p>",
    "correct_choice_id": 80886,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 20233,
    "choices": [
      {
        "id": 80893,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L&ouml;fgren syndrome</span></span></p>"
      },
      {
        "id": 80894,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heerfordt syndrome</span></span></p>"
      },
      {
        "id": 80895,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mikulicz syndrome</span></span></p>"
      },
      {
        "id": 80896,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blau syndrome</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old African American woman presents with bilateral hilar lymphadenopathy, erythema nodosum, and arthritis. She also reports occasional fever and malaise. What is the most likely clinical syndrome associated with her presentation in the context of sarcoidosis?</span></span></p>",
    "unique_key": "Q8389529",
    "question_audio": null,
    "question_video": null,
    "map_id": 20181,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) L&ouml;fgren syndrome</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">L&ouml;fgren syndrome is a clinical syndrome associated with sarcoidosis characterized by the triad of bilateral hilar lymphadenopathy, erythema nodosum, and arthritis, often accompanied by fever and malaise. It is more common in women and has a good prognosis with spontaneous resolution in many cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Heerfordt syndrome</span></strong><span style=\"font-size:12.0pt\">: Associated with uveoparotid fever, characterized by parotid gland enlargement, uveitis, fever, and facial nerve palsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mikulicz syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by chronic, painless enlargement of the parotid and lacrimal glands, not specific to sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Blau syndrome:&nbsp;</span></strong><span style=\"font-size:12.0pt\">A genetic disorder presenting with granulomatous arthritis, uveitis, and dermatitis, seen in children, not related to L&ouml;fgren syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">L&ouml;fgren syndrome is a clinical syndrome associated with sarcoidosis characterized by the triad of bilateral hilar lymphadenopathy, erythema nodosum, and arthritis, often accompanied by fever and malaise.</span></span></span></p>",
    "correct_choice_id": 80893,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20235,
    "choices": [
      {
        "id": 80901,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lupus vulgaris</span></span></p>"
      },
      {
        "id": 80902,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leprosy</span></span></p>"
      },
      {
        "id": 80903,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lupus pernio</span></span></p>"
      },
      {
        "id": 80904,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Discoid lupus</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman presents with multiple facial lesions as shown in the image. She also reports chronic fatigue and dyspnea. Biopsy of the skin lesions shows non-caseating granulomas. What is the most likely diagnosis?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-131733.png\" style=\"height:273px; width:300px\" /></span></span></p>",
    "unique_key": "Q4927909",
    "question_audio": null,
    "question_video": null,
    "map_id": 20183,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lupus pernio</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lupus pernio is a specific form of cutaneous sarcoidosis characterized by chronic, violaceous, indurated lesions on the face, especially around the nose, cheeks, and ears. It is associated with systemic sarcoidosis, which can present with symptoms like chronic fatigue and dyspnea. The presence of non-caseating granulomas on biopsy confirms the diagnosis of sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lupus vulgaris:</span></strong><span style=\"font-size:12.0pt\"> A form of cutaneous tuberculosis that presents with reddish-brown plaques, not typically associated with non-caseating granulomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Leprosy:</span></strong><span style=\"font-size:12.0pt\"> Presents with hypopigmented or reddish skin lesions with sensory loss and is diagnosed by the presence of Mycobacterium leprae in skin biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Discoid lupus</span></strong><span style=\"font-size:12.0pt\">: Presents with chronic discoid lesions, erythematous plaques with scaling, and can be associated with systemic lupus erythematosus, but does not typically show non-caseating granulomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lupus pernio is a specific form of cutaneous sarcoidosis characterized by chronic, violaceous, indurated lesions on the face, especially around the nose, cheeks, and ears, and is associated with systemic sarcoidosis.</span></span></span></p>",
    "correct_choice_id": 80903,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 20239,
    "choices": [
      {
        "id": 80917,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Optic neuritis</span></span></p>"
      },
      {
        "id": 80918,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CN VII nerve palsy</span></span></p>"
      },
      {
        "id": 80919,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior hypothalamic involvement</span></span></p>"
      },
      {
        "id": 80920,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Basilar meningitis</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman with a known diagnosis of sarcoidosis presents with new-onset vision problems and facial droop on one side. Which of the following neurological manifestations is least likely to be associated with her condition?</span></span></span></p>",
    "unique_key": "Q7723633",
    "question_audio": null,
    "question_video": null,
    "map_id": 20192,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Posterior hypothalamic involvement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:&nbsp; </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcoidosis can involve the nervous system, leading to various neurological manifestations. Common ones include CN VII palsy, Basilar meningitis &nbsp;and anterior hypothalamic involvement (causing Diabetes Insipidus)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CN VII involvement is usually acute and transient (may mimic Bell&rsquo;s Palsy), whereas optic neuritis can be chronic and needs long term treatment. </span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients can also develop seizures and cognitive dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Optic neuritis</span></strong><span style=\"font-size:12.0pt\">: Sarcoidosis can cause inflammation of the optic nerve, leading to vision problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 7th nerve palsy</span></strong><span style=\"font-size:12.0pt\">: Facial nerve palsy is a well-known manifestation of neurosarcoidosis, presenting as facial droop.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Basilar meningitis</span></strong><span style=\"font-size:12.0pt\">: Sarcoidosis can lead to chronic basilar meningitis, presenting with symptoms such as headache and cranial nerve deficits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcoidosis can involve the nervous system, leading to various neurological manifestations such as CN VII palsy, optic neuritis, and basilar meningitis. Posterior hypothalamic involvement is least likely in this context.</span></span></span></p>",
    "correct_choice_id": 80919,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20246,
    "choices": [
      {
        "id": 80945,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></p>"
      },
      {
        "id": 80946,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infliximab</span></span></p>"
      },
      {
        "id": 80947,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisone</span></span></p>"
      },
      {
        "id": 80948,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Azathioprine</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman with biopsy-proven pulmonary sarcoidosis presents with worsening dyspnea and cough. Imaging shows progressive pulmonary involvement which is progressing despite initial management by his clinician. Which of the following is the treatment for refractory disease?</span></span></p>",
    "unique_key": "Q6739578",
    "question_audio": null,
    "question_video": null,
    "map_id": 20194,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Infliximab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For refractory sarcoidosis, where the disease does not respond adequately to corticosteroids (such as prednisone) or other first-line treatments, infliximab, a TNF-alpha inhibitor, may be considered. Infliximab is used for severe or refractory sarcoidosis, particularly in cases where other treatments have failed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methotrexate</span></strong><span style=\"font-size:12.0pt\">: Used as a second-line treatment or steroid-sparing agent, but not typically first-line for refractory disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prednisone</span></strong><span style=\"font-size:12.0pt\">: The first-line treatment for sarcoidosis, but the patient has refractory disease, indicating that prednisone alone is not sufficient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Azathioprine:</span></strong><span style=\"font-size:12.0pt\"> An immunosuppressive agent used as a second-line treatment or steroid-sparing agent, but not the first choice for refractory disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infliximab, a TNF-alpha inhibitor, is used for treating severe or refractory sarcoidosis when initial treatments such as corticosteroids (e.g., prednisone) and second-line agents (e.g., methotrexate, azathioprine) are not effective.</span></span></span></p>",
    "correct_choice_id": 80946,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20247,
    "choices": [
      {
        "id": 80949,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphangioleiomyomatosis (LAM)</span></span></p>"
      },
      {
        "id": 80950,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
      },
      {
        "id": 80951,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary fibrosis (IPF)</span></span></p>"
      },
      {
        "id": 80952,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with progressive dyspnea, recurrent pneumothoraces, and chylous pleural effusions. High-resolution CT of the chest shows diffuse thin-walled cysts. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q1794911",
    "question_audio": null,
    "question_video": null,
    "map_id": 20195,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) Lymphangioleiomyomatosis (LAM)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. It is characterized by the abnormal proliferation of smooth muscle-like cells (LAM cells) that can lead to the formation of cysts, recurrent pneumothoraces, and chylous pleural effusions. The presence of diffuse thin-walled cysts on high-resolution CT is a key diagnostic feature of LAM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Typically presents with bilateral hilar lymphadenopathy and non-caseating granulomas, not diffuse thin-walled cysts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Idiopathic pulmonary fibrosis (IPF):</span></strong><span style=\"font-size:12.0pt\"> Characterized by progressive fibrosis and honeycombing on CT, not thin-walled cysts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic obstructive pulmonary disease (COPD):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Characterized by airflow obstruction and emphysematous changes, not diffuse thin-walled cysts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphangioleiomyomatosis (LAM) is a rare lung disease affecting women of childbearing age, characterized by diffuse thin-walled cysts on high-resolution CT, recurrent pneumothoraces, and chylous pleural effusions. It involves the proliferation of abnormal smooth muscle-like cells, distinguishing it from other conditions like sarcoidosis, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease.</span></span></span></p>",
    "correct_choice_id": 80949,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20248,
    "choices": [
      {
        "id": 80953,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary fibrosis (IPF)</span></span></p>"
      },
      {
        "id": 80954,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary alveolar proteinosis (PAP)</span></span></p>"
      },
      {
        "id": 80955,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
      },
      {
        "id": 80956,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumocystis jirovecii pneumonia (PJP)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old man presents with progressive dyspnea and a chronic cough productive of white, frothy sputum. Chest X-ray shows bilateral alveolar infiltrates, and high-resolution CT of the chest reveals a &quot;crazy paving&quot; pattern. Bronchoalveolar lavage (BAL) yields milky fluid with periodic acid-Schiff (PAS)-positive material. Which of the following is the most likely diagnosis ?</span></span></p>",
    "unique_key": "Q9023735",
    "question_audio": null,
    "question_video": null,
    "map_id": 20196,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary alveolar proteinosis (PAP</span></strong><span style=\"font-size:12.0pt\">)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of surfactant-like material in the alveoli, leading to symptoms such as progressive dyspnea and a chronic cough productive of white, frothy sputum. Radiographic findings include bilateral alveolar infiltrates and a &quot;crazy paving&quot; pattern on high-resolution CT. The presence of PAS-positive material in bronchoalveolar lavage (BAL) fluid is a key diagnostic feature of PAP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Idiopathic pulmonary fibrosis (IPF):</span></strong><span style=\"font-size:12.0pt\"> Typically presents with progressive fibrosis and honeycombing on CT, not a &quot;crazy paving&quot; pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Characterized by bilateral hilar lymphadenopathy and non-caseating granulomas, not PAS-positive material in BAL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pneumocystis jirovecii pneumonia (PJP):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Can present with diffuse bilateral infiltrates, but the BAL fluid would typically show Pneumocystis organisms on special staining, not PAS-positive material.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary alveolar proteinosis (PAP) is diagnosed by the accumulation of surfactant-like material in the alveoli, presenting with progressive dyspnea, a chronic cough with white frothy sputum, bilateral alveolar infiltrates on chest X-ray, and a &quot;crazy paving&quot; pattern on high-resolution CT. The presence of PAS-positive material in bronchoalveolar lavage fluid confirms the diagnosis. This condition is distinct from idiopathic pulmonary fibrosis, sarcoidosis, and Pneumocystis jirovecii pneumonia, each having unique diagnostic features and findings.</span></span></span></p>",
    "correct_choice_id": 80954,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20250,
    "choices": [
      {
        "id": 80961,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cryptogenic organizing pneumonia (COP)</span></span></p>"
      },
      {
        "id": 80962,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary fibrosis (IPF)</span></span></span></p>"
      },
      {
        "id": 80963,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
      },
      {
        "id": 80964,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic eosinophilic pneumonia (CEP)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man presents with a three-month history of non-productive cough, low-grade fever, and progressive dyspnea. Chest X-ray reveals bilateral patchy infiltrates, and high-resolution CT shows peripheral consolidation and ground-glass opacities. Lung biopsy reveals organizing pneumonia with granulation tissue within the alveolar ducts and bronchioles. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q7757250",
    "question_audio": null,
    "question_video": null,
    "map_id": 20198,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) Cryptogenic organizing pneumonia (COP)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryptogenic organizing pneumonia (COP), previously known as bronchiolitis obliterans organizing pneumonia (BOOP), is characterized by the presence of granulation tissue within the alveolar ducts and bronchioles. It often presents with a subacute onset of symptoms such as non-productive cough, low-grade fever, and progressive dyspnea. Radiographic findings include bilateral patchy infiltrates and peripheral consolidation with ground-glass opacities on high-resolution CT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Idiopathic pulmonary fibrosis (IPF):</span></strong><span style=\"font-size:12.0pt\"> Typically presents with progressive fibrosis and honeycombing on CT, not peripheral consolidation and ground-glass opacities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sarcoidosis</span></strong><span style=\"font-size:12.0pt\">: Characterized by bilateral hilar lymphadenopathy and non-caseating granulomas, not organizing pneumonia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic eosinophilic pneumonia (CEP):</span></strong><span style=\"font-size:12.0pt\"> Characterized by peripheral infiltrates on imaging and an increased number of eosinophils in the lung and blood, not organizing pneumonia with granulation tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryptogenic organizing pneumonia (COP) is identified by granulation tissue within the alveolar ducts and bronchioles, presenting with a non-productive cough, low-grade fever, and progressive dyspnea. Imaging shows bilateral patchy infiltrates and peripheral consolidation with ground-glass opacities. It is differentiated from idiopathic pulmonary fibrosis, sarcoidosis, and chronic eosinophilic pneumonia, each having unique histopathological and radiological features.</span></span></span></p>",
    "correct_choice_id": 80961,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20252,
    "choices": [
      {
        "id": 80969,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic eosinophilic pneumonia (CEP)</span></span></span></p>"
      },
      {
        "id": 80970,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute eosinophilic pneumonia</span></span></p>"
      },
      {
        "id": 80971,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypereosinophilic syndrome</span></span></p>"
      },
      {
        "id": 80972,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loeffler&#39;s syndrome</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a history of asthma, progressive dyspnea, and weight loss over the past few months. She also reports night sweats and cough. Chest X-ray shows peripheral infiltrates, and blood tests reveal marked eosinophilia. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q2491638",
    "question_audio": null,
    "question_video": null,
    "map_id": 20201,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>A) Chronic eosinophilic pneumonia (CEP)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic eosinophilic pneumonia (CEP) is characterized by the presence of peripheral infiltrates on chest imaging (often referred to <u>photographic negative of pulmonary edema</u>) and marked eosinophilia in the blood. Patients often present with a history of asthma, progressive dyspnea, weight loss, night sweats, and cough. The combination of these clinical features and imaging findings is highly suggestive of CEP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute eosinophilic pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Typically presents with acute onset of respiratory failure, diffuse pulmonary infiltrates, and eosinophilia in bronchoalveolar lavage fluid but not always in blood.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypereosinophilic syndrome</span></strong><span style=\"font-size:12.0pt\">: Characterized by persistent eosinophilia and multi-organ involvement, not specifically peripheral infiltrates on chest X-ray.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Loeffler&#39;s syndrome</span></strong><span style=\"font-size:12.0pt\">: Characterized by transient pulmonary infiltrates and blood eosinophilia, often due to parasitic infections, and usually resolves within a few weeks without leading to chronic symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic eosinophilic pneumonia (CEP) is identified by peripheral infiltrates on chest imaging and marked eosinophilia in the blood. It presents with a history of asthma, progressive dyspnea, weight loss, night sweats, and cough. This condition is distinguished from acute eosinophilic pneumonia, hypereosinophilic syndrome, and Loeffler&#39;s syndrome based on the specific clinical features, imaging findings, and chronicity of symptoms.</span></span></span></p>",
    "correct_choice_id": 80969,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20260,
    "choices": [
      {
        "id": 81001,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-resolution computed tomography (HRCT) chest</span></span></p>"
      },
      {
        "id": 81002,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluorescence in situ hybridization (FISH)</span></span></p>"
      },
      {
        "id": 81003,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bronchoalveolar lavage (BAL)</span></span></span></p>"
      },
      {
        "id": 81004,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung biopsy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man presents with cough, dyspnea, fatigue, weight loss, and splenomegaly. Blood tests reveal marked eosinophilia and elevated white blood cell count. Chest X-ray shows diffuse infiltrates. Bone marrow biopsy shows increased cellularity with eosinophil precursors and myeloid hyperplasia. What is the next step ?</span></span></p>",
    "unique_key": "Q1662989",
    "question_audio": null,
    "question_video": null,
    "map_id": 20208,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fluorescence in situ hybridization (FISH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Given the clinical presentation, marked eosinophilia, and bone marrow findings, it is crucial to evaluate for specific genetic mutations associated with myeloproliferative neoplasms (MPN) variants of hypereosinophilic syndrome (HES). Fluorescence in situ hybridization (FISH) is a molecular diagnostic tool that can detect specific genetic abnormalities, such as the PDGFRA mutation, which is commonly associated with MPN-HES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. High-resolution computed tomography (HRCT) chest:</span></strong><span style=\"font-size:12.0pt\"> While it provides detailed imaging of lung pathology, it does not identify specific genetic mutations needed for diagnosing MPN-HES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bronchoalveolar lavage (BAL):</span></strong><span style=\"font-size:12.0pt\"> Useful for diagnosing infections and certain interstitial lung diseases but not for identifying genetic mutations associated with MPN-HES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung biopsy:</span></strong><span style=\"font-size:12.0pt\"> While it can provide histopathological information, it is invasive and does not identify specific genetic mutations crucial for diagnosing MPN-HES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For patients with marked eosinophilia and bone marrow findings suggestive of hypereosinophilic syndrome (HES), FISH testing for specific genetic mutations is essential to confirm the diagnosis and guide treatment</span></span></span></p>",
    "correct_choice_id": 81002,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20257,
    "choices": [
      {
        "id": 80989,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic<strong> </strong>eosinophilic pneumonia</span></span></p>"
      },
      {
        "id": 80990,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberculosis</span></span></p>"
      },
      {
        "id": 80991,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tropical pulmonary eosinophilia</span></span></p>"
      },
      {
        "id": 80992,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loeffler&#39;s syndrome</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old man presents with a chronic cough, wheezing, and night sweats. Blood tests reveal marked eosinophilia. Chest X-ray shows diffuse miliary nodules. Which of the following is the most likely diagnosis ?</span></span></p>",
    "unique_key": "Q1345297",
    "question_audio": null,
    "question_video": null,
    "map_id": 20205,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Tropical pulmonary eosinophilia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tropical pulmonary eosinophilia (TPE) is characterized by chronic cough, wheezing, night sweats, and marked eosinophilia. It is caused by an immunological reaction to filarial parasites, commonly presenting with persistent infiltrates in CXR. Some patients can even have diffuse miliary mottling. This diagnosis is likely given the combination of eosinophilia, respiratory symptoms, and characteristic radiographic findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic eosinophilic pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Typically presents with peripheral infiltrates on chest imaging, not miliary nodules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tuberculosis</span></strong><span style=\"font-size:12.0pt\">: Miliary tuberculosis can present with diffuse miliary nodules, but it is not typically associated with marked eosinophilia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Loeffler&#39;s syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by transient pulmonary infiltrates and blood eosinophilia, often due to parasitic infections, but typically resolves within a few weeks and does not present with chronic symptoms or miliary nodules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tropical pulmonary eosinophilia (TPE) is characterized by chronic cough, wheezing, night sweats, and marked eosinophilia. It is caused by an immunological reaction to filarial parasites and commonly presents with persistent infiltrates and diffuse miliary nodules on chest X-ray. This condition is distinguished from chronic eosinophilic pneumonia, tuberculosis, and Loeffler&#39;s syndrome based on the combination of eosinophilia, respiratory symptoms, and characteristic radiographic findings.</span></span></span></p>",
    "correct_choice_id": 80991,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20272,
    "choices": [
      {
        "id": 81049,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphangioleiomyomatosis (LAM)</span></span></p>"
      },
      {
        "id": 81050,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary Langerhans cell histiocytosis (PLCH)</span></span></span></p>"
      },
      {
        "id": 81051,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary fibrosis (IPF)</span></span></span></p>"
      },
      {
        "id": 81052,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sarcoidosis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old male smoker presents with chronic cough and dyspnea. He reports unintentional weight loss and episodes of spontaneous pneumothorax. High-resolution CT of the chest shows numerous thin-walled cysts and nodules predominantly in the upper lobes. Lung biopsy reveals characteristic tennis racquet like granules on electron microscopy. What is the likely diagnosis?</span></span></p>",
    "unique_key": "Q8834561",
    "question_audio": null,
    "question_video": null,
    "map_id": 20227,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary Langerhans cell histiocytosis (PLCH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary Langerhans cell histiocytosis (PLCH) is a smoking-related interstitial lung disease characterized by the presence of Langerhans cells. Patients typically present with chronic cough, dyspnea, spontaneous pneumothorax, and weight loss. High-resolution CT shows numerous thin-walled cysts and nodules predominantly in the upper lobes. Lung biopsy revealing Birbeck granules on electron microscopy confirms the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lymphangioleiomyomatosis (LAM):</span></strong><span style=\"font-size:12.0pt\"> Typically affects women of childbearing age and is characterized by diffuse thin-walled cysts but not associated with Birbeck granules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Idiopathic pulmonary fibrosis (IPF</span></strong><span style=\"font-size:12.0pt\">): Presents with progressive fibrosis and honeycombing on imaging, not thin-walled cysts and nodules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Characterized by bilateral hilar lymphadenopathy and non-caseating granulomas, not thin-walled cysts and Birbeck granules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary Langerhans cell histiocytosis (PLCH) is a smoking-related interstitial lung disease characterized by numerous thin-walled cysts and nodules predominantly in the upper lobes and presence of Birbeck granules on electron microscopy.</span></span></span></p>",
    "correct_choice_id": 81050,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20263,
    "choices": [
      {
        "id": 81013,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measurement of serum precipitating antibodies</span></span></p>"
      },
      {
        "id": 81014,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laboratory testing for connective tissue disease</span></span></span></p>"
      },
      {
        "id": 81015,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transbronchial biopsy</span></span></p>"
      },
      {
        "id": 81016,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Surgical lung biopsy</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old non-smoker male with progressive dry cough, SOB, and NYHA Class III presents with fine bibasilar crackles and no clubbing. HRCT is shown. Which investigation is required for further evaluation?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-133026.png\" style=\"height:296px; width:300px\" /></span></span></p>",
    "unique_key": "Q3633700",
    "question_audio": null,
    "question_video": null,
    "map_id": 20211,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Laboratory testing for connective tissue disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HRCT shows Bibasilar symmetric ground glass opacities with reticulation and traction bronchiectasis which is highly suggestive of Non Specific Interstitial Pneumonia (NSIP). Presence of NSIP suggests the possibility of an underlying connective tissue disease (CTD). Laboratory testing for connective tissue diseases can help identify any underlying autoimmune conditions that may be contributing to the patient&#39;s lung pathology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Measurement of serum precipitating antibodies:</span></strong><span style=\"font-size:12.0pt\"> Typically used to diagnose hypersensitivity pneumonitis, which is less likely given the lack of exposure history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Transbronchial biopsy:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Can be helpful in certain interstitial lung diseases but may not provide sufficient tissue for a definitive diagnosis of NSIP or an underlying CTD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Surgical lung biopsy</span></strong><span style=\"font-size:12.0pt\">: Provides more tissue for diagnosis but is more invasive. It may be considered if initial non-invasive tests do not yield a diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laboratory testing for connective tissue diseases is essential when HRCT shows features suggestive of Non Specific Interstitial Pneumonia (NSIP) to identify any underlying autoimmune conditions.</span></span></span></p>",
    "correct_choice_id": 81014,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 20266,
    "choices": [
      {
        "id": 81025,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pirfenidone&nbsp;&nbsp;&nbsp;&nbsp;</span></span></p>"
      },
      {
        "id": 81026,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bosentan</span></span></p>"
      },
      {
        "id": 81027,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acetylcysteine</span></span></p>"
      },
      {
        "id": 81028,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone/azathioprine</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old female is referred for chronic cough and dyspnea with exertion. Over the past year, her symptoms have steadily worsened. Pulmonary function testing shows FVC: 72%, FEV1: 80%, DLCO: 38%. HRCT of the chest is shown. Lung biopsy shows foci of scarring dispersed and surrounded by healthy lung parenchyma and fibroblasts. Which of the following is the appropriate therapy for this patient?<strong>&nbsp; </strong></span></span></span></p>",
    "unique_key": "Q6669731",
    "question_audio": null,
    "question_video": null,
    "map_id": 20214,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Pirfenidone</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">HRCT shows bibasilar reticular markings with traction bronchiectasis and honeycombing which is suggestive of Usual Interstitial Pneumonia (UIP). The</span><span style=\"font-size:12.0pt\"> patient&rsquo;s clinical presentation, pulmonary function test results, CT findings, and lung biopsy are consistent with the diagnosis of idiopathic pulmonary fibrosis (IPF). Pirfenidone is an antifibrotic agent specifically approved for the treatment of IPF, as it helps to slow disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bosentan:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Primarily used to treat pulmonary arterial hypertension, not idiopathic pulmonary fibrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Acetylcysteine</span></strong><span style=\"font-size:12.0pt\">: An antioxidant used in the management of various conditions, but not first-line for IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisolone/azathioprine:</span></strong><span style=\"font-size:12.0pt\"> Immunosuppressive therapy that has not shown benefit and may even be harmful in patients with IPF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pirfenidone is the appropriate therapy for idiopathic pulmonary fibrosis (IPF), as it helps to slow disease progression.</span></span></span></p>",
    "correct_choice_id": 81025,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 20245,
    "choices": [
      {
        "id": 80941,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACE is elevated in 60% of cases</span></span></span></p>"
      },
      {
        "id": 80942,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypercalcemia occurs in about 10% of patients</span></span></span></p>"
      },
      {
        "id": 80943,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BAL CD4/CD8 ratio &gt; 3.5 is a characteristic finding</span></span></span></p>"
      },
      {
        "id": 80944,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung biopsy is the gold standard for diagnosis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with suspected sarcoidosis presents with bilateral hilar lymphadenopathy, erythema nodosum, and distal renal tubular acidosis (dRTA). Which of the following statements about the disease is false?</span></span></p>",
    "unique_key": "Q4983349",
    "question_audio": null,
    "question_video": null,
    "map_id": 20193,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Lung biopsy is the gold standard for diagnosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While lung biopsy showing non-caseating granulomas is highly suggestive of sarcoidosis and can be a critical component in diagnosing the disease, it is not considered the definitive gold standard as the diagnosis often relies on a combination of clinical, radiographic, and histopathological findings. Other conditions, such as berylliosis and tuberculosis, can also present with non-caseating granulomas, so clinical correlation and exclusion of other diseases are essential for an accurate diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. ACE is elevated in 60% of cases</span></strong><span style=\"font-size:12.0pt\">: Elevated angiotensin-converting enzyme (ACE) levels are seen in about 60% of patients with sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypercalcemia occurs in about 10% of patients</span></strong><span style=\"font-size:12.0pt\">: Hypercalcemia occurs in approximately 10% of patients with sarcoidosis due to increased production of vitamin D by granulomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BAL CD4/CD8 ratio &gt; 3.5 is a characteristic finding</span></strong><span style=\"font-size:12.0pt\">: A high CD4/CD8 ratio in bronchoalveolar lavage (BAL) fluid is a characteristic finding in sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While lung biopsy showing non-caseating granulomas is highly suggestive of sarcoidosis and can be critical in diagnosis, it is not considered the gold standard as the diagnosis often relies on a combination of clinical, radiographic, and histopathological findings. Other conditions can also present with non-caseating granulomas, necessitating clinical correlation and exclusion of other diseases for accurate diagnosis.</span></span></span></p>",
    "correct_choice_id": 80944,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20196,
    "choices": [
      {
        "id": 80746,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></p>"
      },
      {
        "id": 80747,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></p>"
      },
      {
        "id": 80748,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bleomycin</span></span></p>"
      },
      {
        "id": 80749,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisplatin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 70-year-old male with a history of atrial fibrillation presents with progressive dyspnea and a dry cough over the past three months. He has been on amiodarone therapy for the past year. High-resolution CT of the chest reveals findings consistent with interstitial lung disease (ILD). All of the following medications are known to cause ILD except:</span></span></span></p>",
    "unique_key": "Q1346440",
    "question_audio": null,
    "question_video": null,
    "map_id": 20144,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12pt\"><strong> D)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Cisplatin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone, methotrexate, and bleomycin are well-documented causes of drug-induced interstitial lung disease (ILD). Amiodarone is an antiarrhythmic medication often associated with pulmonary toxicity, methotrexate is used for autoimmune diseases and certain cancers, and bleomycin is a chemotherapeutic agent known for its pulmonary toxicity. Cisplatin, another chemotherapeutic agent, is not typically associated with ILD; its primary toxicities are nephrotoxicity and ototoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span style=\"font-size:12.0pt\">A. Amiodarone:</span></strong><span style=\"font-size:12.0pt\"> Known to cause ILD, particularly with long-term use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span style=\"font-size:12.0pt\">B. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> Associated with ILD in patients, particularly those with rheumatoid arthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span style=\"font-size:12.0pt\">C. Bleomycin:</span></strong><span style=\"font-size:12.0pt\"> A chemotherapeutic agent well known for its potential to cause ILD</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone, methotrexate, and bleomycin are known to cause drug-induced interstitial lung disease (ILD), while cisplatin is not typically associated with ILD; its primary toxicities are nephrotoxicity and ototoxicity.</span></span></span></p>",
    "correct_choice_id": 80749,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20205,
    "choices": [
      {
        "id": 80781,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Respiratory bronchiolitis associated ILD</span></span></p>"
      },
      {
        "id": 80782,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desquamative Interstitial Pneumonia</span></span></p>"
      },
      {
        "id": 80783,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Langerhans Cell Histiocytosis</span></span></span></p>"
      },
      {
        "id": 80784,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usual Interstitial Pneumonia</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male with a 30-pack-year smoking history presents with progressive dyspnea and chronic cough. High-resolution CT of the chest shows diffuse interstitial changes. Which of the following interstitial lung diseases is least likely to be associated with smoking?</span></span></p>",
    "unique_key": "Q2706473",
    "question_audio": null,
    "question_video": null,
    "map_id": 20153,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Ans. D)&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Usual Interstitial Pneumonia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usual Interstitial Pneumonia (UIP) is the histopathological pattern seen in idiopathic pulmonary fibrosis, which is not specifically associated with smoking. In contrast, respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia, and Langerhans cell histiocytosis are all strongly associated with smoking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Respiratory bronchiolitis associated ILD:</span></strong><span style=\"font-size:12.0pt\"> Commonly seen in smokers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Desquamative Interstitial Pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Strongly associated with smoking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Langerhans Cell Histiocytosis:</span></strong><span style=\"font-size:12.0pt\"> Typically seen in smokers and characterized by cystic lung disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usual Interstitial Pneumonia <strong>is least likely to be associated with smoking.</strong></span></span></span></p>",
    "correct_choice_id": 80784,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20207,
    "choices": [
      {
        "id": 80789,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute silicosis</span></span></p>"
      },
      {
        "id": 80790,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary alveolar proteinosis (PAP)</span></span></p>"
      },
      {
        "id": 80791,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic pulmonary fibrosis (IPF)</span></span></p>"
      },
      {
        "id": 80792,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypersensitivity pneumonitis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of working in a construction agency involved in rock tunnelling presents with acute onset of dyspnea, cough, and fatigue for the last 3 weeks. High-resolution CT shows diffuse ground-glass opacities and a crazy paving pattern. Bronchoalveolar lavage reveals large amounts of periodic acid-Schiff-positive material. Which of the following conditions is most likely ?</span></span></p>",
    "unique_key": "Q7012063",
    "question_audio": null,
    "question_video": null,
    "map_id": 20154,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute silicosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute silicosis can present with features similar to pulmonary alveolar proteinosis (PAP), including diffuse ground-glass opacities and a crazy paving pattern on high-resolution CT. The exposure to silica dust leads to the accumulation of surfactant-like material in the alveoli, which can be identified as periodic acid-Schiff-positive material on bronchoalveolar lavage. Whole lung lavage can provide symptomatic relief but the disease is progressive despite treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Pulmonary alveolar proteinosis (PAP):</span></strong><span style=\"font-size:12.0pt\"> Although PAP can present with similar imaging findings, the patient&#39;s occupational history and acute onset suggest acute silicosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Idiopathic pulmonary fibrosis (IPF):</span></strong><span style=\"font-size:12.0pt\"> Typically presents with chronic progressive dyspnea and honeycombing on imaging, not acute symptoms and crazy paving pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Hypersensitivity pneumonitis:</span></strong><span style=\"font-size:12.0pt\"> Related to environmental exposures, presenting with cough, dyspnea, and fatigue, but typically involves centrilobular nodules rather than crazy paving pattern</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute silicosis can present with diffuse ground-glass opacities and a crazy paving pattern on high-resolution CT, and bronchoalveolar lavage may reveal large amounts of periodic acid-Schiff-positive material, reflecting occupational exposure to silica dust.</span></span></span></p>",
    "correct_choice_id": 80789,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20208,
    "choices": [
      {
        "id": 80793,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interstitial lung disease (ILD)</span></span></span></p>"
      },
      {
        "id": 80794,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD)</span></span></p>"
      },
      {
        "id": 80795,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rheumatoid arthritis</span></span></p>"
      },
      {
        "id": 80796,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphoma</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a long history of working in construction presents with chronic cough and shortness of breath. He reports joint pain and stiffness, and a recent chest X-ray shows interstitial lung disease (ILD). Which of the following conditions is least likely to be associated with his diagnosis of silicosis?</span></span></p>",
    "unique_key": "Q9128133",
    "question_audio": null,
    "question_video": null,
    "map_id": 20156,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Lymphoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Silicosis is primarily associated with pulmonary conditions such as interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) due to the inhalation of silica dust. It can also be associated with autoimmune conditions like rheumatoid arthritis, known as Caplan&#39;s syndrome. However, there is no direct association between silicosis and the development of lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Interstitial lung disease (ILD):</span></strong><span style=\"font-size:12.0pt\"> Silicosis is a form of ILD caused by inhalation of silica dust.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chronic obstructive pulmonary disease (COPD):</span></strong><span style=\"font-size:12.0pt\"> Long-term exposure to silica can lead to COPD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Rheumatoid arthritis:</span></strong><span style=\"font-size:12.0pt\"> Silicosis can be associated with rheumatoid arthritis in the form of Caplan&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Silicosis is primarily associated with interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) due to inhalation of silica dust and can also be associated with autoimmune conditions like rheumatoid arthritis, but not with lymphoma.</span></span></span></p>",
    "correct_choice_id": 80796,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InstrumentsBased"
    ]
  },
  {
    "id": 20210,
    "choices": [
      {
        "id": 80801,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mesotheliomas are strongly associated with smoking</span></span></p>"
      },
      {
        "id": 80802,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Short-term asbestos exposures of &le;1&ndash;2 years can lead to mesotheliomas</span></span></p>"
      },
      {
        "id": 80803,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mesotheliomas are not associated with asbestos exposure</span></span></p>"
      },
      {
        "id": 80804,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mesotheliomas develop within a few years of exposure to asbestos</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a history of working in shipyards presents with chest pain and shortness of breath. Imaging reveals a pleural mass, and biopsy confirms malignant mesothelioma. Which of the following is true regarding the association of mesotheliomas with asbestos exposure?</span></span></p>",
    "unique_key": "Q4768282",
    "question_audio": null,
    "question_video": null,
    "map_id": 20159,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Ans. B) Short-term asbestos exposures of &le;1&ndash;2 years can lead to mesotheliomas</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesotheliomas, both pleural and peritoneal, are strongly associated with asbestos exposure. Unlike lung cancers, they are not associated with smoking. Even relatively short-term asbestos exposures of &le;1&ndash;2 years, occurring up to 40 years in the past, can lead to the development of mesotheliomas. This underscores the importance of obtaining a thorough environmental exposure history in patients with suspected mesothelioma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mesotheliomas are strongly associated with smoking:</span></strong><span style=\"font-size:12.0pt\"> Mesotheliomas are not associated with smoking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mesotheliomas are not associated with asbestos exposure:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Mesotheliomas are indeed associated with asbestos exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mesotheliomas develop within a few years of exposure to asbestos:</span></strong><span style=\"font-size:12.0pt\"> Mesotheliomas can develop decades after exposure to asbestos.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesotheliomas are strongly associated with asbestos exposure and can develop even after short-term exposures of &le;1&ndash;2 years, occurring up to 40 years in the past. They are not associated with smoking.</span></span></span></p>",
    "correct_choice_id": 80802,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 20212,
    "choices": [
      {
        "id": 80809,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Significant pulmonary impairment</span></span></p>"
      },
      {
        "id": 80810,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Past exposure to asbestos</span></span></p>"
      },
      {
        "id": 80811,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pleural effusion</span></span></p>"
      },
      {
        "id": 80812,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Active tuberculosis infection</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old retired construction worker presents for a routine check-up. His chest radiograph is shown. What does it indicate?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-124125.png\" style=\"height:285px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q5853742",
    "question_audio": null,
    "question_video": null,
    "map_id": 20160,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Past exposure to asbestos</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CXR shows bilateral calcified pleural plaques consistent with asbestos-related pleural disease (usually seen along the parietal pleura, particularly in the lower lung fields, diaphragm, and cardiac border). This indicates past exposure to asbestos. Pleural plaques imply exposure to asbestos but do not indicate pulmonary impairment by themselves.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation</u></strong><strong>: </strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Significant pulmonary impairment:</span></strong><span style=\"font-size:12.0pt\"> Pleural plaques indicate exposure but do not imply pulmonary impairment without additional manifestations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pleural effusion</span></strong><span style=\"font-size:12.0pt\">: Benign pleural effusions can occur with asbestos exposure but are not seen in this CXR</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Active tuberculosis infection:</span></strong><span style=\"font-size:12.0pt\"> Pleural plaques are not associated with tuberculosis (but silicosis has association)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest X-ray showing bilateral calcified pleural plaques indicates past exposure to asbestos. Pleural plaques are a hallmark of asbestos exposure but do not imply significant pulmonary impairment without additional findings.</span></span></span></p>",
    "correct_choice_id": 80810,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 20270,
    "choices": [
      {
        "id": 81041,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute interstitial pneumonia (AIP)</span></span></p>"
      },
      {
        "id": 81042,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute respiratory distress syndrome (ARDS)</span></span></p>"
      },
      {
        "id": 81043,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cryptogenic organizing pneumonia (COP)</span></span></p>"
      },
      {
        "id": 81044,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idiopathic pulmonary fibrosis (IPF)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents with acute onset of severe dyspnea and fever. She was previously healthy but has rapidly deteriorated over the past week. Chest X-ray shows diffuse bilateral alveolar infiltrates, and HRCT of the chest reveals widespread ground-glass opacities and consolidation. Routine work up did not reveal any identifiable cause. Lung biopsy demonstrates diffuse alveolar damage with hyaline membrane formation. What is the likely diagnosis ?</span></span></p>",
    "unique_key": "Q2021493",
    "question_audio": null,
    "question_video": null,
    "map_id": 20217,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute interstitial pneumonia (AIP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute interstitial pneumonia (AIP), also known as Hamman-Rich syndrome, is characterized by the rapid onset of severe respiratory symptoms, including dyspnea and fever, in a previously healthy individual. The imaging findings of diffuse bilateral alveolar infiltrates, widespread ground-glass opacities, and consolidation, along with lung biopsy showing diffuse alveolar damage and hyaline membrane formation, are classic for AIP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute respiratory distress syndrome (ARDS):</span></strong><span style=\"font-size:12.0pt\"> While ARDS also presents with diffuse alveolar damage and similar imaging findings, it is typically secondary to an identifiable cause such as sepsis, trauma, or pneumonia, whereas AIP occurs without a known trigger.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cryptogenic organizing pneumonia (COP)</span></strong><span style=\"font-size:12.0pt\">: Usually presents with subacute symptoms and patchy lung infiltrates, not rapid onset and diffuse alveolar damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Idiopathic pulmonary fibrosis (IPF):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Characterized by chronic progressive dyspnea and fibrosis with honeycombing, not acute onset or diffuse alveolar damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute interstitial pneumonia (AIP) is characterized by rapid onset of severe respiratory symptoms, diffuse bilateral alveolar infiltrates, and lung biopsy showing diffuse alveolar damage with hyaline membrane formation.</span></span></span></p>",
    "correct_choice_id": 81041,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 16331,
    "choices": [
      {
        "id": 65284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ARDS</span></span></span></p>"
      },
      {
        "id": 65285,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Atelectasis</span></span></span></p>"
      },
      {
        "id": 65286,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Heart Failure</span></span></span></p>"
      },
      {
        "id": 65287,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pulmonary Fibrosis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient with a history of fever for the past 4 days and new onset of breathlessness was admitted to ICU as he was deteriorating. He was unresponsive to the incremental flow rate of oxygen and his oxygen saturation was progressively decreasing. He was intubated and a Chest X-ray was ordered, and the findings are shown in the image below. His PaO2/FiO2 was 204 mmHg. What is the most likely diagnosis? (FMGE JUNE 2021)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/28/screenshot-2024-09-28-175412.png\" style=\"height:241px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q5643798",
    "question_audio": null,
    "question_video": null,
    "map_id": 20238,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) ARDS</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute Respiratory Distress Syndrome (ARDS) is characterized by the following criteria, updated in the </span><strong><span style=\"font-size:12.0pt\">New </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Berlin criteria:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute onset</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: The patient&#39;s condition should worsen within a week of a known clinical insult or new/worsening respiratory symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bilateral opacities on imaging</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: The chest X-ray shows bilateral</span><span style=\"font-size:12.0pt\"> extensive</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> infiltrates, which are not fully explained by effusions, lobar/lung collapse, or nodules.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Non-cardiogenic pulmonary edema</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: The respiratory failure should not be fully explained by cardiac failure or fluid overload.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PaO2/FiO2 ratio</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mild ARDS: PaO2/FiO2 ratio </span><span style=\"font-size:12.0pt\">&lt;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">300 mmHg</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Moderate ARDS: PaO2/FiO2 ratio </span><span style=\"font-size:12.0pt\">&lt;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">200 mmHg</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe ARDS: PaO2/FiO2 ratio </span><span style=\"font-size:12.0pt\">&lt;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">100 mmHg</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In this case, the patient has an acute onset of symptoms, bilateral infiltrates on the chest X-ray, and a PaO2/FiO2 ratio of 204 mmHg, indicating moderate ARDS.</span> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Atelectasis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This condition involves the collapse of part or all of a lung and typically does not present with the extensive bilateral infiltrates seen in ARDS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Heart Failure</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Cardiogenic pulmonary edema is usually associated with elevated left atrial pressure, and imaging might show cardiomegaly and pleural effusions, which are not mentioned here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Pulmonary Fibrosis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is a chronic condition that leads to progressive scarring of the lung tissue. It usually presents with a more gradual onset and not the acute, severe respiratory failure seen in ARDS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ARDS is diagnosed based on acute onset, bilateral infiltrates on chest imaging, non-cardiogenic pulmonary edema, and a PaO2/FiO2 ratio indicative of the severity of hypoxemia. Recognizing these criteria is crucial for timely and appropriate management.</span></span></span></p>",
    "correct_choice_id": 65284,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased",
      "DiagnosisBased",
      "Factual",
      "FMGE",
      "ImageBased"
    ]
  },
  {
    "id": 11206,
    "choices": [
      {
        "id": 44790,
        "text": "<p><span style=\"font-size:12.0pt;\">PaO2/FiO2 ratio 200-300 mm/Hg</span></p>"
      },
      {
        "id": 44791,
        "text": "<p><span style=\"font-size:12.0pt;\">Bilateral interstitial infiltrates</span></p>"
      },
      {
        "id": 44792,
        "text": "<p><span style=\"font-size:12.0pt;\">Symptom onset within a week</span></p>"
      },
      {
        "id": 44793,
        "text": "<p><span style=\"font-size:12.0pt;\">No cardiac failure on echocardiography</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">According to the berlin definition, moderate ARDS is characterized by all, except: (NEET PG 2018)</span></p>",
    "unique_key": "Q4992857",
    "question_audio": null,
    "question_video": null,
    "map_id": 20236,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. PaO2/FiO2 ratio 200-300 mm/Hg</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A:</strong></span><br><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Berlin definition of Acute Respiratory Distress Syndrome (ARDS) classifies the severity based on the PaO2/FiO2 ratio assessed under specific conditions of oxygenation support. According to this definition, a PaO2/FiO2 ratio of 200-300 mmHg characterizes mild ARDS, not moderate ARDS. Moderate ARDS is defined by a PaO2/FiO2 ratio of 100-200 mm/Hg when assessed with at least 5 cm of water Positive End-Expiratory Pressure (PEEP).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Bilateral interstitial infiltrates:</strong> This is correct and consistent with all classifications of ARDS, which require bilateral opacities on imaging, either from chest radiographs or CT, indicative of pulmonary edema not fully explained by cardiac failure or fluid overload.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Symptom onset within a week:</strong> True for the Berlin definition, which stipulates that ARDS must occur within 7 days of a known clinical insult or new or worsening respiratory symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. No cardiac failure on echocardiography:</strong> Also true according to the Berlin definition, as the pulmonary edema should not be fully explained by cardiac failure or fluid overload, thus necessitating the exclusion of cardiac failure through echocardiography.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>2012 Berlin Definition:</strong></span></p><p>&nbsp;</p><ol style=\"list-style-type:upper-alpha;\"><li><span style=\"font-size:12.0pt;\"><strong>Onset within 7 days&nbsp;</strong>after a known clinical insult or new or worsening respiratory symptoms</span></li><li><span style=\"font-size:12.0pt;\">B/L opacities (Alveolar/Interstitial that are <strong>\"consistent with pulmonary edema\"</strong> on chest radiographs or chest CT)</span></li><li><span style=\"font-size:12.0pt;\">Minimum PEEP setting or CPAP, 5 cm of water.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">PaO<sub>2</sub>: FiO<sub>2</sub> assessed on invasive mechanical ventilation (CPAP criterion used for the diagnosis of mild ARDS).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><i><strong>Categorization of ARDS severity (on the basis of FiO<sub>2</sub>):</strong></i></span></p><p>&nbsp;</p><ol style=\"list-style-type:upper-alpha;\"><li><span style=\"font-size:12.0pt;\">Mild: 200-300</span></li><li><span style=\"font-size:12.0pt;\">Moderate: 100-200</span></li><li><span style=\"font-size:12.0pt;\">Severe: &lt;100</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In resource limited settings <i><strong>Kigali Modifications&nbsp;</strong></i>was proposed (2016):</span></p><p>&nbsp;</p><ol style=\"list-style-type:upper-alpha;\"><li><span style=\"font-size:12.0pt;\">Bilateral opacities could be documented by <i>either ultrasonography or chest radiograph</i>.</span></li><li><span style=\"font-size:12.0pt;\">Oxygenation criteria: pulse oximetry oxygen saturation <i><strong>(SpO<sub>2</sub>)/FiO<sub>2</sub> ratio \u2264 315 without the requirement for PEEP.</strong></i></span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference - Harrison/Respiratory Failure/Chap 301</strong></span></p>",
    "correct_choice_id": 44790,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased",
      "DiagnosisBased",
      "Factual",
      "OlderNEETPG"
    ]
  },
  {
    "id": 20292,
    "choices": [
      {
        "id": 81129,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></p>"
      },
      {
        "id": 81130,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia</span></span></p>"
      },
      {
        "id": 81131,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoventilation</span></span></p>"
      },
      {
        "id": 81132,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Respiratory Distress Syndrome (ARDS)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man presents to the emergency department with severe shortness of breath and confusion. On&nbsp; examination, he is febrile, has a turbid urine and tachypneic with diffuse crackles heard on lung auscultation. His arterial blood gas (ABG) shows pH 7.50, PaCO2 30 mmHg, and PaO2 45 mmHg despite being on 100% oxygen. What is the most likely cause of his hypoxemia ?</span></span></p>",
    "unique_key": "Q8892310",
    "question_audio": null,
    "question_video": null,
    "map_id": 20242,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Acute Respiratory Distress Syndrome (ARDS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoxemia that does not correct with 100% oxygen, along with an increased A-a gradient, is characteristic of ARDS. ARDS causes severe V/Q mismatch and shunting due to widespread inflammation and damage to the alveolar-capillary membrane, leading to refractory hypoxemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pulmonary embolism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically causes an increased V/Q ratio and can result in hypoxemia, but it often responds to 100% oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Pneumonia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Causes hypoxemia due to V/Q mismatch or shunting, but some improvement is usually seen with 100% oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypoventilation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Leads to hypercapnia and hypoxemia but usually presents with a normal A-a gradient and improves with supplemental oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARDS causes severe V/Q mismatch and shunting due to widespread inflammation and damage to the alveolar-capillary membrane, leading to refractory hypoxemia.</span></span></span></p>",
    "correct_choice_id": 81132,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 20290,
    "choices": [
      {
        "id": 81121,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></p>"
      },
      {
        "id": 81122,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe pneumonia</span></span></p>"
      },
      {
        "id": 81123,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atelectasis</span></span></p>"
      },
      {
        "id": 81124,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary arteriovenous malformation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents to the emergency department with sudden onset of shortness of breath and pleuritic chest pain. Her arterial blood gas (ABG) shows pH 7.45, PaCO2 35 mmHg, and PaO2 60 mmHg on room air. Which condition is associated with an increased V/Q ratio and results in increased dead space ?</span></span></span></p>",
    "unique_key": "Q1947327",
    "question_audio": null,
    "question_video": null,
    "map_id": 20240,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Pulmonary embolism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An increased V/Q ratio and increased dead space are typical in pulmonary embolism due to the obstruction of blood flow. This leads to areas of the lung being ventilated but not perfused, resulting in hypoxemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Severe pneumonia</strong>: Typically causes a decreased V/Q ratio due to alveolar filling with inflammatory exudate, leading to a shunt-like effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Atelectasis</strong>: Causes a decreased V/Q ratio due to collapse of alveoli, leading to areas of the lung being under-ventilated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pulmonary arteriovenous malformation</strong>: Typically causes a right-to-left shunt, leading to a decreased V/Q ratio and hypoxemiaTop of Form</span></span></span></p>\r\n\r\n<h3>&nbsp;</h3>\r\n\r\n<h3><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri Light&quot;,sans-serif\"><span style=\"color:#1f3763\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></span></u></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism increases the V/Q ratio and dead space by obstructing blood flow, causing areas of the lung to be ventilated but not perfused, leading to hypoxemia.</span></span></span></p>",
    "correct_choice_id": 81121,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20293,
    "choices": [
      {
        "id": 81133,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple nasal cannula (SNC)</span></span></p>"
      },
      {
        "id": 81134,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-rebreather mask (NRBM)</span></span></p>"
      },
      {
        "id": 81135,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Venturi mask</span></span></span></p>"
      },
      {
        "id": 81136,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial rebreather mask (PRBM)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a history of COPD exacerbation is brought to the emergency department with worsening shortness of breath and wheezing. Her arterial blood gas (ABG) shows a PaO2 of 55 mmHg on room air. The intervening physician decides to deliver oxygen precisely at 24-28% FiO2. Which oxygen delivery system would be most appropriate for this patient?</span></span></p>",
    "unique_key": "Q4661400",
    "question_audio": null,
    "question_video": null,
    "map_id": 20243,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C)&nbsp;</span></span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Venturi mask</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Venturi (Venti) mask provides a controlled FiO2, which stays constant, making it ideal for patients needing consistent oxygen levels, such as those with COPD exacerbation. It ensures precise delivery of the desired oxygen concentration and avoids the risk of oxygen toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Simple nasal cannula (SNC):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Provides variable FiO2 (24-44%) depending on the flow rate and the patient&#39;s breathing pattern, which does not ensure consistent oxygen delivery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Non-rebreather mask (NRBM):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Delivers a high FiO2 (60-90%) but does so variably and is generally used for short-term situations due to the risk of oxygen toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Partial rebreather mask (PRBM):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Provides a variable FiO2 (40-70%) and is less precise in delivering a controlled and consistent oxygen concentration, which is not ideal for patients with COPD who need stable oxygen levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Venturi mask provides a controlled FiO2, ideal for patients needing consistent oxygen levels, such as those with COPD exacerbation, ensuring precise delivery of the desired oxygen concentration.</span></span></span></p>",
    "correct_choice_id": 81135,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20294,
    "choices": [
      {
        "id": 81137,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple nasal cannula (SNC)</span></span></p>"
      },
      {
        "id": 81138,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High flow nasal oxygen (HFNO)</span></span></p>"
      },
      {
        "id": 81139,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple face mask (SFM)</span></span></p>"
      },
      {
        "id": 81140,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-rebreather mask (NRBM)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old patient in the ICU has just been extubated after mechanical ventilation. The medical team wants to prevent reintubation by providing adequate respiratory support. Which oxygen delivery system should be considered? </span></span></span></p>",
    "unique_key": "Q3492693",
    "question_audio": null,
    "question_video": null,
    "map_id": 20244,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) &nbsp;High flow nasal oxygen (HFNO)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High flow nasal oxygen (HFNO) provides high oxygen flow rates, small CPAP-like effects, and reduced inspiratory effort. It is effective in preventing reintubation in post-extubation patients by providing better respiratory support and reducing the risk of respiratory failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Simple nasal cannula (SNC):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Provides variable and lower flow rates (1-6 L/min) with FiO2 ranging from 24-44%, which may not be sufficient for post-extubation support.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Simple face mask (SFM):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Delivers variable FiO2 (35-60%) with flow rates of 5-10 L/min, but does not provide the high flow and CPAP-like effects needed for post-extubation support.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Non-rebreather mask (NRBM):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Provides high FiO2 (60-90%) and is suitable for short-term use in severe hypoxemia, but does not offer the same level of support and comfort as HFNO for preventing reintubation in post-extubation patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High flow nasal oxygen (HFNO) provides effective respiratory support and reduces the risk of reintubation in post-extubation patients by delivering high oxygen flow rates, CPAP-like effects, and reducing inspiratory effort.</span></span></span></p>",
    "correct_choice_id": 81138,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20295,
    "choices": [
      {
        "id": 81141,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A &ndash; iv, B-i, C-iv, D-iii</span></span></p>"
      },
      {
        "id": 81142,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-iii, B-iv, C-i, D-ii</span></span></span></p>"
      },
      {
        "id": 81143,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-iii, B-i, C-iv, D-ii</span></span></p>"
      },
      {
        "id": 81144,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-i, B-ii, C-iii, D-iv</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the Oxygen delivery systems: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-120216.png\" style=\"height:1634px; width:1000px\" /></p>",
    "unique_key": "Q6305892",
    "question_audio": null,
    "question_video": null,
    "map_id": 20245,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) A-iii, B-i, C-iv, D-ii</span></strong></span></span></p>\r\n\r\n<h3>&nbsp;</h3>\r\n\r\n<h3><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong><br />\r\n&nbsp;</h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple Nasal Cannula</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A lightweight tube with two prongs that fit into the nostrils, providing a variable and lower flow of oxygen.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-Rebreather Mask</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A mask with a reservoir bag attached; designed to deliver high concentrations of oxygen.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Venti Mask</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Also known as a Venturi mask; provides a precise and controlled oxygen concentration.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bag Valve Mask</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A manual resuscitator used to provide positive pressure ventilation to patients who are not breathing or not breathing adequately.</span></span></span></li>\r\n</ul>\r\n\r\n<h3>&nbsp;</h3>\r\n\r\n<h3><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri Light&quot;,sans-serif\"><span style=\"color:#1f3763\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></span></u></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understand and correctly identify the various oxygen delivery systems and their corresponding features to ensure appropriate usage in clinical settings.</span></span></span></p>",
    "correct_choice_id": 81143,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "InstrumentsBased"
    ]
  },
  {
    "id": 20296,
    "choices": [
      {
        "id": 81145,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Claustrophobia</span></span></p>"
      },
      {
        "id": 81146,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe upper gastrointestinal bleeding (UGIB)</span></span></span></p>"
      },
      {
        "id": 81147,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Poor mask fit</span></span></p>"
      },
      {
        "id": 81148,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe dyspnea with increased work of breathing</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old woman with a history of congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) presents to the emergency department with severe shortness of breath, a respiratory rate of 28 breaths per minute, and signs of increased work of breathing. The medical team considers initiating non-invasive ventilation (NIV). All of the following are contraindications except:</span></span></p>",
    "unique_key": "Q7746898",
    "question_audio": null,
    "question_video": null,
    "map_id": 20246,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Severe dyspnea with increased work of breathing</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe dyspnea with increased work of breathing is an indication for NIV, not a contraindication. NIV is used to support patients with respiratory distress and failure, helping to avoid intubation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n<br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Claustrophobia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Patients with claustrophobia may not tolerate the mask required for NIV, making it a contraindication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Severe upper gastrointestinal bleeding (UGIB):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> UGIB poses a risk for aspiration, which can be exacerbated by positive pressure ventilation, making NIV unsafe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Poor mask fit:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An effective seal is crucial for NIV to work properly. Poor mask fit can lead to air leaks, reducing the efficacy of the treatment and increasing the risk of failure.</span></span></span></p>",
    "correct_choice_id": 81148,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 20297,
    "choices": [
      {
        "id": 81149,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate NIPPV for 24 hours post-extubation</span></span></span></p>"
      },
      {
        "id": 81150,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Place the patient on a simple nasal cannula</span></span></p>"
      },
      {
        "id": 81151,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Observe without additional support</span></span></span></p>"
      },
      {
        "id": 81152,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reintubate immediately</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with a history of congestive heart failure (CHF) is in the ICU after being successfully extubated following mechanical ventilation. During a spontaneous breathing trial (SBT), his PaCO2 is measured at 48 mmHg. What is the most appropriate management to reduce this risk?</span></span></p>",
    "unique_key": "Q2545362",
    "question_audio": null,
    "question_video": null,
    "map_id": 20247,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Initiate NIPPV for 24 hours post-extubation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong><br />\r\n<br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-risk extubation patients, especially those with elevated PaCO2 during an SBT, benefit from NIPPV (non-invasive positive pressure ventilation) for 24 hours post-extubation to reduce the risk of reintubation and associated mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Place the patient on a simple nasal cannula:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This provides supplemental oxygen but does not offer the same level of respiratory support as NIPPV, which is crucial for preventing reintubation in high-risk patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Observe without additional support:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Observation alone does not address the underlying risk of respiratory failure and reintubation in a high-risk patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Reintubate immediately:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Immediate reintubation is not necessary if the patient is currently stable and NIPPV can provide sufficient support to prevent respiratory failure.</span></span></span></p>\r\n\r\n<h3>&nbsp;</h3>\r\n\r\n<h3><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri Light&quot;,sans-serif\"><span style=\"color:#1f3763\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></span></u></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NIPPV should be initiated for 24 hours post-extubation in high-risk patients to reduce the risk of reintubation and associated mortality.</span></span></span></p>",
    "correct_choice_id": 81149,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49915,
    "choices": [
      {
        "id": 199219,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-EPAP, B-IPAP</span></span></span></p>"
      },
      {
        "id": 199220,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-IPAP, B-EPAP</span></span></span></p>"
      },
      {
        "id": 199221,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-CPAP, B-IPAP</span></span></span></p>"
      },
      {
        "id": 199222,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A-IPAP, B-CPAP</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify A and B:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-104756.png\" style=\"height:180px; width:300px\" /></span></span></p>",
    "unique_key": "Q7701686",
    "question_audio": null,
    "question_video": null,
    "map_id": 24887,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) A-EPAP, B-IPAP</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong><br />\r\n<br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the provided image:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> represents EPAP (Expiratory Positive Airway Pressure), which is the lower level of pressure during exhalation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> represents IPAP (Inspiratory Positive Airway Pressure), which is the higher level of pressure during inhalation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These pressure levels are characteristic of bilevel positive airway pressure (BPAP) therapy. EPAP helps to keep the airways open during exhalation, while IPAP provides additional support during inhalation to improve ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. A-IPAP, B-EPAP:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect because A represents the lower pressure during exhalation (EPAP), and B represents the higher pressure during inhalation (IPAP), not the other way around.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. A-CPAP, B-IPAP:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect because CPAP provides a constant level of pressure throughout the breathing cycle, not the variable pressures shown in the image. The image illustrates the variable pressures of BPAP, not CPAP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. A-IPAP, B-CPAP:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect because CPAP provides a single, continuous pressure and does not have variable pressures like those shown for IPAP and EPAP in the image. The image illustrates BPAP, with A as EPAP and B as IPAP.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<h3><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri Light&quot;,sans-serif\"><span style=\"color:#1f3763\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></span></u></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In bilevel positive airway pressure (BPAP) therapy, EPAP (Expiratory Positive Airway Pressure) keeps airways open during exhalation, while IPAP (Inspiratory Positive Airway Pressure) provides support during inhalation to improve ventilation.</span></span></span></p>",
    "correct_choice_id": 199219,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "ImageBased",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49887,
    "choices": [
      {
        "id": 199111,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mask seal</span></span></span></span></p>"
      },
      {
        "id": 199112,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obesity</span></span></p>"
      },
      {
        "id": 199113,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age</span></span></p>"
      },
      {
        "id": 199114,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck mobility</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are features of the MOANS criteria except:</span></span></p>",
    "unique_key": "Q6078398",
    "question_audio": null,
    "question_video": null,
    "map_id": 24860,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Neck mobility</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck mobility is not a feature of the MOANS criteria. The MOANS criteria include Mask seal, Obstruction/Obesity, Age, No teeth, and Stiff lungs, which are used to predict difficult bag-mask ventilation. Neck mobility is part of the LEMON criteria, which is used to assess difficult intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Mask seal:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Difficulty in achieving a proper mask seal due to facial hair, facial injuries, etc., is a feature of MOANS.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Obesity:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obesity is a factor in the MOANS criteria that can complicate bag-mask ventilation due to increased airway obstruction and difficulty in ventilation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Age:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age over 55 can affect airway anatomy and lung compliance, making ventilation more challenging.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck mobility is part of the LEMON criteria for assessing difficult intubation, not the MOANS criteria for predicting difficult bag-mask ventilation.</span></span></span></span></p>",
    "correct_choice_id": 199114,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49888,
    "choices": [
      {
        "id": 199115,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Look externally</span></span></p>"
      },
      {
        "id": 199116,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Evaluate 3-3-2 rule</span></span></p>"
      },
      {
        "id": 199117,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mallampati score</span></span></span></span></p>"
      },
      {
        "id": 199118,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No teeth</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are features of the LEMON criteria except:</span></span></p>",
    "unique_key": "Q4737829",
    "question_audio": null,
    "question_video": null,
    "map_id": 24861,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) No teeth</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&quot;No teeth&quot; is not a feature of the LEMON criteria. The LEMON criteria include Look externally, Evaluate 3-3-2 rule, Mallampati score, Obstruction, and Neck mobility, which are used to predict difficult intubation. &quot;No teeth&quot; is part of the MOANS criteria, which is used to assess difficult bag-mask ventilation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Look externally:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This involves a visual assessment of external features that might predict difficulty with intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Evaluate 3-3-2 rule:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This assesses mouth opening, mandible space, and neck distance to predict intubation difficulty.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Mallampati score:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This evaluates the visibility of oropharyngeal structures to predict intubation difficulty.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&quot;No teeth&quot; is part of the MOANS criteria for assessing difficult bag-mask ventilation, not the LEMON criteria for predicting difficult intubation.</span></span></span></span></p>",
    "correct_choice_id": 199118,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49889,
    "choices": [
      {
        "id": 199119,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Entire soft palate, uvula, and tonsillar pillars are visible</span></span></p>"
      },
      {
        "id": 199120,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Soft palate, base of uvula, and part of the tonsillar pillars are visible</span></span></p>"
      },
      {
        "id": 199121,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Soft palate and base of uvula are visible, but the tonsillar pillars are not visible</span></span></span></span></p>"
      },
      {
        "id": 199122,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only the hard palate is visible</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man is being assessed for intubation. The clinician uses the Mallampati score to evaluate the visibility of the oropharyngeal structures. Which of the following best describes a Mallampati Grade III?</span></span></p>",
    "unique_key": "Q8483855",
    "question_audio": null,
    "question_video": null,
    "map_id": 24862,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Soft palate and base of uvula are visible, but the tonsillar pillars are not visible</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Mallampati Grade III indicates that the soft palate and base of the uvula are visible, but the tonsillar pillars are not visible. This classification helps predict the difficulty of intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Entire soft palate, uvula, and tonsillar pillars are visible:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Mallampati Grade I, indicating an easy intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Soft palate, base of uvula, and part of the tonsillar pillars are visible:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Mallampati Grade II, suggesting a slightly more difficult intubation than Grade I.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Only the hard palate is visible:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Mallampati Grade IV, indicating a very difficult intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Mallampati Grade III indicates that the soft palate and base of the uvula are visible, but the tonsillar pillars are not visible, predicting a moderately difficult intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-093638.png\" style=\"height:386px; width:300px\" /></span></span></span></span></p>",
    "correct_choice_id": 199121,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49890,
    "choices": [
      {
        "id": 199123,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Full view of the glottis</span></span></p>"
      },
      {
        "id": 199124,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial view of the glottis</span></span></p>"
      },
      {
        "id": 199125,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only the epiglottis is visible, no part of the glottis can be seen</span></span></p>"
      },
      {
        "id": 199126,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neither the glottis nor the epiglottis is visible</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is undergoing intubation, and the clinician uses the Cormack-Lehane classification to describe the view of the glottis during laryngoscopy. Which of the following best describes a Cormack-Lehane Grade III view?</span></span></p>",
    "unique_key": "Q5864834",
    "question_audio": null,
    "question_video": null,
    "map_id": 24863,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Only the epiglottis is visible, no part of the glottis can be seen</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Cormack-Lehane Grade III view indicates that only the epiglottis is visible, with no view of the glottis. This classification is used to predict the difficulty of intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Full view of the glottis:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Cormack-Lehane Grade I, indicating an easy intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Partial view of the glottis:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Cormack-Lehane Grade II, suggesting a moderately difficult intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Neither the glottis nor the epiglottis is visible:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes a Cormack-Lehane Grade IV, indicating a very difficult intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Cormack-Lehane Grade III view indicates that only the epiglottis is visible, with no view of the glottis, predicting a difficult intubation.</span></span></span></span></p>",
    "correct_choice_id": 199125,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49892,
    "choices": [
      {
        "id": 199127,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple head extension</span></span></p>"
      },
      {
        "id": 199128,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple head flexion</span></span></p>"
      },
      {
        "id": 199129,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HEAD/RAMP</span></span></p>"
      },
      {
        "id": 199130,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recovery position</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old obese patient with a history of obstructive sleep apnea presents with breathlessness. Rapid Sequence Intubation is initiated, and the emergency physician decides to use a modified position for intubation. What is the ideal position ?</span></span></p>",
    "unique_key": "Q9169204",
    "question_audio": null,
    "question_video": null,
    "map_id": 24864,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) HEAD/RAMP</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The HEAD (Head-Elevated Laryngoscopy Position) or RAMP (Rapid Airway Management Position) position is ideal for intubating an obese patient, especially one with a history of obstructive sleep apnea. This position involves elevating the patient&#39;s head and upper body to align the external auditory meatus with the sternal notch, improving the alignment of the oral, pharyngeal, and laryngeal axes. This enhanced alignment provides a better glottic view during laryngoscopy, facilitating easier and more effective intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-094119_Lcv5tQt.png\" style=\"height:226px; width:300px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Simple head extension:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position may not provide the optimal alignment needed for intubation in obese patients or those with obstructive sleep apnea.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Simple head flexion:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position is not suitable for intubation as it can obstruct the airway and worsen the glottic view.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Recovery position:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position is used for unconscious but breathing patients to maintain an open airway, not for intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The HEAD/RAMP (Head-Elevated Laryngoscopy Position/Rapid Airway Management Position) is ideal for intubating obese patients or those with obstructive sleep apnea, aligning the external auditory meatus with the sternal notch to improve glottic view during laryngoscopy.</span></span></span></span></p>",
    "correct_choice_id": 199129,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49893,
    "choices": [
      {
        "id": 199131,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lying flat on his back with head extension</span></span></p>"
      },
      {
        "id": 199132,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lying flat on his back with head flexion</span></span></p>"
      },
      {
        "id": 199133,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lying on his side with his lower arm extended and upper leg bent</span></span></p>"
      },
      {
        "id": 199134,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitting up with head tilted forward</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old man is found unconscious but breathing with a stable pulse at a park. To ensure his airway remains open and to prevent aspiration, the first responder decides to place him in the recovery position. What is the correct description of the recovery position ?</span></span></p>",
    "unique_key": "Q5512581",
    "question_audio": null,
    "question_video": null,
    "map_id": 24865,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lying on his side with his lower arm extended and upper leg bent</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The recovery position involves placing the patient on their side with their lower arm extended and their upper leg bent. This position helps to maintain an open airway, allows fluids to drain from the mouth to prevent aspiration, and ensures that the patient does not roll onto their stomach or back.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/25/screenshot-2024-06-25-171344.png\" style=\"height:401px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Lying flat on his back with head extension:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position does not protect the airway from aspiration and may not keep it open in an unconscious patient.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lying flat on his back with head flexion:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position can obstruct the airway and increase the risk of aspiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sitting up with head tilted forward:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this can help maintain an airway, it is not a stable position for an unconscious person and does not prevent aspiration as effectively as the recovery position.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The recovery position involves placing an unconscious but breathing patient on their side with the lower arm extended and the upper leg bent to maintain an open airway and prevent aspiration.</span></span></span></span></p>",
    "correct_choice_id": 199133,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49894,
    "choices": [
      {
        "id": 199135,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine</span></span></p>"
      },
      {
        "id": 199136,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate</span></span></p>"
      },
      {
        "id": 199137,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Midazolam</span></span></p>"
      },
      {
        "id": 199138,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propofol</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient in septic shock requires intubation and sedation. The intensivist gives a bolus of hydrocortisone after intubation. What sedative is given ?</span></span></p>",
    "unique_key": "Q1142653",
    "question_audio": null,
    "question_video": null,
    "map_id": 24866,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Etomidate</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate is known to suppress adrenal cortisol output, which can be detrimental in septic patients. To counteract this effect, the intensivist gives a bolus of hydrocortisone after intubation to support adrenal function. This practice suggests that Etomidate was used as the sedative, as it provides excellent sedation with no hypotension, which is beneficial in septic shock. However, due to its effect on adrenal suppression, corticosteroids are administered to mitigate this risk.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ketamine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine does not suppress adrenal function and is known for its bronchodilatory properties and catecholamine release.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Midazolam:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Midazolam is an amnestic and antiepileptic but does not have significant effects on adrenal function.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Propofol:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propofol does not suppress adrenal function but can cause hypotension, which is undesirable in septic shock.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate is often used for sedation in septic shock due to its excellent sedation profile and minimal hypotensive effects, but it requires administration of hydrocortisone to counteract its adrenal suppression.</span></span></span></span></p>",
    "correct_choice_id": 199136,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49895,
    "choices": [
      {
        "id": 199139,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRIS is associated with use of high doses of propofol (&gt; 5 mg/kg/h)</span></span></span></span></p>"
      },
      {
        "id": 199140,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRIS can present with metabolic acidosis and rhabdomyolysis</span></span></p>"
      },
      {
        "id": 199141,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRIS is characterized by hyperglycemia</span></span></p>"
      },
      {
        "id": 199142,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRIS can lead to cardiac and renal failure</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presented with refractory status epilepticus and propofol infusion was started. Which of the following is false regarding propofol infusion syndrome (PRIS) ?</span></span></p>",
    "unique_key": "Q4525743",
    "question_audio": null,
    "question_video": null,
    "map_id": 24867,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) PRIS is characterized by hyperglycemia</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propofol infusion syndrome (PRIS) is not typically characterized by hyperglycemia. Instead, it is associated with metabolic acidosis, rhabdomyolysis, hyperkalemia, and can lead to cardiac and renal failure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. PRIS is associated with high doses of propofol (&gt; 5 mg/kg/h):&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is true. High doses and prolonged infusions of propofol are risk factors for developing PRIS.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. PRIS can present with metabolic acidosis and rhabdomyolysis:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is true. Metabolic acidosis and rhabdomyolysis are key features of PRIS.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PRIS can lead to cardiac and renal failure:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is true. PRIS can result in severe complications, including cardiac and renal failure.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propofol infusion syndrome (PRIS) is associated with metabolic acidosis, rhabdomyolysis, hyperkalemia, and can lead to cardiac and renal failure, but it is not typically characterized by hyperglycemia.</span></span></span></span></p>",
    "correct_choice_id": 199141,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49896,
    "choices": [
      {
        "id": 199143,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate</span></span></p>"
      },
      {
        "id": 199144,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine</span></span></p>"
      },
      {
        "id": 199145,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Midazolam</span></span></p>"
      },
      {
        "id": 199146,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiopental sodium</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of asthma presents with status asthmaticus and requires sedation for intubation. Which sedative from the table is the most appropriate choice due to its bronchodilatory properties ?</span></span></p>",
    "unique_key": "Q2784948",
    "question_audio": null,
    "question_video": null,
    "map_id": 24868,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Ketamine</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine is the most appropriate choice for sedation in a patient with status asthmaticus due to its bronchodilatory properties. It not only provides effective sedation but also causes bronchodilation, which is beneficial in managing severe asthma exacerbations.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Etomidate:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While Etomidate provides excellent sedation without causing hypotension, it does not have bronchodilatory properties.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Midazolam:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Midazolam is an amnestic and antiepileptic but does not have bronchodilatory effects.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Thiopental sodium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiopental sodium is a potent sedative and myocardial depressant but is relatively contraindicated in patients with reactive airway disease (RAD) and does not have bronchodilatory properties.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine is the preferred sedative for intubation in patients with status asthmaticus due to its bronchodilatory properties, which help manage severe asthma exacerbations.</span></span></span></span></p>",
    "correct_choice_id": 199144,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49897,
    "choices": [
      {
        "id": 199147,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia</span></span></p>"
      },
      {
        "id": 199148,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignant hyperthermia</span></span></p>"
      },
      {
        "id": 199149,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></p>"
      },
      {
        "id": 199150,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Muscular dystrophy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man with a history of muscular dystrophy presents to the emergency department with severe respiratory distress. The team decides to perform rapid sequence intubation (RSI). Which of the following conditions is NOT a contraindication for the use of succinylcholine in this patient ? </span></span></p>",
    "unique_key": "Q8041439",
    "question_audio": null,
    "question_video": null,
    "map_id": 24869,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hypokalemia</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia is not a contraindication for the use of succinylcholine. Succinylcholine is contraindicated in conditions such as malignant hyperthermia, muscular dystrophy, and other situations where there is an increased risk of hyperkalemia, as it can exacerbate elevated potassium levels and lead to serious complications.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Malignant hyperthermia:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine can trigger malignant hyperthermia, a potentially life-threatening condition, making it a contraindication.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypertension:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension itself is not a contraindication for succinylcholine, but it is important to monitor blood pressure as succinylcholine can have cardiovascular effects.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Muscular dystrophy:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine is contraindicated in patients with muscular dystrophy because it can cause severe hyperkalemia and rhabdomyolysis, leading to potentially fatal complications.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia is not a contraindication for the use of succinylcholine; however, conditions like malignant hyperthermia and muscular dystrophy are contraindications due to the risk of severe hyperkalemia and other complications.</span></span></span></span></p>",
    "correct_choice_id": 199147,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49898,
    "choices": [
      {
        "id": 199151,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></p>"
      },
      {
        "id": 199152,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bradycardia</span></span></p>"
      },
      {
        "id": 199153,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperglycemia</span></span></p>"
      },
      {
        "id": 199154,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypothermia</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child requires rapid sequence intubation (RSI) due to severe trauma after falling from a height. What is a potential side effect of succinylcholine in this patient ?</span></span></p>",
    "unique_key": "Q2751392",
    "question_audio": null,
    "question_video": null,
    "map_id": 24870,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Bradycardia</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine can cause bradycardia, especially in pediatric patients. This effect is often seen after the administration of the first dose and can be more pronounced with subsequent doses. In children, the bradycardia can be profound and may require treatment with atropine. Other potential side effects of succinylcholine include hyperkalemia, myalgia, increased intraocular pressure, and malignant hyperthermia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypertension:</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While succinylcholine can cause transient increases in blood pressure, it is not as significant a concern as bradycardia, especially in pediatric patients.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperglycemia:</span></span></strong></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></strong></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperglycemia is not a known side effect of succinylcholine.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypothermia:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine is associated with malignant hyperthermia, which is a hypermetabolic state, not hypothermia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine can cause bradycardia, particularly in pediatric patients, often requiring treatment with atropine.</span></span></span></span></p>",
    "correct_choice_id": 199152,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49899,
    "choices": [
      {
        "id": 199155,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine</span></span></p>"
      },
      {
        "id": 199156,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rocuronium</span></span></p>"
      },
      {
        "id": 199157,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vecuronium</span></span></p>"
      },
      {
        "id": 199158,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisatracurium</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old chronic alcoholic with cirrhosis and portal hypertension requires intubation and continuous neuromuscular blockade in the ICU. Which agent is the most appropriate ?</span></span></p>",
    "unique_key": "Q4213667",
    "question_audio": null,
    "question_video": null,
    "map_id": 24871,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Cisatracurium</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisatracurium is metabolized through Hofmann elimination and ester hydrolysis, which are independent of liver function. This makes it suitable for continuous neuromuscular blockade in patients with cirrhosis and portal hypertension, as it avoids the risk of prolonged effects and toxicity associated with impaired hepatic metabolism.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Succinylcholine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine is used for rapid sequence intubation due to its fast onset and short duration, but it is not suitable for continuous neuromuscular blockade due to its short duration and potential side effects such as hyperkalemia and malignant hyperthermia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Rocuronium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rocuronium is primarily metabolized by the liver, making it less suitable for continuous use in patients with significant liver impairment like cirrhosis, due to the risk of prolonged effects.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vecuronium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vecuronium also relies significantly on hepatic metabolism and renal elimination, which can lead to prolonged neuromuscular blockade in patients with liver failure, making it less ideal for continuous use in such patients.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisatracurium is the preferred agent for continuous neuromuscular blockade in patients with liver dysfunction, such as cirrhosis and portal hypertension, due to its metabolism via Hofmann elimination and ester hydrolysis, which are independent of liver function.</span></span></span></span></p>",
    "correct_choice_id": 199158,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49900,
    "choices": [
      {
        "id": 199159,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine</span></span></p>"
      },
      {
        "id": 199160,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rocuronium</span></span></p>"
      },
      {
        "id": 199161,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vecuronium</span></span></p>"
      },
      {
        "id": 199162,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancuronium</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 67-year-old man with sick sinus syndrome requires intubation. Which neuromuscular blocker could be beneficial in him?</span></span></p>",
    "unique_key": "Q9478020",
    "question_audio": null,
    "question_video": null,
    "map_id": 24872,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Pancuronium</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancuronium has vagal blocking properties, which can help mitigate bradycardia in patients with sick sinus syndrome. This makes it a beneficial choice for neuromuscular blockade in such patients, as it can reduce the risk of bradycardia during intubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Succinylcholine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine is not ideal for patients with sick sinus syndrome as it can cause bradycardia and is primarily used for rapid sequence intubation rather than continuous blockade.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Rocuronium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rocuronium does not have vagal blocking properties and would not provide the same benefit in preventing bradycardia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vecuronium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vecuronium also lacks vagal blocking properties and would not be as beneficial in managing bradycardia associated with sick sinus syndrome.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancuronium is beneficial for patients with sick sinus syndrome requiring intubation due to its vagal blocking properties, which help mitigate bradycardia.</span></span></span></span></p>",
    "correct_choice_id": 199162,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49901,
    "choices": [
      {
        "id": 199163,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mivacurium</span></span></p>"
      },
      {
        "id": 199164,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate</span></span></p>"
      },
      {
        "id": 199165,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine</span></span></p>"
      },
      {
        "id": 199166,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succinylcholine</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22 year old lady patient presents with an anaphylactic shock after consuming a peanut. Which of the following drugs should be avoided?</span></span></p>",
    "unique_key": "Q9357157",
    "question_audio": null,
    "question_video": null,
    "map_id": 24873,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Mivacurium</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mivacurium can cause histamine release, which may exacerbate anaphylactic reactions. Given the patient&#39;s current state of anaphylactic shock, avoiding drugs that can release histamine is crucial to prevent worsening of the reaction.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Etomidate:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etomidate is not known to cause histamine release and is generally considered safe in anaphylactic shock.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ketamine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine is also safe in anaphylactic reactions and can be beneficial due to its bronchodilatory properties.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Succinylcholine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While succinylcholine has other side effects, it does not typically cause significant histamine release that would exacerbate anaphylactic shock.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mivacurium should be avoided in patients experiencing anaphylactic shock as it can cause histamine release, potentially worsening the anaphylactic reaction.</span></span></span></span></p>",
    "correct_choice_id": 199163,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49902,
    "choices": [
      {
        "id": 199167,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased gastric reflux</span></span></p>"
      },
      {
        "id": 199168,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Esophageal rupture</span></span></p>"
      },
      {
        "id": 199169,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased ventilation</span></span></p>"
      },
      {
        "id": 199170,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchospasm</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During rapid sequence intubation (RSI), the Sellick maneuver is performed to prevent aspiration. What is a potential complication associated with improper application of this maneuver?</span></span></p>",
    "unique_key": "Q9833446",
    "question_audio": null,
    "question_video": null,
    "map_id": 24874,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Decreased ventilation</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Sellick maneuver, or cricoid pressure, involves compressing the cricoid cartilage to occlude the esophagus and prevent aspiration of gastric contents during intubation. Improper application of the Sellick maneuver, such as applying excessive pressure, can lead to decreased ventilation by compressing the trachea or obstructing the airway.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-100044.png\" style=\"height:368px; width:500px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Increased gastric reflux:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The maneuver is intended to prevent this by occluding the esophagus.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Esophageal rupture:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While theoretically possible, this is extremely rare and not a common complication.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Bronchospasm:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is not typically associated with the Sellick maneuver; it is more related to airway irritants or asthma.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Improper application of the Sellick maneuver (cricoid pressure) during rapid sequence intubation can lead to decreased ventilation by compressing the trachea or obstructing the airway.</span></span></span></span></p>",
    "correct_choice_id": 199169,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 49903,
    "choices": [
      {
        "id": 199171,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To increase the diameter of the trachea</span></span></p>"
      },
      {
        "id": 199172,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To improve visualization of the vocal cords</span></span></p>"
      },
      {
        "id": 199173,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To prevent aspiration</span></span></p>"
      },
      {
        "id": 199174,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To stabilize the patient&#39;s neck</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is undergoing rapid sequence intubation (RSI), and the initial attempt to visualize the vocal cords is unsuccessful. The clinician applies the BURP maneuver. What is the primary purpose of this maneuver ?</span></span></p>",
    "unique_key": "Q4071361",
    "question_audio": null,
    "question_video": null,
    "map_id": 24875,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) To improve visualization of the vocal cords</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary purpose of the BURP maneuver (Backward Upward Rightward Pressure) is to improve visualization of the vocal cords during intubation by optimizing the position of the larynx.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. To increase the diameter of the trachea:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The maneuver does not affect the tracheal diameter.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. To prevent aspiration:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is not the primary goal of the BURP maneuver; cricoid pressure is used for preventing aspiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. To stabilize the patient&#39;s neck:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While it may help to some extent, stabilization is not the primary goal of the BURP maneuver.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary purpose of the BURP maneuver (Backward Upward Rightward Pressure) is to improve visualization of the vocal cords during intubation by optimizing the position of the larynx.</span></span></span></span></p>",
    "correct_choice_id": 199172,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49904,
    "choices": [
      {
        "id": 199175,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C-E technique</span></span></p>"
      },
      {
        "id": 199176,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">V-E technique</span></span></p>"
      },
      {
        "id": 199177,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BURP technique</span></span></p>"
      },
      {
        "id": 199178,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sellick technique</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the technique &ndash;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-100504.png\" style=\"height:257px; width:300px\" /></p>",
    "unique_key": "Q5096454",
    "question_audio": null,
    "question_video": null,
    "map_id": 24876,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) C-E technique</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The C-E technique involves using the thumb and index finger to form a &quot;C&quot; shape around the mask to create a seal, while the other three fingers form an &quot;E&quot; shape to lift the mandible and open the airway. This technique helps ensure a tight seal and proper ventilation with a bag-valve-mask.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. V-E technique:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With this technique, the thumbs and thenar eminence are placed over each side of the mask while the second through fifth digits pull the jaw upward&nbsp;</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-100609_q8LfTRt.png\" style=\"height:267px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. BURP technique:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The BURP technique involves applying backward, upward, and rightward pressure on the thyroid cartilage to improve glottic visualization, not related to mask sealing.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-100826.png\" style=\"height:221px; width:300px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sellick technique:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Sellick technique involves applying pressure to the cricoid cartilage to prevent aspiration, not related to the mask sealing technique shown.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-100857.png\" style=\"height:219px; width:300px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The C-E technique for bag-valve-mask ventilation involves using the thumb and index finger to form a &quot;C&quot; shape around the mask to create a seal, while the other three fingers form an &quot;E&quot; shape to lift the mandible and open the airway.</span></span></span></span></p>",
    "correct_choice_id": 199175,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49905,
    "choices": [
      {
        "id": 199179,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neostigmine</span></span></p>"
      },
      {
        "id": 199180,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sugammadex</span></span></p>"
      },
      {
        "id": 199181,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atropine</span></span></p>"
      },
      {
        "id": 199182,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Edrophonium</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which reversal agent is used for quick reversal of rocuronium ?</span></span></p>",
    "unique_key": "Q9760286",
    "question_audio": null,
    "question_video": null,
    "map_id": 24877,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Sugammadex</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sugammadex is a specific reversal agent for rocuronium and vecuronium. It works by encapsulating the neuromuscular blocking agents, thereby reversing their effects quickly and effectively.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Neostigmine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neostigmine is a cholinesterase inhibitor used to reverse non-depolarizing neuromuscular blockers, but it is not as rapid or specific as sugammadex for rocuronium.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Atropine:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atropine is an anticholinergic agent used to treat bradycardia and to reduce secretions, not for reversing neuromuscular blockade.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Edrophonium:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Edrophonium is a cholinesterase inhibitor used for diagnosing myasthenia gravis and reversing neuromuscular blockade, but it is not as effective or specific as sugammadex for rocuronium.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sugammadex is the specific and rapid reversal agent for rocuronium, encapsulating the neuromuscular blocking agent to quickly reverse its effects.</span></span></span></span></p>",
    "correct_choice_id": 199180,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49906,
    "choices": [
      {
        "id": 199183,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Safe to extubate</span></span></p>"
      },
      {
        "id": 199184,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unsafe to extubate</span></span></p>"
      },
      {
        "id": 199185,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">He is at risk of reintubation</span></span></p>"
      },
      {
        "id": 199186,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incomplete recovery from neuromuscular blockade</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old patient presented with severe pneumonia and was intubated. His condition improved and he was planned to extubate. On TOF stimulation, he has a TOF ratio of 0.9. What does this suggest?</span></span></p>",
    "unique_key": "Q7214923",
    "question_audio": null,
    "question_video": null,
    "map_id": 24878,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Safe to extubate</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A TOF ratio (TOFR) of 0.9 or higher is generally considered indicative of adequate recovery from neuromuscular blockade, suggesting it is safe to proceed with extubation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Unsafe to extubate:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A TOFR of 0.9 indicates adequate recovery, so it is not unsafe to extubate.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. He is at risk of reintubation:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While all extubated patients should be monitored, a TOFR of 0.9 suggests that the patient has sufficiently recovered from neuromuscular blockade, making the risk of reintubation due to neuromuscular weakness low.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Incomplete recovery from neuromuscular blockade:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incomplete recovery is suggested by a TOFR below 0.9; a TOFR of 0.9 indicates complete recovery.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A TOF ratio (TOFR) of 0.9 or higher indicates adequate recovery from neuromuscular blockade, suggesting that it is safe to proceed with extubation.</span></span></span></span></p>",
    "correct_choice_id": 199183,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49907,
    "choices": [
      {
        "id": 199187,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoventilation</span></span></p>"
      },
      {
        "id": 199188,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchospasm</span></span></p>"
      },
      {
        "id": 199189,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rebreathing</span></span></p>"
      },
      {
        "id": 199190,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Esophageal intubation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows an end-tidal CO2 (ETCO2) waveform. What does the pattern in the ETCO2 waveform suggest ?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-101651.png\" style=\"height:62px; width:300px\" /></span></span></p>",
    "unique_key": "Q9391172",
    "question_audio": null,
    "question_video": null,
    "map_id": 24879,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Esophageal intubation</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The flat ETCO2 waveform suggests that there is no significant CO2 being detected in the exhaled breath, which is indicative of esophageal intubation. In esophageal intubation, the endotracheal tube is incorrectly placed in the esophagus rather than the trachea, preventing proper ventilation and resulting in minimal or absent CO2 detection.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypoventilation:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoventilation would show a gradual rise in the ETCO2 levels, not a flat line.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bronchospasm:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchospasm typically produces a shark-fin appearance in the ETCO2 waveform due to prolonged expiration.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rebreathing:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rebreathing results in a gradually rising baseline of the ETCO2 waveform, not a flat line.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A flat ETCO2 waveform suggests esophageal intubation, indicating that the endotracheal tube is incorrectly placed in the esophagus rather than the trachea, preventing proper ventilation and resulting in minimal or absent CO2 detection.</span></span></span></span></p>",
    "correct_choice_id": 199190,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 49908,
    "choices": [
      {
        "id": 199191,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoventilation</span></span></p>"
      },
      {
        "id": 199192,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spontaneous diaphragmatic movements</span></span></p>"
      },
      {
        "id": 199193,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rebreathing of exhaled gases</span></span></p>"
      },
      {
        "id": 199194,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Esophageal intubation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old male patient is undergoing surgery and is intubated with mechanical ventilation. The ETCO2 waveform shown in the image is observed. What does this indicate ?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-101933.png\" style=\"height:88px; width:300px\" /></span></span></p>",
    "unique_key": "Q2060323",
    "question_audio": null,
    "question_video": null,
    "map_id": 24880,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Spontaneous diaphragmatic movements</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ETCO2 waveform shows a characteristic &quot;curare cleft,&quot; which indicates spontaneous diaphragmatic movements or breaths in a patient who is partially recovering from neuromuscular blockade. This typically occurs when the effects of muscle relaxants are wearing off, and the patient begins to take spontaneous breaths.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypoventilation:&nbsp;</span></span></strong></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoventilation would show elevated ETCO2 levels with longer intervals between the peaks but would not have the characteristic cleft.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rebreathing of exhaled gases:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rebreathing results in a gradually rising baseline of the ETCO2 waveform due to the accumulation of CO2.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Esophageal intubation:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Esophageal intubation would result in a flat or very low ETCO2 waveform, indicating minimal CO2 detection.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The &quot;curare cleft&quot; in the ETCO2 waveform indicates spontaneous diaphragmatic movements or breaths in a patient who is partially recovering from neuromuscular blockade. This occurs when the effects of muscle relaxants are wearing off, and the patient begins to take spontaneous breaths.</span></span></span></span></p>",
    "correct_choice_id": 199192,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 49909,
    "choices": [
      {
        "id": 199195,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right Hemothorax</span></span></p>"
      },
      {
        "id": 199196,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right upper lobe collapse</span></span></p>"
      },
      {
        "id": 199197,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right Pneumothorax</span></span></p>"
      },
      {
        "id": 199198,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration Pneumonia (R) lower lobe</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man presents with sudden onset of chest pain and shortness of breath shortly after the insertion of a subclavian catheter. The chest X-ray shown in the image was taken following the procedure. What is the most likely diagnosis based on the X-ray findings ?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-102105.png\" style=\"height:339px; width:300px\" /></span></span></p>",
    "unique_key": "Q8784160",
    "question_audio": null,
    "question_video": null,
    "map_id": 24881,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Right Pneumothorax</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The chest X-ray shows a clear indication of pneumothorax, characterized by the presence of a visible pleural line with absence of lung markings beyond this line on the right side. This is a common complication following subclavian catheter insertion, leading to the collapse of the right lung.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Right Hemothorax:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemothorax would present with fluid accumulation in the pleural space, appearing as a homogenous opacity on the affected side, not the absence of lung markings seen in pneumothorax.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Right upper lobe collapse:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper lobe collapse would show signs of volume loss such as elevation of the horizontal fissure, not the absence of lung markings characteristic of pneumothorax.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Aspiration Pneumonia (R) lower lobe:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration pneumonia would present with infiltrates or consolidation in the lower lobe, not the absence of lung markings seen in pneumothorax.Top of Form</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The chest X-ray shows a right pneumothorax, indicated by the presence of a visible pleural line with the absence of lung markings beyond this line on the right side, a common complication following subclavian catheter insertion.</span></span></span></span></p>",
    "correct_choice_id": 199197,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 49910,
    "choices": [
      {
        "id": 199199,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measuring from the nose to the xiphoid process</span></span></p>"
      },
      {
        "id": 199200,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measuring from the nose to the earlobe to the xiphoid process</span></span></p>"
      },
      {
        "id": 199201,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measuring from the nose to the earlobe to the umbilicus</span></span></p>"
      },
      {
        "id": 199202,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measuring from the nose to the sternum to the umbilicus</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old female patient requires the insertion of a nasogastric (NG) tube for feeding. What describes the best method to ensure adequate length of the tube ?</span></span></p>",
    "unique_key": "Q7911783",
    "question_audio": null,
    "question_video": null,
    "map_id": 24882,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Measuring from the nose to the earlobe to the xiphoid process</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The NEX method involves measuring the distance from the tip of the nose (N) to the earlobe (E) and then to the xiphoid process (X). This measurement ensures that the NG tube is long enough to reach the stomach without coiling in the esophagus or stopping short of the stomach.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Measuring from the nose to the xiphoid process:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This method does not account for the curvature of the nasopharynx and esophagus.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Measuring from the nose to the earlobe to the umbilicus:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This method would result in an excessively long tube length.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Measuring from the nose to the sternum to the umbilicus:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This method is not a recognized technique for NG tube placement and would result in an incorrect tube length.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The NEX method for measuring the adequate length of a nasogastric (NG) tube involves measuring from the nose (N) to the earlobe (E) to the xiphoid process (X) to ensure the tube reaches the stomach without coiling in the esophagus or stopping short.</span></span></span></span></p>",
    "correct_choice_id": 199200,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 49911,
    "choices": [
      {
        "id": 199203,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right Hemothorax</span></span></p>"
      },
      {
        "id": 199204,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right Pneumothorax</span></span></p>"
      },
      {
        "id": 199205,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right endobronchial intubation</span></span></p>"
      },
      {
        "id": 199206,
        "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Left Tension Pneumothorax</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male patient presents to the emergency department after a motor vehicle accident. He is experiencing severe shortness of breath and chest pain on the left side. The chest X-ray shown in the image was taken upon arrival. What is the most likely diagnosis based on the X-ray findings ?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/20/screenshot-2024-06-20-102454.png\" style=\"height:295px; width:300px\" /></span></span></p>",
    "unique_key": "Q7349585",
    "question_audio": null,
    "question_video": null,
    "map_id": 24883,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Right endobronchial intubation</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The chest X-ray shows hyperinflation of the right lung and collapse of the left lung, which is indicative of right endobronchial intubation. This occurs when the endotracheal tube is inserted too far and enters the right mainstem bronchus, leading to overventilation of the right lung and collapse of the left lung.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Right Hemothorax:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A hemothorax would present with fluid accumulation, appearing as a homogenous opacity on the affected side rather than hyperinflation of one lung and collapse of the other.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Right Pneumothorax:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pneumothorax would show absence of lung markings on the affected side and potentially tracheal deviation, not hyperinflation and collapse.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Left Tension Pneumothorax:&nbsp;</span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A tension pneumothorax would show absence of lung markings on the affected side and tracheal deviation away from the affected side, which is not seen here.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The chest X-ray shows hyperinflation of the right lung and collapse of the left lung, indicating right endobronchial intubation, where the endotracheal tube is inserted too far and enters the right mainstem bronchus, leading to overventilation of the right lung and collapse of the left lung.</span></span></span></span></p>",
    "correct_choice_id": 199205,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 49854,
    "choices": [
      {
        "id": 198979,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IMV</span></span></p>"
      },
      {
        "id": 198980,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SIMV</span></span></p>"
      },
      {
        "id": 198981,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AC</span></span></p>"
      },
      {
        "id": 198982,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PSV</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old female patient is on mechanical ventilation and is being weaned off. Which mode of ventilation is best in this situation ?</span></span></p>",
    "unique_key": "Q8858093",
    "question_audio": null,
    "question_video": null,
    "map_id": 24840,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) PSV</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pressure Support Ventilation (PSV) is the most suitable mode for weaning a patient off mechanical ventilation. PSV provides no mandatory breaths but offers partial pressure support to patient-initiated breaths, allowing the patient to gradually assume more of the work of breathing while still receiving assistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. IMV:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Intermittent Mandatory Ventilation provides a set number of mandatory breaths per minute with no support to patient-initiated breaths, which is not ideal for weaning.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. SIMV:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Synchronized Intermittent Mandatory Ventilation provides a set number of mandatory breaths per minute with synchronized support to patient-initiated breaths, but it may still provide more support than necessary for a weaning patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. AC:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Assist Control Ventilation provides a set number of mandatory breaths per minute with full support to any additional breaths initiated by the patient, which is ideal to support respiratory failure but not during weaning. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pressure Support Ventilation (PSV) is the most suitable mode for weaning a patient off mechanical ventilation as it provides partial support to patient-initiated breaths, facilitating gradual assumption of breathing effort by the patient.</span></span></span></p>",
    "correct_choice_id": 198982,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49856,
    "choices": [
      {
        "id": 198987,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assist Control (AC)</span></span></p>"
      },
      {
        "id": 198988,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intermittent Mandatory Ventilation (IMV)</span></span></p>"
      },
      {
        "id": 198989,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Synchronized Intermittent Mandatory Ventilation (SIMV)</span></span></p>"
      },
      {
        "id": 198990,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pressure Support Ventilation (PSV)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male with acute respiratory distress syndrome (ARDS) is admitted to the ICU and placed on mechanical ventilation. The physician needs to set the ventilator to ensure the patient receives a fixed number of mandatory breaths per minute with full support to patient-initiated breaths. Which mode of ventilation should be used ?</span></span></p>",
    "unique_key": "Q3594655",
    "question_audio": null,
    "question_video": null,
    "map_id": 24841,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Assist Control (AC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assist Control (AC):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This mode delivers a set number of mandatory breaths per minute with full support to any patient-initiated breaths, making it suitable for patients with ARDS who require consistent ventilatory support.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Intermittent Mandatory Ventilation (IMV):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> IMV delivers a set number of mandatory breaths per minute but does not provide support for patient-initiated breaths, making it less suitable for a patient requiring full support.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Synchronized Intermittent Mandatory Ventilation (SIMV):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> SIMV delivers a set number of mandatory breaths per minute and synchronizes support with patient-initiated breaths but does not provide full support to each breath, which may not be sufficient for severe ARDS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pressure Support Ventilation (PSV):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PSV does not deliver mandatory breaths and only provides support to spontaneous breaths, which is not adequate for a patient with severe ARDS who requires consistent mandatory ventilation support.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assist Control (AC) ventilation is suitable for patients with ARDS as it provides a set number of mandatory breaths per minute with full support to any patient-initiated breaths, ensuring consistent ventilatory support.</span></span></span></p>",
    "correct_choice_id": 198987,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49858,
    "choices": [
      {
        "id": 198995,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&le; 20 cm H2O</span></span></p>"
      },
      {
        "id": 198996,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&le; 25 cm H2O</span></span></p>"
      },
      {
        "id": 198997,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&le; 30 cm H2O</span></span></p>"
      },
      {
        "id": 198998,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&le; 40 cm H2O</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old male patient with ARDS is on mechanical ventilation. What is the target peak Plateau pressure (P-PLATEAU) to ensure lung protection?</span></span></p>",
    "unique_key": "Q1151832",
    "question_audio": null,
    "question_video": null,
    "map_id": 24842,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) &le; 30 cm H2O</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For patients with ARDS on mechanical ventilation, it is recommended to maintain a plateau pressure (P-PLATEAU) of &le; 30 cm H2O to reduce the risk of ventilator-induced lung injury (VILI). This target helps to prevent overdistention and barotrauma of the alveoli.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. &le; 20 cm H2O:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While a plateau pressure this low would certainly minimize the risk of VILI, it is often not practical or achievable in patients with ARDS who require higher pressures to maintain adequate oxygenation and ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. &le; 25 cm H2O:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Incorrect since the target plateau pressure is &le; 30 cm H2O</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. &le; 40 cm H2O:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the target PIP (Peak Inspiratory Pressure) and not plateau pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For patients with ARDS on mechanical ventilation, the target plateau pressure (P-PLATEAU) should be &le; 30 cm H2O to minimize the risk of ventilator-induced lung injury.</span></span></span></p>",
    "correct_choice_id": 198997,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49859,
    "choices": [
      {
        "id": 198999,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C = 10, Poor compliance </span></span></p>"
      },
      {
        "id": 199000,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C = 60, good compliance </span></span></p>"
      },
      {
        "id": 199001,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C = 10, good compliance </span></span></p>"
      },
      {
        "id": 199002,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C = 60, poor compliance</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a ventilated patient, the tidal volume (VT) is 350 mL, PEEP is 5 cm H2O and Plateau pressure is 40 cm H2O. What is the inference?</span></span></p>",
    "unique_key": "Q4152699",
    "question_audio": null,
    "question_video": null,
    "map_id": 24843,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) C = 10, Poor compliance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Compliance </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">= </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">V<sub>T</sub>/</span><span dir=\"ltr\" lang=\"EL\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&Delta;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EL\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&Delta;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> =</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> P<sub>PLATEAU </sub></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ndash;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PEEP</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (</span><span dir=\"ltr\" lang=\"EL\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&Delta;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> = 40-5 = 35 cm H2O)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Compliance </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">= </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">V<sub>T</sub>/</span><span dir=\"ltr\" lang=\"EL\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&Delta;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (Compliance 350/35 = 10 ml/ cm H2O)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Target compliance in IPPV is &gt; 60. Since its just 10 in this patient, indicating a very poor compliance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. C = 60, good compliance:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Incorrect calculation and interpretation. Compliance is not 60 and poor compliance is inferred.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. C = 10, good compliance:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The calculation is correct, but compliance of 10 is poor, not good.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. C = 60, poor compliance:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Incorrect calculation. Compliance of 60 mL/cm H2O would indicate good compliance, not poor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For ventilated patients, a compliance value significantly lower than 60 mL/cm H2O indicates poor lung compliance, reflecting increased lung stiffness or decreased distensibility.</span></span></span></p>",
    "correct_choice_id": 198999,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 49860,
    "choices": [
      {
        "id": 199003,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchospasm </span></span></p>"
      },
      {
        "id": 199004,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism&nbsp; </span></span></p>"
      },
      {
        "id": 199005,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Respiratory Distress Syndrome&nbsp; </span></span></p>"
      },
      {
        "id": 199006,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia </span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old woman with history of SLE presents to the emergency department with sudden onset of severe shortness of breath. She is rapidly intubated due to respiratory failure. During mechanical ventilation, both the peak inspiratory pressure (PIP) and plateau pressure (P-PLATEAU) are observed to be within normal limits. What is the most likely cause of her symptoms ?</span></span></p>",
    "unique_key": "Q7655096",
    "question_audio": null,
    "question_video": null,
    "map_id": 24844,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Pulmonary embolism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pulmonary embolism: </strong>PE can cause sudden respiratory symptoms due to obstruction of pulmonary arteries, leading to ventilation-perfusion mismatch without affecting airway pressures. Normal PIP and P-PLATEAU in the presence of severe symptoms suggest an extra-thoracic cause such as PE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Bronchospasm:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This condition usually increases airway resistance, leading to elevated PIP with a normal P-PLATEAU.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Acute Respiratory Distress Syndrome:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARDS typically results in decreased lung compliance, causing increased PIP and P-PLATEAU.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pneumonia:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia can cause increased airway pressures due to reduced compliance or increased secretions, typically resulting in elevated PIP and sometimes P-PLATEAU depending on the severity and extent of the infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal PIP and P-PLATEAU in mechanically ventilated patients with severe respiratory symptoms suggest an extra-thoracic cause such as pulmonary embolism.</span></span></span></p>",
    "correct_choice_id": 199004,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49861,
    "choices": [
      {
        "id": 199007,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary embolism</span></span></p>"
      },
      {
        "id": 199008,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchospasm</span></span></p>"
      },
      {
        "id": 199009,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumothorax</span></span></p>"
      },
      {
        "id": 199010,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration of mucus</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic obstructive pulmonary disease (COPD) is admitted to the ICU with severe respiratory distress. He is placed on mechanical ventilation. During his course, you observe an increase in plateau pressure (P-PLATEAU). Which condition is most likely causing the increase P-PLATEAU?</span></span></p>",
    "unique_key": "Q4239038",
    "question_audio": null,
    "question_video": null,
    "map_id": 24845,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Pneumothorax</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pneumothorax causes a sudden increase in intrathoracic pressure due to the collapse of the lung. This in turn results in reduced lung compliance leading to increased Plateau pressure. This subsequently will lead to increased PIP and P-Plateau. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pulmonary embolism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Presents with normal pressures</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bronchospasm:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Bronchospasm increases airway resistance, which would elevate PIP but not P-PLATEAU because the issue lies within the airways rather than lung compliance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Aspiration of mucus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Aspiration of mucus primarily increases airway resistance, leading to an elevated PIP but P-PLATEAU will be normal as lung compliance is relatively normal</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An increase in plateau pressure (P-PLATEAU) in a mechanically ventilated patient suggests a decrease in lung compliance, which is commonly seen in conditions such as pneumothorax.</span></span></span></p>",
    "correct_choice_id": 199009,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 49864,
    "choices": [
      {
        "id": 199019,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TOFR 0.9 &amp; off paralysis</span></span></p>"
      },
      {
        "id": 199020,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hb of 10g/dL</span></span></p>"
      },
      {
        "id": 199021,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pH of 7.26</span></span></p>"
      },
      {
        "id": 199022,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RR of 32/min</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old male patient has been on mechanical ventilation for several days. Currently he is being weaned. Which of the following conditions excludes performing a spontaneous breathing trial (SBT)?</span></span></p>",
    "unique_key": "Q8949243",
    "question_audio": null,
    "question_video": null,
    "map_id": 24846,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) RR of 32/min</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A respiratory rate (RR) of 32/min is higher than the required RR &lt; 30/min, indicating the patient is not ready for an SBT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. TOFR 0.9 &amp; off paralysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a required condition for performing an SBT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hb of 10g/dL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an additional criterion but does not exclude performing an SBT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. pH of 7.26:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This meets the required condition of pH &gt; 7.25 and does not exclude performing an SBT.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A respiratory rate (RR) of 32/min is higher than the required threshold for a spontaneous breathing trial (SBT), indicating the patient is not ready for an SBT.</span></span></span></p>",
    "correct_choice_id": 199022,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 49866,
    "choices": [
      {
        "id": 199027,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T piece ventilation</span></span></p>"
      },
      {
        "id": 199028,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NIPPV</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (Non-Invasive Positive Pressure Ventilation)</span></span></p>"
      },
      {
        "id": 199029,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NRBM </span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Non-Rebreather Mask) </span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">at 10-15L per minute</span></span></p>"
      },
      {
        "id": 199030,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple Face Mask at 8L per minute</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old male patient has been on mechanical ventilation for several days. The medical team is assessing his readiness for a spontaneous breathing trial (SBT). Which of the following is appropriate for conducting a spontaneous breathing trial (SBT)?</span></span></p>",
    "unique_key": "Q9356651",
    "question_audio": null,
    "question_video": null,
    "map_id": 24847,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) T piece ventilation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T piece ventilation is commonly used for SBT as it allows the patient to breathe spontaneously without any assistance, closely simulating the conditions the patient will experience post-extubation. Alternative is a pressure support ventilation (PSV)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. NIPPV (Non-Invasive Positive Pressure Ventilation):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Used post intubation to reduce the rates of re-intubation in a high risk patient. Since SBTs are performed prior to extubation NIPPV makes no sense. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. NRBM (Non-Rebreather Mask) at 10-15L per minute:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is used to deliver high concentrations of oxygen but does not support SBTs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Simple Face Mask at 8L per minute:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Unsuitable for SBTs. Can be used post-extubation if patients are NOT at high risk, to provide O2 support. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T piece ventilation is commonly used for spontaneous breathing trials (SBT) as it allows the patient to breathe spontaneously without any assistance, closely simulating the conditions post-extubation</span></span></span></p>",
    "correct_choice_id": 199027,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49867,
    "choices": [
      {
        "id": 199031,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Piperacillin + tazobactam + Amikacin</span></span></p>"
      },
      {
        "id": 199032,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cefepime + Doxycycline + Linezolid </span></span></p>"
      },
      {
        "id": 199033,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levofloxacin + Vancomycin</span></span></p>"
      },
      {
        "id": 199034,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Meropenem + levofloxacin + Linezolid</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old female patient with a history of COPD is admitted to the ICU and requires mechanical ventilation due to a severe exacerbation. On the 10th day of mechanical ventilation, she develops a fever and worsening oxygenation. CXR revealed new infiltrates. The patient has a recent history of hospitalization for a UTI. Which of the following antibiotic regimens is most appropriate ?</span></span></p>",
    "unique_key": "Q5977094",
    "question_audio": null,
    "question_video": null,
    "map_id": 24848,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Meropenem + Levofloxacin + Linezolid</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This regimen provides broad coverage for multidrug-resistant gram-negative bacteria and MRSA. Meropenem is effective against many resistant gram-negative organisms, Levofloxacin provides additional gram-negative and atypical coverage, and Linezolid covers MRSA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Piperacillin + tazobactam + Amikacin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This combination MRSA coverage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cefepime + Doxycycline + Linezolid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Second drug must be an aminoglycoside or a respiratory quinolone or a polypeptide drug (colistin/polymyxin B). Doxycycline is not recommended in VAP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Levofloxacin + Vancomycin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta lactams are a must in VAP, hence this regime is inadequate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Broad-spectrum antibiotic regimens, such as Meropenem + Levofloxacin + Linezolid, are necessary to cover multidrug-resistant gram-negative bacteria and MRSA in ventilator-associated pneumonia (VAP).</span></span></span></p>",
    "correct_choice_id": 199034,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49869,
    "choices": [
      {
        "id": 199039,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3-5 days</span></span></p>"
      },
      {
        "id": 199040,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">7 days</span></span></p>"
      },
      {
        "id": 199041,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10-14 days</span></span></p>"
      },
      {
        "id": 199042,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">21 days</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old male patient has been diagnosed with ventilator-associated pneumonia (VAP) and is receiving appropriate antibiotic therapy. What is the recommended duration of antibiotic treatment for VAP to ensure optimal clinical outcomes ?</span></span></p>",
    "unique_key": "Q3407459",
    "question_audio": null,
    "question_video": null,
    "map_id": 24849,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 7 days</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Current guidelines recommend a duration of 7 days for antibiotic treatment of VAP. Studies have shown that a 7-day course of antibiotics is typically sufficient for most patients and is associated with similar clinical outcomes compared to longer durations, while also reducing the risk of antibiotic resistance and other complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 3-5 days:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This duration is generally considered too short for treating VAP and may not be sufficient to ensure complete eradication of the infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 10-14 days:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although previously recommended, this longer duration is not typically necessary for most cases of VAP and can increase the risk of antibiotic resistance and adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 21 days:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Such an extended duration is rarely necessary and would likely contribute to the development of antibiotic resistance and other negative consequences.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The recommended duration of antibiotic treatment for ventilator-associated pneumonia (VAP) is 7 days to ensure optimal clinical outcomes and minimize the risk of antibiotic resistance.</span></span></span></p>",
    "correct_choice_id": 199040,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49871,
    "choices": [
      {
        "id": 199047,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hand hygiene practices</span></span></p>"
      },
      {
        "id": 199048,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevation of the head of the bed</span></span></p>"
      },
      {
        "id": 199049,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Routine suctioning of subglottic secretions</span></span></p>"
      },
      {
        "id": 199050,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoiding unnecessary antibiotic use</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male patient is intubated and on mechanical ventilation in the ICU. Which of the following strategies is least likely to reduce the risk of VAP ?</span></span></p>",
    "unique_key": "Q8349676",
    "question_audio": null,
    "question_video": null,
    "map_id": 24850,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Avoiding unnecessary antibiotic use</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoiding unnecessary antibiotic use is crucial in preventing the development of antibiotic resistance and reducing the risk of Clostridioides difficile infection, but it does not directly reduce the risk of VAP. Antibiotic stewardship is important for overall patient safety but is not a primary preventive measure for VAP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prevention</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> of VAP</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> washing hands, HOB elevation</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> by 30-45<sup>o</sup></span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, oral ETT, enteral nutrition, routine suctioning of subglottic secretions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hand hygiene practices:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Effective hand hygiene practices are fundamental in preventing hospital-acquired infections, including VAP, by reducing the transmission of pathogens.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Elevation of the head of the bed:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Elevating the head of the bed to 30-45 degrees helps prevent aspiration, a significant risk factor for VAP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Routine suctioning of subglottic secretions:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This practice helps remove secretions that accumulate above the cuff of the endotracheal tube, which can reduce the risk of aspiration and subsequent pneumonia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoiding unnecessary antibiotic use is essential for preventing antibiotic resistance but does not directly reduce the risk of ventilator-associated pneumonia (VAP).</span></span></span></p>",
    "correct_choice_id": 199050,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 49873,
    "choices": [
      {
        "id": 199055,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Muscle biopsy</span></span></p>"
      },
      {
        "id": 199056,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Electroneuromyography (ENMG)</span></span></p>"
      },
      {
        "id": 199057,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoxic response test</span></span></p>"
      },
      {
        "id": 199058,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">End-tidal CO2 (EtCO2) measurements</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male with COPD is admitted due to worsening fever, fatigue, and shortness of breath. Chest X-ray shows left lower lobe consolidation. Despite treatment and resolution of pneumonia, the patient develops dyspnea and elevated pCO2 during attempts to wean from<strong> </strong>mechanical ventilation. Which test is used to identify the cause of weaning failure ?</span></span></p>",
    "unique_key": "Q3996447",
    "question_audio": null,
    "question_video": null,
    "map_id": 24851,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Electroneuromyography (ENMG)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Electroneuromyography (ENMG) is used to assess neuromuscular function and can help identify causes of weaning failure related to critical illness polyneuropathy or myopathy, which are common in ICU patients and can impair the ability to wean from mechanical ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Muscle biopsy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While a muscle biopsy can provide detailed information about muscle pathology, it is invasive and not typically the first-line diagnostic test for weaning failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypoxic response test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is not relevant for diagnosing the cause of weaning failure and is more commonly used to assess chemoreceptor function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. End-tidal CO2 (EtCO2) measurements:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While EtCO2 can monitor ventilation and detect issues like hypoventilation, it does not diagnose neuromuscular causes of weaning failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Electroneuromyography (ENMG) is used to assess neuromuscular function and can help identify causes of weaning failure related to critical illness polyneuropathy or myopathy.</span></span></span></p>",
    "correct_choice_id": 199056,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 49874,
    "choices": [
      {
        "id": 199059,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer Methylprednisolone </span></span></p>"
      },
      {
        "id": 199060,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perform an immediate tracheostomy </span></span></p>"
      },
      {
        "id": 199061,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase the inspiratory pressure</span></span></p>"
      },
      {
        "id": 199062,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer Salbutamol</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old female patient who has been on mechanical ventilation for 10 days is found to have stridor upon an attempted extubation. What is the most appropriate management in this patient ?</span></span></p>",
    "unique_key": "Q6652358",
    "question_audio": null,
    "question_video": null,
    "map_id": 24852,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Administer Methylprednisolone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administering Methylprednisolone is the standard management for stridor caused by laryngeal edema in ventilated patients. Corticosteroids help reduce inflammation and edema, which can alleviate the stridor and facilitate a safer extubation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Perform an immediate tracheostomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is not the first-line treatment for stridor due to laryngeal edema. It is considered if less invasive measures fail and if the airway obstruction is severe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Increase the inspiratory pressure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This approach does not address the underlying issue of laryngeal edema and can lead to further complications by increasing airway pressures unnecessarily.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Administer Salbutamol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While useful for bronchospasm and lower airway obstruction, Salbutamol does not reduce inflammation or edema in the upper airway, such as the larynx.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administering methylprednisolone is the standard management for stridor caused by laryngeal edema in ventilated patients, as it helps reduce inflammation and edema.</span></span></span></p>",
    "correct_choice_id": 199059,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49876,
    "choices": [
      {
        "id": 199067,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARDS is a diagnosis of exclusion </span></span></p>"
      },
      {
        "id": 199068,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral infiltrates on lung USG </span></span></p>"
      },
      {
        "id": 199069,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PaO2/FiO2 ratio of 250 on HFNO 20L per minute</span></span></p>"
      },
      {
        "id": 199070,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SpO2 of 95% and SpO2/FiO2 ratio of 295</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40 year old man developed severe respiratory distress after a viral pneumonia. Which of the following is incorrect regarding ARDS ?</span></span></p>",
    "unique_key": "Q2263225",
    "question_audio": null,
    "question_video": null,
    "map_id": 24853,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) PaO2/FiO2 ratio of 250 on HFNO 20L per minute </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Here is the revised definition for ARDS. PaO2/FiO2 ratio can now be measured with NIV/CPAP (or) with HFNC with O2 flow &gt; 30L/min. SpO2/FiO2 ratio has been suggested as an alternative to PaO2/FiO2 ratio in resource poor settings (And it should be &le; 315 with an SpO2 of &le; 97%). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/19/picture1_ORDcJzP.jpg\" style=\"height:570px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. To diagnose ARDS</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, other causes has to be ruled out, hence it is a true statement. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bilateral infiltrates on lung USG</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (or Chest X ray or CT scan) is a requirement for ARDS diagnosis, hence it is a true statement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. SpO2/FiO2 &le; 315 with SpO2 &le; 97%</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a new addition and can be used as an alternative to the traditional PaO2/FiO2 ratio in resource poor settings. Hence it is a true statement</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PaO2/FiO2 ratio for ARDS diagnosis can now be measured with NIV/CPAP or HFNC with O2 flow &gt; 30 L/min. SpO2/FiO2 ratio should be &le; 315 with SpO2 &le; 97%.</span></span></span></p>",
    "correct_choice_id": 199069,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 49878,
    "choices": [
      {
        "id": 199075,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelial injury </span></span></p>"
      },
      {
        "id": 199076,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exudative damage </span></span></p>"
      },
      {
        "id": 199077,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diffuse Alveolar Damage </span></span></p>"
      },
      {
        "id": 199078,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 2 Pneumocyte hyperplasia</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33 year old man developed sepsis and ARDS following a penetrating injury to the abdomen. Which of the following is the earliest pathology in ARDS ?</span></span></span></p>",
    "unique_key": "Q3662080",
    "question_audio": null,
    "question_video": null,
    "map_id": 24854,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Endothelial injury</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp; </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The earliest pathology in ARDS involves injury to the pulmonary endothelium, which leads to increased permeability, allowing protein-rich fluid to leak into the alveoli, causing edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Exudative damage</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This phase follows endothelial injury and is characterized by the accumulation of protein-rich fluid in the alveoli, formation of hyaline membranes, and the presence of inflammatory cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Diffuse Alveolar Damage</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a histopathological term often used to describe the changes seen in the exudative and proliferative phases of ARDS, but it is not the earliest event.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Type 2 Pneumocyte hyperplasia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This occurs later in the course of ARDS as part of the reparative process during the proliferative or fibrotic phases.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The earliest pathology in ARDS involves injury to the pulmonary endothelium, which leads to increased permeability and edema.</span></span></span></p>",
    "correct_choice_id": 199075,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49879,
    "choices": [
      {
        "id": 199079,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration </span></span></p>"
      },
      {
        "id": 199080,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trauma </span></span></p>"
      },
      {
        "id": 199081,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pneumonia </span></span></p>"
      },
      {
        "id": 199082,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sepsis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common cause of ARDS?</span></span></p>",
    "unique_key": "Q7785326",
    "question_audio": null,
    "question_video": null,
    "map_id": 24855,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Sepsis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sepsis is the most common cause of ARDS. The systemic inflammatory response in sepsis leads to widespread endothelial injury and increased vascular permeability, resulting in acute respiratory distress syndrome.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Aspiration:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While aspiration can cause ARDS, it is less common than sepsis. The patient&#39;s clinical context and history of sepsis make this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Trauma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trauma is another cause of ARDS but is not relevant in this patient&rsquo;s history, which centers on sepsis from a urinary tract infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pneumonia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pneumonia can lead to ARDS, but in this case, the primary underlying cause is sepsis secondary to a urinary tract infection, as indicated by the patient&rsquo;s clinical presentation and progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sepsis is the most common cause of ARDS due to the systemic inflammatory response leading to widespread endothelial injury and increased vascular permeability.</span></span></span></p>",
    "correct_choice_id": 199082,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 49880,
    "choices": [
      {
        "id": 199083,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">360 mL </span></span></p>"
      },
      {
        "id": 199084,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">480 mL </span></span></p>"
      },
      {
        "id": 199085,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">600 mL </span></span>&nbsp;&nbsp;&nbsp;&nbsp;</p>"
      },
      {
        "id": 199086,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">720 mL</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60kg female with a history of diabetes and hypertension is admitted to the ICU with acute respiratory distress syndrome (ARDS) secondary to severe pneumonia. She is intubated and placed on mechanical ventilation. What is the most appropriate tidal volume setting for this patient to minimize ventilator-induced lung injury ?</span></span></p>",
    "unique_key": "Q6915209",
    "question_audio": null,
    "question_video": null,
    "map_id": 24856,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 360 mL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The recommended tidal volume for ARDS management is 4-6 mL/kg of predicted body weight. For a patient with a body weight of 60 kg, a tidal volume of 360 mL (6 mL/kg) is within the recommended range and helps minimize the risk of ventilator-induced lung injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 480 mL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This tidal volume (8 mL/kg) exceeds the recommended range and could increase the risk of lung injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 600 mL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This tidal volume (10 mL/kg) is too high and significantly increases the risk of barotrauma and volutrauma in ARDS patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 720 mL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This tidal volume (12 mL/kg) is excessively high and would likely cause severe ventilator-induced lung injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The recommended tidal volume for ARDS management is 4-6 mL/kg of predicted body weight to minimize the risk of ventilator-induced lung injury.</span></span></span></p>",
    "correct_choice_id": 199083,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49881,
    "choices": [
      {
        "id": 199087,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase tidal volume to 8 mL/kg</span></span></span></p>"
      },
      {
        "id": 199088,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer diuretics </span></span></p>"
      },
      {
        "id": 199089,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prone positioning </span></span></p>"
      },
      {
        "id": 199090,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase FiO2 to 100%</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old male) is admitted to the ICU with severe ARDS secondary to COVID-19 pneumonia. Despite optimal ventilator settings, the patient remains severely hypoxemic with a PaO2/FiO2 ratio of 80.Which of the following interventions is most appropriate to improve oxygenation in this patient ?</span></span></p>",
    "unique_key": "Q3079177",
    "question_audio": null,
    "question_video": null,
    "map_id": 24857,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Prone positioning</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Prone positioning:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prone positioning (for </span><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 16h/day) is an evidence-based intervention that can significantly improve oxygenation in patients with severe ARDS. It helps redistribute lung perfusion, improve ventilation-perfusion matching, and enhance alveolar recruitment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Increase tidal volume to 8 mL/kg:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing the tidal volume to 8 mL/kg is not recommended in ARDS as it can lead to ventilator-induced lung injury due to overdistention of the alveoli. The recommended tidal volume for ARDS is 4-6 mL/kg of predicted body weight.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Administer diuretics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While diuretics can be useful in managing fluid overload, they are not a primary intervention for improving oxygenation in severe ARDS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increase FiO2 to 100%:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing FiO2 to 100% may temporarily improve oxygenation but can lead to oxygen toxicity if used for prolonged periods. It does not address the underlying issue of poor oxygenation due to lung mechanics and is not a sustainable long-term solution.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prone positioning is an evidence-based intervention that can significantly improve oxygenation in patients with severe ARDS by redistributing lung perfusion, improving ventilation-perfusion matching, and enhancing alveolar recruitment.</span></span></span></p>",
    "correct_choice_id": 199089,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49882,
    "choices": [
      {
        "id": 199091,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase tidal volume to 400 mL</span></span></p>"
      },
      {
        "id": 199092,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase FiO2 to 100%</span></span></p>"
      },
      {
        "id": 199093,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase PEEP to 12 cm H2O</span></span></p>"
      },
      {
        "id": 199094,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase respiratory rate</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50 kg female is admitted to the ICU with severe ARDS. he is intubated and on mechanical ventilation. Her ventilator settings are as follows: Tidal volume 300 mL, FiO2 80% and PEEP 8 cm H2O. Her ABG reports show a PaO2/FiO2 ratio of 100 and her SpO2 is 94%. Which of the following interventions should be the next step ?</span></span></p>",
    "unique_key": "Q9035878",
    "question_audio": null,
    "question_video": null,
    "map_id": 24858,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Increase PEEP to 12 cm H2O</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increasing Positive End-Expiratory Pressure (PEEP) helps improve oxygenation by increasing alveolar recruitment, preventing alveolar collapse, and improving ventilation-perfusion matching. This can allow for a reduction in FiO2, minimizing the risk of O2 toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Increase tidal volume to 400 mL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing the tidal volume is not recommended in ARDS as it can lead to ventilator-induced lung injury. The current tidal volume of 300 mL (6 mL/kg) is appropriate for this 50 kg patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Increase FiO2 to 100%:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing FiO2 to 100% can temporarily improve oxygenation, but prolonged use can lead to oxygen toxicity. The goal is to reduce FiO2 while maintaining adequate oxygenation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increase respiratory rate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing the respiratory rate helps with carbon dioxide removal but does not directly improve oxygenation. The primary intervention should focus on enhancing oxygenation through alveolar recruitment.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increasing Positive End-Expiratory Pressure (PEEP) helps improve oxygenation in severe ARDS by increasing alveolar recruitment, preventing alveolar collapse, and improving ventilation-perfusion matching, thereby reducing the need for high FiO2 and minimizing the risk of oxygen toxicity.</span></span></span></p>",
    "correct_choice_id": 199093,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 49883,
    "choices": [
      {
        "id": 199095,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce tidal volume to 200 mL</span></span></p>"
      },
      {
        "id": 199096,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase PEEP to 18 cm H2O</span></span></p>"
      },
      {
        "id": 199097,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase the duration of prone position</span></span></p>"
      },
      {
        "id": 199098,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider ECMO</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70 kg male is admitted to the ICU with ARDS after cholangitis. His ventilator settings in the prone position are as follows: Tidal volume 300 mL, PEEP 15 cm H2O, FiO2 100%. His ABG reveals a PaO2/FiO2 ratio of 50, PaCO2 of 50 mmHg, and an arterial pH of 7.13. His SpO2 is 85%, and his plateau pressure is 35 cm H2O. What is the most appropriate next step ?</span></span></span></p>",
    "unique_key": "Q7637253",
    "question_audio": null,
    "question_video": null,
    "map_id": 24859,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Consider ECMO</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ECMO (Extracorporeal Membrane Oxygenation) is indicated for patients with severe ARDS who have refractory hypoxemia and hypercapnia despite optimal ventilatory management. ECMO provides adequate oxygenation and CO2 removal, allowing the lungs to rest and recover.</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce tidal volume to 200 mL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Reducing tidal volume below the recommended 4-6 mL/kg would likely lead to inadequate ventilation and worsening hypercapnia without significantly improving oxygenation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Increase PEEP to 18 cm H2O:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increasing PEEP might marginally improve oxygenation, but with a high plateau pressure of 35 cm H2O, further increasing PEEP carries a significant risk of barotrauma and overdistention of the lungs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Increase the duration of prone position:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While prolonged prone positioning can sometimes enhance oxygenation, the patient&#39;s severe hypoxemia and hypercapnia suggest that a more advanced intervention, such as ECMO, is necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ECMO (Extracorporeal Membrane Oxygenation) is indicated for patients with severe ARDS who have refractory hypoxemia and hypercapnia despite optimal ventilatory management, providing adequate oxygenation and CO2 removal, allowing the lungs to rest and recover.</span></span></span></p>",
    "correct_choice_id": 199098,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Pulmonary Medicine & Critical Care';
        const quizFilename = 'pulmonary-medicine-critical-care-9b24f9cc.html';
        let hierarchy = ["Cerebellum", "qBank", "Medicine"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>